<!DOCTYPE html>
<html class="">
   <head>
      <meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
      <title>Pulmonary embolism - Treatment algorithm | BMJ Best Practice</title>
      <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1">
      <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
      <meta name="description" content="Pulmonary embolism (PE) is a life-threatening condition resulting from dislodged thrombi occluding the pulmonary vasculature; right heart failure and cardiac arrest may ensue if not aggressively treated. Symptoms include chest pain, dyspnoea, and a sense of apprehension. Haemoptysis and syncope a...">
      <!-- Optimize Page Hiding Snippet --> 
      <!-- <style>.async-hide
         { opacity: 0 !important}
      </style>
      <script async="" src="../js/adrum-ext.0086dbec5e8a6e717bf36d3a06b62042.js"></script><script src="../js/414393182248444" async=""></script><script async="" src="../js/fbevents.js"></script><script type="text/javascript" async="" src="../js/analytics.js"></script><script async="" src="../js/get-loader.js"></script><script type="text/javascript" async="" src="../js/insight.min.js"></script><script type="text/javascript" async="" src="../js/js"></script><script type="text/javascript" async="" src="../js/uwt.js"></script><script type="text/javascript" async="" src="../js/4896.js"></script><script type="text/javascript" async="" src="../js/analytics.js"></script><script async="" src="../js/gtm.js"></script><script>(function(a,s,y,n,c,h,i,d,e){s.className+=' '+y;h.start=1*new Date; h.end=i=function()
         {s.className=s.className.replace(RegExp(' ?'+y),'')}
         ; (a[n]=a[n]||[]).hide=h;setTimeout(function()
         
         {i();h.end=null}
         ,c);h.timeout=c;})(window,document.documentElement,'async-hide','dataLayer',3000,
         
         {'GTM-K3TZ3JV':true}
         );
      </script> -->
      <!-- end Optimize Page Hiding Snippet -->
      <!-- Google Tag Manager -->
      <!-- <script>
         /*<![CDATA[*/
         
          
         window.dataLayer = window.dataLayer || [];
         window.dataLayer.push({
                    'icsId': null,
                    'pi_icsId': "id82087",
                    'pi_icsName': "BMJ Group (Online access from BMA House)",
                    'access_rights': true,
                    'ics_groupings': [{"name":"Country Grouping"}],
                    'ics_countryName': "GB and ROW",
                    'siteLanguage': "en-gb",
                    'contentLanguage': "en-gb"
                 });
         		  
         /*]]>*/
            
      </script> -->
      <!-- <script>
         (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
         new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
         j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
         'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
         })(window,document,'script','dataLayer', 'GTM-K3TZ3JV');
      </script> -->
      <!-- End Google Tag Manager -->
      <!-- /* if user in China */ -->
      <link rel="stylesheet" type="text/css" media="screen" href="../css/material.css">
      <link rel="stylesheet" type="text/css" media="screen" href="../css/styles.css">
      <link rel="stylesheet" type="text/css" media="screen" href="../css/external.css">
      <link rel="shortcut icon" href="https://resources.bmj.com/repository/images/favicon.ico">
      <!-- <link rel="canonical" href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm">
      <link rel="alternate" hreflang="uk-ua" href="https://bestpractice.bmj.com/topics/uk-ua/116/treatment-algorithm">
      <link rel="alternate" hreflang="en-ie" href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm">
      <link rel="alternate" hreflang="az-az" href="https://bestpractice.bmj.com/topics/az-az/116/treatment-algorithm">
      <link rel="alternate" hreflang="en-us" href="https://bestpractice.bmj.com/topics/en-us/116/treatment-algorithm">
      <link rel="alternate" hreflang="ru" href="https://bestpractice.bmj.com/topics/ru-ru/116/treatment-algorithm">
      <link rel="alternate" hreflang="pt" href="https://bestpractice.bmj.com/topics/pt-br/116/treatment-algorithm">
      <link rel="alternate" hreflang="ka-ge" href="https://bestpractice.bmj.com/topics/ka-ge/116/treatment-algorithm">
      <link rel="alternate" hreflang="pt-br" href="https://bestpractice.bmj.com/topics/pt-br/116/treatment-algorithm">
      <link rel="alternate" hreflang="en" href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm">
      <link rel="alternate" hreflang="es-es" href="https://bestpractice.bmj.com/topics/es-es/116/treatment-algorithm">
      <link rel="alternate" hreflang="zh-cn" href="https://bestpractice.bmj.com/topics/zh-cn/116/treatment-algorithm">
      <link rel="alternate" hreflang="es" href="https://bestpractice.bmj.com/topics/es-es/116/treatment-algorithm">
      <link rel="alternate" hreflang="zh" href="https://bestpractice.bmj.com/topics/zh-cn/116/treatment-algorithm">
      <link rel="alternate" hreflang="x-default" href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm">
      <link rel="alternate" hreflang="ru-ru" href="https://bestpractice.bmj.com/topics/ru-ru/116/treatment-algorithm">
      <link rel="alternate" hreflang="vi" href="https://bestpractice.bmj.com/topics/vi-vn/116/treatment-algorithm">
      <link rel="alternate" hreflang="uk" href="https://bestpractice.bmj.com/topics/uk-ua/116/treatment-algorithm">
      <link rel="alternate" hreflang="ka" href="https://bestpractice.bmj.com/topics/ka-ge/116/treatment-algorithm">
      <link rel="alternate" hreflang="az" href="https://bestpractice.bmj.com/topics/az-az/116/treatment-algorithm">
      <link rel="alternate" hreflang="vi-vn" href="https://bestpractice.bmj.com/topics/vi-vn/116/treatment-algorithm">
      <link rel="alternate" hreflang="en-gb" href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm"> -->
      <!--[if lte IE 9]>
      <link rel="stylesheet" type="text/css" media="screen" href="/gzip_1791a8687c5480ce19e791d0825e7a6b/css/lte-ie-9.css" >
      <![endif]-->
      <!-- <script>
         /*<![CDATA[*/
           var appdynamics_app_key="AD-AAB-AAF-RGR";
         /*]]>*/
           	window["adrum-app-key"] = appdynamics_app_key;
           	window['adrum-start-time'] = new Date().getTime();
           
      </script>
      <script type="text/javascript" src="../js/appdynamics.js"></script> -->
      <script type="application/ld+json">
         [
         
         { "@context": "http://schema.org", "@type": "MedicalCondition" }
         ,{
         "isAccessibleForFree": "False",
         "hasPart":
         
         { "@type": "WebPageElement", "isAccessibleForFree": "False", "cssSelector" : ".gpw" }
         }]
      </script>
      <style></style>
   </head>
   <body class="gpw">
      <div role="dialog" aria-live="polite" aria-label="cookieconsent" aria-describedby="cookieconsent:desc" class="cc-window cc-banner cc-type-info cc-theme-classic cc-bottom cc-color-override--38786966 cc-invisible" style="display: none;">
         <!--googleoff: all--><span id="cookieconsent:desc" class="cc-message">We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our 
         <a aria-label="learn more about cookies" role="button" tabindex="0" class="cc-link" href="https://www.bmj.com/company/your-privacy/cookies-policy/" target="_blank">cookies policy</a></span>
         <div class="cc-compliance"><a aria-label="dismiss cookie message" role="button" tabindex="0" class="cc-btn cc-dismiss">OK!</a></div>
         <!--googleon: all-->
      </div>
      <!-- Google Tag Manager (noscript) -->
      <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-K3TZ3JV" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
      <!-- End Google Tag Manager (noscript) -->
      <!-- /* if user in China */ -->
      <header id="header" role="banner">
         <a class="sr-only" href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#sr-content">Skip to main content</a>
         <div class="bg-info text-white">
         </div>
         <nav id="globalNav" class="logo-img-mob navbar navbar-toggleable-md">
            <div class="container">
               <a href="https://koba7c.axshare.com/#g=1&p=start_1&c=1" class="mobLogo"><span class="remove"><abbr>BMJ</abbr> Best Practice</span></a>
               <button class="navbar-toggler navbar-toggler-right" type="button" data-toggle="collapse" data-target="#navbarNav" aria-controls="navbarNav" aria-expanded="false" aria-label="Toggle navigation">
               <span class="material-icons"></span>
               </button>
               <div id="navbarNav" class="collapse navbar-collapse">
                  <ul id="globalNav-ul" class="navbar-nav" role="menubar">
                     <li id="globalNav-access" class="nav-item" role="presentation">
                        <span class="nav-link"> 
                        Access provided by: 
                        BMJ Group (Online access from BMA House)
                        </span>
                     </li>
                     <li id="globalNav-help" class="nav-item dropdown" role="menuitem">
                        <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" id="navbarDropdownMenuLink02" class="nav-link dropdown-toggle" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false"> 
                        Help <span class="states">
                        <span class="material-icons"></span>
                        <span class="material-icons"></span>
                        </span>
                        </a>
                        <div id="globalNav-help-options" class="dropdown-menu dropdown-menu-right" aria-labelledby="navbarDropdownMenuLink02">
                           <span class="material-icons"></span>
                           <ul role="menu">
                              <li class="dropdown-item"><a href="https://bestpractice.bmj.com/info/getting-started/" target="_blank">Getting started</a></li>
                              <li class="dropdown-item"><a href="https://bestpractice.bmj.com/info/faq/" target="_blank">FAQs</a></li>
                              <li class="dropdown-item"><a href="https://bestpractice.bmj.com/info/benefits-features/earn-cme-points/" target="_blank">About CME/CPD</a></li>
                              <li class="dropdown-item"><a href="https://bestpractice.bmj.com/info/contact-us/" target="_blank">Contact us</a></li>
                           </ul>
                        </div>
                     </li>
                     <li id="globalNav-register" class="nav-item">
                        <a href="https://bestpractice.bmj.com/registration" class="nav-link">Create account</a>
                     </li>
                     <li id="globalNav-login" class="nav-item">
                        <a href="https://bestpractice.bmj.com/login" class="nav-link">Log in</a>
                     </li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/recent-updates"><span class="icon icon-bp-icons-recent-updates"></span><span>Recent updates</span></a></li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/specialties"><span class="icon icon-bp-icons-specialties"></span><span>Specialties</span></a></li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/calculators"><span class="icon icon-bp-icons-calculators"></span><span>Calculators</span></a></li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/patient-leaflets"><span class="icon icon-bp-icons-patient-leaflets"></span><span>Patient leaflets</span></a></li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/procedural-videos"><span class="icon icon-bp-icons-procedural-videos"></span><span>Procedural videos</span></a></li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/evidence"><span class="icon icon-bp-icons-evidence"></span><span>Evidence</span></a></li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/drugs"><span class="icon icon-bp-icons-drugs"></span><span>Drugs</span></a></li>
                  </ul>
               </div>
            </div>
         </nav>
         <div id="mainSearch" class="container">
            <div class="row">
               <div class="col-lg-7">
                  <div class="logo-img"><a href="https://koba7c.axshare.com/#g=1&p=start_1&c=1"><span class="remove"><abbr title="British Medical Journal">BMJ</abbr> Best Practice</span></a></div>
               </div>
               <div class="col-lg-5">
                  <style type="text/css">
                     #searchBoxWrap .tt-open:before {content: "Recently viewed topics:"; }
                     #searchBoxWrap .tt-label-override:before,
                     #searchBoxWrap .tt-suggested:before {content: "Suggested topics:" !important; }
                  </style>
                  <form id="searchBoxForm" action="https://bestpractice.bmj.com/search" role="search" novalidate="novalidate">
                     <div class="input-group">
                        <div id="searchBoxWrap">
                           <label for="q" class="sr-only">Search</label>
                           <span class="twitter-typeahead" style="position: relative; display: inline-block;">
                              <input id="q" type="text" name="q" placeholder="Search conditions, symptoms..." value="" class="tt-input" autocomplete="off" spellcheck="false" dir="auto" style="position: relative; vertical-align: top;">
                              <pre aria-hidden="true" style="position: absolute; visibility: hidden; white-space: pre; font-family: sans-serif; font-size: 16px; font-style: normal; font-variant: normal; font-weight: 400; word-spacing: 0px; letter-spacing: 0px; text-indent: 0px; text-rendering: auto; text-transform: none;"></pre>
                              <div class="tt-menu" style="position: absolute; top: 100%; left: 0px; z-index: 100; display: none;">
                                 <div class="tt-dataset tt-dataset-0"></div>
                              </div>
                           </span>
                           <button id="mainSearchBtn" type="submit"><span class="material-icons"></span></button>
                        </div>
                     </div>
                  </form>
                  <script>
                     /*<![CDATA[*/
                     
                            // These are required in completion, see BP-232 -->
                            var searchDefaultLanguageCode = "en-gb";
                            var regionName = "GB and ROW";
                            var regionAvailableLanguagesCodes = [{"id":"1","code":"en-gb","displayName":"English"},{"id":"3","code":"pt-br","displayName":"Portugu\u00EAs"},{"id":"5","code":"es-es","displayName":"Espa\u00F1ol"},{"id":"7","code":"ru-ru","displayName":"\u0420\u0443\u0441\u0441\u043A\u0438\u0439"}];
                            var availableLanguages = [];
                     
                            for (i = 0; i < regionAvailableLanguagesCodes.length; i++) {
                                availableLanguages.push(regionAvailableLanguagesCodes[i].code);
                            }
                     /*]]>*/
                  </script>
               </div>
            </div>
         </div>
         <nav id="mainNav" class="navbar navbar-toggleable-md" role="navigation">
            <div class="container">
               <div id="mainNavbarNav">
                  <ul class="navbar-nav" role="menubar">
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/recent-updates"><span class="icon icon-bp-icons-recent-updates"></span><span>Recent updates</span></a></li>
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/specialties"><span class="icon icon-bp-icons-specialties"></span><span>Specialties</span></a></li>
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/calculators"><span class="icon icon-bp-icons-calculators"></span><span>Calculators</span></a></li>
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/patient-leaflets"><span class="icon icon-bp-icons-patient-leaflets"></span><span>Patient leaflets</span></a></li>
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/procedural-videos"><span class="icon icon-bp-icons-procedural-videos"></span><span>Procedural videos</span></a></li>
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/evidence"><span class="icon icon-bp-icons-evidence"></span><span>Evidence</span></a></li>
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/drugs"><span class="icon icon-bp-icons-drugs"></span><span>Drugs</span></a></li>
                  </ul>
               </div>
            </div>
         </nav>
      </header>
      <script type="text/javascript" id="">(function(){var f=google_tag_manager["GTM-K3TZ3JV"].macro(4),b=google_tag_manager["GTM-K3TZ3JV"].macro(5),a=function(a,b,d){var e="",c=new Date;d&&(c.setTime(c.getTime()+864E5*d),e="; expires\x3d"+c.toGMTString());document.cookie=a+"\x3d"+b+e+"; path\x3d/; domain\x3dbmj.com"};f?"true"!=b&&("justLoggedIn"==b?a("loggedIn","true",2):a("loggedIn","justLoggedIn",2)):a("loggedIn","false",2)})();</script>
      <main id="tmp" class="container tmp treatment-table more-pops main-container" role="main">
         <script type="text/javascript">
            /*<![CDATA[*/ 
            var topicId = 116; 
            var langCode="en-gb"; 
            /*]]>*/
         </script>
         <div id="topicNav" class="container">
            <div class="lang">
               <ul role="menu">
                  <li><a href="https://bestpractice.bmj.com/topics/en-gb/116" class="active">English</a></li>
                  <li><a href="https://bestpractice.bmj.com/topics/pt-br/116">Português</a></li>
                  <li><a href="https://bestpractice.bmj.com/topics/es-es/116">Español</a></li>
                  <li><a href="https://bestpractice.bmj.com/topics/ru-ru/116">Русский</a></li>
               </ul>
            </div>
            <div id="topicMenuTopBg" style="height: 110px;"></div>
            <div id="topicMenuTopWrap" style="height: 110px;">
               <div id="topicMenuTop" style="height: 110px;">
                  <h1>Pulmonary embolism</h1>
                  <div class="pdf-links-nav">
                     <div class="pdf">
                        <a href="https://bestpractice.bmj.com/topics/en-gb/116/pdf/116.pdf" target="_blank">
                        <span class="icon icon-bp-icons-pdf-extra-small-on-white"></span> <span>View PDF</span>
                        </a>
                     </div>
                  </div>
                  <div id="mobileMenu" class="mUp">
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="button">
                     <span><span class="material-icons"></span> Menu</span>
                     <span><span class="material-icons"></span> Close</span>
                     </a>
                  </div>
                  <ul id="menuLinks" role="menu">
                     <li><a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#smenu-0" aria-owns="menu-0">Overview <span class="material-icons"></span><span class="material-icons"></span></a></li>
                     <li><a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#smenu-1" aria-owns="menu-1">Theory <span class="material-icons"></span><span class="material-icons"></span></a></li>
                     <li><a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#smenu-2" aria-owns="menu-2">Diagnosis <span class="material-icons"></span><span class="material-icons"></span></a></li>
                     <li><a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#smenu-3" aria-owns="menu-3">Management <span class="material-icons"></span><span class="material-icons"></span></a></li>
                     <li><a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#smenu-4" aria-owns="menu-4">Follow up <span class="material-icons"></span><span class="material-icons"></span></a></li>
                     <li><a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#smenu-5" aria-owns="menu-5">Resources <span class="material-icons"></span><span class="material-icons"></span></a></li>
                  </ul>
               </div>
               <div id="como-2" class="card" style="display: none;">
                  <div class="card-block">
                      <div class="row">
                          <div class="col-md-3">
                             <span class="material-icons">
                             <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                           <g>
                              <g>
                                 <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                    c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                 <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                    c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                 <g>
                                    <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                 </g>
                              </g>
                              <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                 7.707,19.5 7.707,16 11.207,16 	"></polygon>
                           </g>
                           </svg>
                        </span> 
                        <b>Add comorbidities:</b></div>
                          <div class="col-md-6" id="comoselected-2">  </div>
                          <div class="col-md-2"><button class="btn" data-toggle="modal" data-target="#editComo">Edit</button></div>
                      </div> <!--- row --->
  
                  </div>
              </div>
            </div>
            <div id="topicMenuBottomWrap" style="height: 176px;">
               <nav id="topicMenuBottom" class="mUp" role="navigation" style="height: 176px;">
                  <ul id="menus" role="menubar">
                     <li>
                        <a href="https://bestpractice.bmj.com/topics/en-gb/116/criteria#" class="parent"><span>Overview</span><span class="material-icons"></span><span class="material-icons"></span></a>
                        <ul role="menu" id="menu-0">
                           <li><a href="116_overview_summary.html" id="Summary">Summary</a></li>
                        </ul>
                     </li>
                     <li>
                        <a href="https://bestpractice.bmj.com/topics/en-gb/116/criteria#" class="parent"><span>Theory</span><span class="material-icons"></span><span class="material-icons"></span></a>
                        <ul role="menu" id="menu-1">
                           <li><a href="116_theory_epidemiology.html" id="Epidemiology">Epidemiology</a></li>
                           <li><a href="116_theory_aetiology.html" id="Aetiology">Aetiology</a></li>
                           <li><a href="116_theory_case_history.html" id="Case history">Case history</a></li>
                        </ul>
                     </li>
                     <li>
                        <a href="https://bestpractice.bmj.com/topics/en-gb/116/criteria#" class="parent"><span>Diagnosis</span><span class="material-icons"></span><span class="material-icons"></span></a>
                        <ul role="menu" id="menu-2">
                           <li><a href="116_diagnosis_recommendations.html" id="Approach">Recommendations</a></li>
                           <li><a href="116_diagnosis_history-exam.html" id="History and exam">History and exam</a></li>
                           <li><a href="116_diagnosis_investigations.html" id="Investigations">Investigations</a></li>
                           <li><a href="116_diagnosis_differentials.html" id="Differentials">Differentials</a></li>
                           <li><a href="116_diagnosis_criteria.html" id="Criteria">Criteria</a></li>
                        </ul>
                     </li>
                     <li>
                        <a href="https://bestpractice.bmj.com/topics/en-gb/116/criteria#" class="parent"><span>Management</span><span class="material-icons"></span><span class="material-icons"></span></a>
                        <ul role="menu" id="menu-3">
                           <li><a href="116_management_recommendations.html" id="Approach">Recommendations</a></li>
                           <li><a href="116_management_treatment_algorithm.html" id="Treatment algorithm" class="active">Treatment algorithm</a></li>
                           <li><a href="116_management_emerging.html" id="Emerging">Emerging</a></li>
                           <li><a href="116_management_prevention.html" id="Prevention">Prevention</a></li>
                           <li><a href="116_management_patient_discussions.html" id="Patient discussions">Patient discussions</a></li>
                        </ul>
                     </li>
                     <li>
                        <a href="https://bestpractice.bmj.com/topics/en-gb/116/criteria#" class="parent"><span>Follow up</span><span class="material-icons"></span><span class="material-icons"></span></a>
                        <ul role="menu" id="menu-4">
                           <li><a href="116_follow_up_monitoring.html" id="Monitoring">Monitoring</a></li>
                           <li><a href="116_follow_up_complications.html" id="Complications">Complications</a></li>
                           <li><a href="116_follow_up_prognosis.html" id="Prognosis">Prognosis</a></li>
                        </ul>
                     </li>
                     <li>
                        <a href="https://bestpractice.bmj.com/topics/en-gb/116/criteria#" class="parent"><span>Resources</span><span class="material-icons"></span><span class="material-icons"></span></a>
                        <ul role="menu" id="menu-5">
                           <li><a href="116_resources_guidelines.html" id="Guidelines">Guidelines</a></li>
                           <li><a href="116_resources_images_videos.html" id="Images and videos">Images and videos</a></li>
                           <li><a href="116_resources_references.html" id="References">References</a></li>
                           <li><a href="116_resources_patient_leaflets.html" id="Patient leaflets">Patient leaflets</a></li>
                           <li><a href="116_resources_evidence.html" id="Evidence">Evidence</a></li>
                        </ul>
                     </li>
                     <li class="mpdf"><a href="https://bestpractice.bmj.com/topics/en-gb/116/pdf/116.pdf" target="_blank"><span class="icon icon-bp-icons-pdf-extra-small-on-white"></span> <span>View PDF</span></a></li>
                  </ul>
               </nav>
            </div>
         </div>
         <h2 id="sr-content">Treatment algorithm</h2>
         <p class="w-75">Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups: <a href="https://bestpractice.bmj.com/info/disclaimer/" target="_blank">see disclaimer</a></p>
         <div id="como-1" class="card">
            <div class="card-block">
               <div class="row">
                  <div class="col-md-12">
                     <div class="add-como-icon-and-text">
                        <span class="material-icons">
                           <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                        <g>
                           <g>
                              <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                 c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                              <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                 c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                              <g>
                                 <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                              </g>
                           </g>
                           <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                              7.707,19.5 7.707,16 11.207,16 	"></polygon>
                        </g>
                           </svg>
                        </span> 
                        <b class="add" data-toggle="modal" data-target="#editComo">Add comorbidities:</b>
                        <b class="added unchecked">Added comorbidities:</b>
                     </div>
                     <div id="comoselected-1">
                        <button class="btn hide" data-toggle="modal" data-target="#editComo">Edit</button>
                     </div>
               </div>                  
               </div>
               <!--- row --->
            </div>
         </div>
         
         <div id="poce_contents" class="treatment-algorithm">
            <div class="card">
               <div class="card-block">
                  <div class="container">
                     <div class="rowHead" id="ongoing">
                        <div class="col-md-12">
                           INITIAL
                        </div>
                     </div>
                     <div class="panel">
                        <div class="panel-heading">
                           <h3>
                              <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" id="patientGroup-1-0">
                              <span>PE suspected: haemodynamically unstable (SBP &lt;90) AND/OR hypoxaemic</span>
                              <span class="hidden-sm-down">
                              <span class="msg">VIEW ALL</span>
                              <span class="material-icons" role="button"><span></span><span></span></span>
                              </span>
                              </a>
                           </h3>
                        </div>
                        <!--/.panel-heading -->
                        <div class="panel-body">
                           <section class="panel-group COPD-como-content Asthma-como-content">
                              <div class="panel-header">
                                 <p class="panel-title"> 
                                    <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_1_0_0" aria-controls="panel_1_0_0" aria-expanded="false">
                                    <span class="titles-wrap col-md-12">
                                    <span class="title-02 no-icon">
                                    <span class="title-03 col-md-1">
                                    1st line
                                    <span class="noShow">&nbsp;–&nbsp;</span>
                                    </span>
                                    <span class="title-04">
                                    <span class="material-icons"><span></span><span></span></span>
                                    <span class="txtwrap no-icon">Respiratory support</span>
                                    </span>
                                    <span class="material-icons">
                                       <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                       <g>
                                          <g>
                                             <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                             <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                             <g>
                                                <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                             </g>
                                          </g>
                                          <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                             7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                       </g>
                                       </svg>
                                    </span>
                                    </span>
                                    </span>
                                    </a>
                                 </p>
                              </div>
                              <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_1_0_0" id="panel_1_0_0" aria-expanded="false">
                                    <p><strong>Give high-concentration oxygen, targeting a saturation of 94% to 98% (or 88% to 92% in patients at risk of hypercapnic respiratory failure).[BTS02] </strong></p>
                                    <ul>
                                    <li><strong>Assess oxygen saturation early. </strong>Hypoxaemia is a typical finding in PE; it may be present at rest if a high-risk (massive) PE is present or only on exertion with a smaller PE.[ESC]</li>
                                    <li><strong>Apply mechanical ventilation if required</strong> but use with caution as this may worsen haemodynamic instability in a high-risk (massive) PE. Mechanical ventilation induces positive thoracic pressure which may reduce venous return and worsen right ventricular (RV) failure. [ESC]</li>
                                    </ul>
                                    <p><strong>Involve senior support and/or critical care in patients who are haemodynamically unstable.</strong></p>
                                    <ul>
                                    <li>Patients with suspected or confirmed PE who present with<strong> shock or hypotension are at high risk of in-hospital death</strong>, particularly in the<strong> first few hours</strong> after presentation. [ESC]</li>
                                    </ul>
                                    <div id="tip_pitfall" class="card card-inverse mb-4">
                                       <div class="card-block">
                                          <svg version="1.1" id="pin" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 90 90" enable-background="new 0 0 90 90" xml:space="preserve">
                                          <g>
                                          <g>
                                             <path fill="#333333" d="M42.694,51.942v30.413C42.694,83.816,44.174,85,46,85s3.306-1.184,3.306-2.645V51.942H42.694z"></path>
                                          </g>
                                          <g>
                                             <ellipse fill="#333333" cx="46" cy="47.645" rx="19.835" ry="12.231"></ellipse>
                                          </g>
                                          <g id="cylinder">
                                             <polygon fill="#333333" points="55.256,9.628 46,9.628 36.744,9.628 34.099,47.975 46,47.975 57.901,47.975 		"></polygon>
                                          </g>
                                          <g id="cylinder_highlight">
                                             <polygon fill="#FFFFFF" points="54.595,46.653 50.628,47.975 49.306,13.595 53.273,13.595 		"></polygon>
                                          </g>
                                          <g>
                                             <ellipse fill="#333333" cx="46" cy="13.595" rx="15.207" ry="8.595"></ellipse>
                                          </g>
                                          <g id="highlight">
                                             <path fill="#FFFFFF" d="M47.982,18.929c-0.67,0-1.245-0.508-1.313-1.19c-0.073-0.727,0.456-1.375,1.183-1.448
                                                c3.157-0.318,5.857-1.434,7.224-2.985c0.48-0.547,1.317-0.602,1.866-0.118c0.548,0.482,0.601,1.318,0.118,1.866
                                                c-1.822,2.069-5.082,3.479-8.942,3.868C48.072,18.927,48.027,18.929,47.982,18.929z"></path>
                                          </g>
                                          <g>
                                             <path fill="#333333" d="M46,49.54v-1.322c4.794,0,9.917-1.192,9.917-4.54h1.322C57.239,47.349,53.038,49.54,46,49.54z"></path>
                                          </g>
                                          <g id="highlight_lower">
                                             <path fill="#FFFFFF" d="M48.011,56.926c-0.032,0-0.064,0-0.098,0c-0.73-0.003-1.319-0.598-1.316-1.328
                                                c0.003-0.729,0.595-1.316,1.322-1.316c0.034,0,0.063,0,0.095,0c3.975,0,7.602-1.166,9.719-3.128
                                                c0.533-0.496,1.37-0.467,1.868,0.071c0.496,0.535,0.465,1.372-0.071,1.868C56.937,55.496,52.637,56.926,48.011,56.926z"></path>
                                          </g>
                                          </g>
                                          </svg>
                                          <h3 class="card-title"></h3>
                                          <p><strong>Do not allow supportive therapy to delay thrombolysis (as long as there are no contraindications) - it may quickly restore haemodynamic stability. </strong></p>
                                          <ul>
                                          <li>It is common practice to give thrombolysis as first-line treatment for any patient who is in peri-arrest/cardiac arrest based on clinical suspicion of PE without waiting for results from investigations.</li>
                                          <li>In these situations the decision to thrombolyse would be based on discussion between senior clinicians.</li>
                                          </ul>
                                       </div>
                                    </div>
                                    
                                    <div class="evidence-accordion">
                                          <div class="option">
                                             <input type="checkbox" id="toggle1" class="toggle" />
                                             <label class="title" for="toggle1">                                             
                                                <span class="material-icons"><span></span></span>
                                                <span class="title">Evidence: Patients with high-risk PE are at significant risk of death</span>
                                               </label>
                                             <div class="content">
                                                   <ul>
                                                         <li><strong>The 30-day mortality rate of patients with haemodynamically unstable (high-risk) PE ranges from 16% to 25% and that of patients with cardiac arrest due to PE ranges from 52% to 65%</strong>. [TANABE][KASPER]</li>
                                                         <ul>
                                                         <li>Most deaths in patients presenting with shock occur within the first hour after presentation so rapid therapeutic action is essential to save lives. [HENRY]</li>
                                                         <li>The International Cooperative Pulmonary Embolism Registry (ICOPER) showed 90-day mortality rates of 58.3% in patients with high-risk (massive) PE. [GOLD]</li>
                                                         </ul>
                                                         </ul>
                                             </div>
                                          </div>
                                       </div>


                                         
                                    <!-- CONDITIONAL COMO CONTENT -->
                                    <div class="COPD-como-content Asthma-como-content" style="display: none;">
                                          <div class="poce_drug_msg">
                                                <span class="material-icons">
                                                      <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                         <g>
                                                            <g>
                                                               <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                                  c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                               <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                                  c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                               <g>
                                                                  <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                               </g>
                                                            </g>
                                                            <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                               7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                         </g>
                                                         </svg>
                                                </span> 
                                                <h3 class="poce_title"></h3>
                                                <h3>Oxygen therapy (in COPD)</h3>
                                                <p><strong>Oxygen therapy may be required in patients with COPD who are hypoxic, to maintain saturations. </strong></p>
                                                <ul>
                                                <li><strong>Measure resting oxygen saturations in all acutely unwell patients. <em>(O'Driscoll BR, et al, 2017)</em></strong></li>
                                                </ul>
                                                <p><strong>Use the same initial target oxygen saturation of 94% to 98% for a patient with a critical illness (e.g., shock, sepsis, major trauma) and comorbid COPD as for patients without COPD, pending the results of arterial blood gas (ABG) results. </strong><em>(O'Driscoll BR, et al, 2017)</em></p>
                                                <ul>
                                                <li><strong>Subsequently, depending on ABG results, controlled oxygen therapy with a target oxygen saturation range of 88% to 92% may be needed. </strong></li>
                                                <li>If the patient is severely hypoxaemic and/or has hypercapnia with respiratory acidosis, consider ventilation support.</li>
                                                </ul>
                                                <p><strong>Use an initial target oxygen saturation of 88% to 92% in patients with an acute but not immediately critical medical condition who have comorbid COPD or other risk factors for hypercapnia and no history of respiratory acidosis. </strong><em>(O'Driscoll BR, et al, 2017)</em></p>
                                                <ul>
                                                <li><strong>Measure ABG</strong>, and if the <strong>pCO2</strong> is in the <strong>normal range</strong>, adjust the oxygen saturation <strong>target to 94% to 98%</strong>, unless the patient has a history of hypercapnic respiratory failure requiring ventilatory support.</li>
                                                <li>Some patients with COPD who are <strong>acidotic</strong>, or who have a <strong>history of hypercapnic respiratory failure,</strong> or who are particularly <strong>sensitive to oxygen therapy</strong> may need a <strong>lower target oxygen saturation range.</strong> Check to see if they carry an &lsquo;<strong>alert card</strong>&rsquo; which may guide therapy based on previous blood gas results. <em>(O'Driscoll BR, et al, 2017)</em></li>
                                                <li>If there is no alert card to guide therapy, use target oxygen saturations of <strong>88% to 92% and check arterial blood gases urgently.</strong></li>
                                                <li>Some patients with COPD have a usual <strong>oxygen saturation of &lt;92% when clinically stable</strong>. Target oxygen saturations in these patients should be <strong>88% to 92%.</strong></li>
                                                </ul>
                                                <p><strong>Re-check </strong>ABG after 30 to 60 minutes.</p>
                                             </div>
                                       </div>
                                       <!-- CONDITIONAL COMO CONTENT ends-->
   
                              </div>
                              <!--/.panel-body -->
                           </section>
                           <section class="panel-group HeartFailure-como-content CKD-como-content">
                              <div class="panel-header">
                                 <p class="panel-title"> 
                                    <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_1_0_0" aria-controls="panel_1_0_0" aria-expanded="false">
                                    <span class="titles-wrap col-md-12">
                                    <span class="title-02 no-icon">
                                    <span class="title-03 col-md-1">
                                    Plus
                                    <span class="noShow">&nbsp;–&nbsp;</span>
                                    </span>
                                    <span class="title-04">
                                    <span class="material-icons"><span></span><span></span></span>
                                    <span class="txtwrap no-icon">Fluid resuscitation</span>
                                    </span>
                                    <span class="material-icons">
                                       <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                       <g>
                                          <g>
                                             <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                             <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                             <g>
                                                <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                             </g>
                                          </g>
                                          <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                             7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                       </g>
                                       </svg>
                                    </span>
                                    </span>
                                    </span>
                                    </a>
                                 </p>
                              </div>
                              <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_1_0_0" id="panel_1_0_0" aria-expanded="false">
                                    <ul>
                                          <li>
                                          <p><strong>Give intravenous fluids if systolic BP is &lt;90 mmHg or there are any other signs of shock</strong>. [ESC]</p>
                                          <ul>
                                          <li>Give intravenous fluids with <strong>caution </strong>and <strong>start with a 500 mL</strong> fluid challenge. Determine further fluid based on clinical response.[ESC]</li>
                                          <li>Use <strong>normal saline (0.9% NaCl) or Hartmann&rsquo;s/Ringer&rsquo;s lactate</strong>.[NICEF] Guidelines differ in their recommendations on choice of fluid and clinical practice varies widely so check local protocols.</li>
                                          </ul>
                                          </li>
                                          </ul>
                                    <!-- CONDITIONAL COMO CONTENT -->
                                    <div class="HeartFailure-como-content CKD-como-content" style="display: none;">
                                          <div class="poce_drug_msg">
                                                <span class="material-icons">
                                                      <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                         <g>
                                                            <g>
                                                               <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                                  c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                               <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                                  c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                               <g>
                                                                  <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                               </g>
                                                            </g>
                                                            <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                               7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                         </g>
                                                         </svg>
                                                </span> 
                                                <h3 class="poce_title"></h3>
                                                <h3>Assess fluid status and manage fluid balance particularly closely</h3>
                                                <ul>
                                                      <li>
                                                      <p><strong>Be aware of the difficulties assessing hypotension, low organ perfusion and shock in a person with heart failure and/or CKD</strong></p>
                                                      <ul>
                                                      <li>Hypovolaemia may be <strong>difficult to assess</strong> in a person with <strong>heart failure</strong> and<strong> CKD</strong>. <em>(National Institute for Health and Care Excellence, 2017)</em> It may occur if there isvascular permeability, insensible losses, bleeding, or with sedatives, analgesics, or positive pressure ventilation.</li>
                                                      <li>Establish the patient&rsquo;s<strong> baseline blood pressure</strong>. A systolic blood pressure of &lt;90 mmHg may suggest hypotension, but note that a patient on <strong>medication for chronic heart failure </strong>can have a baseline <strong>systolic blood pressure of &lt;90 mmHg</strong>.</li>
                                                      <li><strong>Fluid resuscitation</strong> is required <strong>initially</strong> in patients with <strong>CKD who are hypotensive</strong>, particularly if they have signs of <strong>shock</strong>. <em>(Verbrugge FH, et al, 2014)</em></li>
                                                      </ul>
                                                      </li>
                                                      <li><strong>Reassess patient</strong> after initial fluid challenge and get senior input if the patient does not rapidly stabilise. <strong>Consider transfer</strong> to a more <strong>intensive level of care</strong>.</li>
                                                      <li>
                                                      <p>Patients with <strong>heart failure </strong>may need fluid resuscitation but, due to thedifficulty in accurate assessment of volume status and the <strong>risk of volume overload</strong>, <strong>seek senior review</strong>. <strong>Consider transferring</strong> the patient to a more intensive level of care <strong>before initiating fluid resuscitation</strong>.</p>
                                                      </li>
                                                      </ul>
                                             </div>
                                       </div>
                                       <!-- CONDITIONAL COMO CONTENT ends-->
                                       <p><strong>Monitor closely for signs of right heart failure. [ESC]</strong></p>
                                       <ul>
                                       <li>The <strong>leading cause of death</strong> in patients with high-risk (massive) PE is <strong>acute right ventricular failure</strong> with resulting hypotension. [ESC]</li>
                                       <li>Patients with haemodynamically unstable PE require early intravenous fluid resuscitation but should be monitored for signs of right heart failure.</li>
                                       </ul>
                                       <p><strong>Involve senior support and/or critical care in patients who are haemodynamically unstable. </strong></p>
                                          
                                    <div class="evidence-accordion">
                                          <div class="option">
                                             <input type="checkbox" id="toggle2" class="toggle" />
                                             <label class="title" for="toggle2">                                             
                                                <span class="material-icons"><span></span></span>
                                                <span class="title">Evidence: Aggressive volume expansion in patients with haemodynamically unstable PE is of no benefit and may even worsen RV function</span>
                                               </label>
                                             <div class="content">
                                                   <ul>
                                                         <li><strong><em>There is only very scarce and conflicting evidence on the balance of risks vs benefits from fluid resuscitation in patients with PE who are haemodynamically unstable. </em></strong></li>
                                                         </ul>
                                                         <ul>
                                                         <ul>
                                                         <li>One prospective study of 13 patients with high-risk haemodynamically unstable PE suggested that fluid loading (an infusion of 500 mL of dextran 40 over 20 mins) can improve hemodynamic status. It was shown to increase right ventricular preload which was associated with an increase in cardiac index without reducing the right ventricular ejection fraction. [MERCAT]</li>
                                                         <li>In contrast, earlier experimental studies in dogs indicated that aggressive volume expansion may be of no benefit and may even worsen RV function. They found that when pulmonary vascular resistance was normal, volume expansion increased stroke volume (SV) and mean blood pressure whereas when RV afterload was increased, this volume expansion resulted in RV failure. [GIRLING][TYBERG].</li>
                                                         </ul>
                                                         </ul>
                                                         <p><strong>The 2014 ESC guideline states that evidence to date indicates that aggressive volume expansion is of no benefit and may even worsen RV function.</strong> [ESC]</p>
                                             </div>
                                          </div>
                                    </div>
                                       
                                    <!-- CONDITIONAL COMO CONTENT -->
                                    <div class="HeartFailure-como-content CKD-como-content" style="display: none;">
                                          <div class="poce_drug_msg">
                                                <span class="material-icons">
                                                      <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                         <g>
                                                            <g>
                                                               <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                                  c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                               <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                                  c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                               <g>
                                                                  <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                               </g>
                                                            </g>
                                                            <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                               7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                         </g>
                                                         </svg>
                                                </span> 
                                                <h3 class="poce_title"></h3>
                                                <h3>Continue to monitor fluid balance particularly closely</h3>
                                                <ul>
                                                      <li>
                                                      <p><strong>Accurate monitoring of volume status is crucial in a person with heart failure and/or CKD. </strong><em>(Verbrugge FH, et al, 2014)</em></p>
                                                      <ul>
                                                      <li>There is a risk of <strong>pulmonary oedema</strong> with fluid resuscitation in patients with<strong> heart failure</strong> and/or <strong>CKD</strong> so these patients need <strong>close monitoring</strong> (every hour initially).</li>
                                                      <li><strong>Monitoring </strong>should include:</li>
                                                      <ul>
                                                      <li>Regular clinical assessment of volume status (including pulse, BP, JVP and examination for pulmonary and peripheral oedema)</li>
                                                      <li>Fluid balance monitoring (input/output chart) and daily weight</li>
                                                      <li>Checking kidney function at least daily.</li>
                                                      </ul>
                                                      <li>Consider urinary catheterisation if measurement of urinary output is difficult but be aware of increased risk of infection.</li>
                                                      <li>Central venous pressure or pulmonary artery catheterisation monitoring may be required in complex patients. <em>(Verbrugge FH, et al, 2014)</em></li>
                                                      <li>It&rsquo;s important to know when to <strong>de-escalate</strong> fluid therapy. Consider<strong> early senior input</strong> to support this decision.</li>
                                                      <li>If the patient has been volume <strong>overloaded with fluid</strong> (signs may include an elevated pulse rate, elevated respiratory rate due to pulmonary oedema, and a raised JVP with peripheral oedema), <strong>stop fluid resuscitation</strong>, ask for <strong>senior help </strong>and consider <strong>intravenous diuretics.</strong></li>
                                                      <li>Diuretics and intravenous fluids should not usually be given together as they&rsquo;re unlikely to be beneficial.</li>
                                                      </ul>
                                                      <br />
                                                      <p><strong>Specialist input may be required from a cardiologist and/or renal physician.</strong></p>
                                                      </li>
                                                      </ul>
                                             </div>
                                    </div>
                                    <!-- CONDITIONAL COMO CONTENT ends-->

                              </div>
                              <!--/.panel-body -->
                           </section>                           
                           <section style="display: none;" class="panel-group HeartFailure-como-content CKD-como-content Stroke-como-content CAD-como-content Hypertension-como-content">
                              <div class="panel-header">
                                 <p class="panel-title"> 
                                    <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_1_0_0" aria-controls="panel_1_0_0" aria-expanded="false">
                                    <span class="titles-wrap col-md-12">
                                    <span class="title-02 no-icon">
                                    <span class="title-03 col-md-1">
                                    Plus
                                    <span class="noShow">&nbsp;–&nbsp;</span>
                                    </span>
                                    <span class="title-04">
                                    <span class="material-icons"><span></span><span></span></span>
                                    <span class="txtwrap no-icon">Withhold antihypertensives and/or diuretics if hypotensive</span>
                                    </span>
                                    <span class="material-icons">
                                       <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                       <g>
                                          <g>
                                             <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                             <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                             <g>
                                                <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                             </g>
                                          </g>
                                          <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                             7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                       </g>
                                       </svg>
                                    </span>
                                    </span>
                                    </span>
                                    </a>
                                 </p>
                              </div>
                              <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_1_0_0" id="panel_1_0_0" aria-expanded="false">
                                      
                                    <!-- CONDITIONAL COMO CONTENT -->
                                    <div class="HeartFailure-como-content CKD-como-content Stroke-como-content CAD-como-content Hypertension-como-content" style="display: none;">
                                       <div class="poce_drug_msg">
                                             <span class="material-icons">
                                                   <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                      <g>
                                                         <g>
                                                            <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                               c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                            <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                               c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                            <g>
                                                               <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                            </g>
                                                         </g>
                                                         <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                            7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                      </g>
                                                      </svg>
                                             </span> 
                                             <h3 class="poce_title"></h3>
                                             <h3>Continue to monitor fluid balance particularly closely</h3>
                                             <p><strong>Consider withholding antihypertensives and/or diuretics in people with a history of hypertension, coronary heart disease, heart failure, stroke, or CKD and who usually take these medications if:</strong></p>
                                             <ul>
                                                <li><strong>The patient is hypotensive with signs of low organ perfusion, particularly if there are signs of shock. </strong>Signs of low organ perfusion include: <em>(Ponikowski, 2016)</em></strong>
                                                   <ul>
                                                      <li>Confusion</li>
                                                      <li>Shock</li>
                                                      <li>Low urine output</li>
                                                      </ul>
                                                </li>
                                                <li><strong>The patient&rsquo;s blood pressure is &ge;40 mmHg lower than baseline.</strong>
                                                   <ul>
                                                      <li>Establish the patient&rsquo;s baseline blood pressure and assess volume status.</li>
                                                      <li>Patients with treated <strong>heart failure</strong> may have<strong> chronically low blood pressure</strong> e.g., systolic BP &le;90 mmHg. In these patients it may be appropriate to withhold these medications with a reduction in systolic blood pressure &gt;10-15 mm/Hg, depending on the clinical context and after seeking expert review.</li>
                                                      </ul>
                                                </li>
                                             </ul>

                                             <p>Diuretics may be withheld <strong>temporarily</strong> but<strong> be careful</strong> in patients with<strong> heart failure</strong> and/or <strong>CKD</strong> as <strong>fluid may build up quickly</strong>.</p>
                                             <p><strong>If antihypertensives or diuretics have been withheld during the acute illness, restart them before discharge.</strong></p>
                                             <p>Most patients won&rsquo;t tolerate restarting all medications at normal doses in one go. Restart one at a time at a lower dose and <strong>ask their GP to follow up</strong> and titrate back to normal dose.</p>
                                          </div>
                                    </div>
                                    <!-- CONDITIONAL COMO CONTENT ends-->

                                       
                              </div>
                              <!--/.panel-body -->
                           </section>
                        </div>
                        <!--/.panel-body -->
                     </div>

                     <!-- /.panel-group -->
                  </div>
               </div>
            </div>
            
            <div class="card">
                  <div class="card-block">
                     <div class="container">
                        <div class="rowHead" id="acute">
                           <div class="col-md-12">
                              ACUTE
                           </div>
                        </div>
                        <div class="panel">
                           <div class="panel-heading">
                              <h3>
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" id="patientGroup-0-0">
                                 <span>Haemodynamically unstable: PE confirmed (on echocardiography or CTPA)</span>
                                 <span class="hidden-sm-down">
                                 <span class="msg">VIEW ALL</span>
                                 <span class="material-icons" role="button"><span></span><span></span></span>
                                 </span>
                                 </a>
                              </h3>
                           </div>
                           <!--/.panel-heading -->
                           <div class="panel-body">
                              <section class="panel-group">
                                 <div class="panel-header">
                                    <p class="panel-title"> 
                                       <a href="#" role="tab header" id="nested-collapse_0_0_3" aria-controls="nested-collapse_0_0_3" aria-expanded="false" class="">
                                       <span class="title-01">
                                       <span>  
                                             No contraindication to anticoagulation or thrombolysis                                                                                                                                                         
                                       </span>
                                       <span class="noShow">&nbsp;–&nbsp;</span>
                                       </span>
                                       <span class="titles-wrap col-md-12">
                                       <span class="title-02">
                                       <span class="title-03 col-md-1">
                                       1st line
                                       <span class="noShow">&nbsp;–&nbsp;</span>
                                       </span>
                                       <span class="title-04">
                                       <span class="material-icons"><span></span><span></span></span>
                                       <span class="txtwrap">Start unfractionated heparin</span>
                                       </span>
                                       </span>
                                       </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_0_0_3" id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">
                              
                                    <p><strong>Involve senior support and/or critical care in patients who are haemodynamically unstable (SBP &lt;90 mmHg or SBP drop of &ge;40 mmHg for &gt;15 minutes).</strong></p>
                                    <p><strong>Start unfractionated heparin (UFH) in haemodynamically unstable patients prior to thrombolysis.</strong></p>
                                    <ul>
                                    <li>UFH has a short half-life, is easy to monitor, and is readily reversed by protamine. [ESC]</li>
                                    </ul>
                                       <div id="tip_pitfall" class="card card-inverse mb-4">
                                       <div class="card-block">
                                          <svg version="1.1" id="pin" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 90 90" enable-background="new 0 0 90 90" xml:space="preserve">
                                          <g>
                                             <g>
                                                <path fill="#333333" d="M42.694,51.942v30.413C42.694,83.816,44.174,85,46,85s3.306-1.184,3.306-2.645V51.942H42.694z"></path>
                                             </g>
                                             <g>
                                                <ellipse fill="#333333" cx="46" cy="47.645" rx="19.835" ry="12.231"></ellipse>
                                             </g>
                                             <g id="cylinder">
                                                <polygon fill="#333333" points="55.256,9.628 46,9.628 36.744,9.628 34.099,47.975 46,47.975 57.901,47.975 		"></polygon>
                                             </g>
                                             <g id="cylinder_highlight">
                                                <polygon fill="#FFFFFF" points="54.595,46.653 50.628,47.975 49.306,13.595 53.273,13.595 		"></polygon>
                                             </g>
                                             <g>
                                                <ellipse fill="#333333" cx="46" cy="13.595" rx="15.207" ry="8.595"></ellipse>
                                             </g>
                                             <g id="highlight">
                                                <path fill="#FFFFFF" d="M47.982,18.929c-0.67,0-1.245-0.508-1.313-1.19c-0.073-0.727,0.456-1.375,1.183-1.448
                                                   c3.157-0.318,5.857-1.434,7.224-2.985c0.48-0.547,1.317-0.602,1.866-0.118c0.548,0.482,0.601,1.318,0.118,1.866
                                                   c-1.822,2.069-5.082,3.479-8.942,3.868C48.072,18.927,48.027,18.929,47.982,18.929z"></path>
                                             </g>
                                             <g>
                                                <path fill="#333333" d="M46,49.54v-1.322c4.794,0,9.917-1.192,9.917-4.54h1.322C57.239,47.349,53.038,49.54,46,49.54z"></path>
                                             </g>
                                             <g id="highlight_lower">
                                                <path fill="#FFFFFF" d="M48.011,56.926c-0.032,0-0.064,0-0.098,0c-0.73-0.003-1.319-0.598-1.316-1.328
                                                   c0.003-0.729,0.595-1.316,1.322-1.316c0.034,0,0.063,0,0.095,0c3.975,0,7.602-1.166,9.719-3.128
                                                   c0.533-0.496,1.37-0.467,1.868,0.071c0.496,0.535,0.465,1.372-0.071,1.868C56.937,55.496,52.637,56.926,48.011,56.926z"></path>
                                             </g>
                                             </g>
                                             </svg>
                                             <h3 class="card-title">In patients who are haemodynamically unstable, evidence of RV dysfunction on echocardiography is sufficient to warrant immediate anticoagulation and thrombolysis.</h3>
                                             <ul>
                                                <li>These patients are normally too unstable to undergo CTPA.</li>
                                             </ul>
                                          </div>
                                       </div>
                                       
                                       <p><strong>Continue anticoagulation with UFH for several hours after the end of thrombolysis</strong>.[ESC] In the UK it is common practice to stop UFH within 24 hours.</p>
                                       
   
                                       <div class="evidence-accordion">
                                             <div class="option">
                                                <input type="checkbox" id="toggle3" class="toggle" />
                                                <label class="title" for="toggle3">                                             
                                                   <span class="material-icons"><span></span></span>
                                                   <span class="title">Evidence: There is insufficient evidence to support use of LMWH in haemodynamically unstable (high-risk) PE</span>
                                             </label>
                                                <div class="content">
                                                   <p><strong>There is some evidence that LMWH has a similar safety profile to UFH when used prior to thrombolysis.</strong></p>                     
                                                   <ul>
                                                      <li>A prospective, observational multicentre trial showed similar bleeding rates following thrombolysis in patients who had UFH or LMWH. However this evidence remains limited.</li>
                                                      <ul>
                                                   <p><strong>There is not enough evidence  to recommend LMWH as a  first-line option for patients with PE who are haemodynamically unstable.</strong> [UCAR]</p>
                                                </div>
                                             </div>
                                          </div>
   
                                          <div class="treatment-wrap">
                                             <h4>Primary options</h4>
                                             <div class="treatment-box">
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">heparin</a><span>: </span><span>10,000 units intravenously as a loading dose initially, followed by 18 units/kg/hour intravenous infusion, adjust dose according to aPTT</span>
                                                </p>
                                             </div>
                                          </div>

                                          
                           <!-- SWITCHABLE DRUG CONTENT BOX -->
                           <div class="treatment-box-cplus mt-4 CKD-como-content">
                              <h4>Primary options</h4>
                              <div class="drug-accordion">
                           
                                 <div class="drug-content2" style="display: none">
                                    <div class="poce_drug_msg" class="warning">
                                       <span class="material-icons">
                                             <svg class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" version="1.1" id="Layer_1" x="0px" y="0px" viewBox="0 0 30 30" style="enable-background:new 0 0 30 30;" xml:space="preserve">
                                                <style type="text/css">
                                                   .st0{fill:#C50084;}
                                                </style>
                                                <path class="st0" d="M15.1,6.6L25.7,26H4.6C4.6,26,15.1,6.6,15.1,6.6z M15.1,1.5L0.4,28.5h29.4L15.1,1.5z M13.9,12.6h2.4v7.3h-2.4  V12.6z M15.1,24.5c-0.8,0-1.5-0.7-1.5-1.5s0.7-1.5,1.5-1.5s1.5,0.7,1.5,1.5S16,24.5,15.1,24.5z"/>
                                                </svg>
                                       </span> 
                                       <h3 class="cplus_title">These drug options and doses relatae to a patient with <strong>no comorbidities.</strong></h3>
                                    </div> 
                                    <div class="treatment-box">
                                       <p>
                                          <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">heparin</a><span>: </span><span>10,000 units intravenously as a loading dose initially, followed by 18 units/kg/hour intravenous infusion, adjust dose according to aPTT</span>
                                       </p>
                                    </div>
                                    <p class="como_link mt-4 drug-title2"><a href="#">&#9664; Back to drug doeses with added comorbidities</a></p>
                                 </div>
                           
                                 <div class="drug-content1">
                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                          <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                             <g>
                                                <g>
                                                   <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                      c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                   <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                      c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                   <g>
                                                      <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                   </g>
                                                </g>
                                                <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                   7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                             </g>
                                             </svg>
                                       </span> 
                                       <h3 class="cplus_title">Drug choice, dose and interactions may be affected by the patient's comorbidities. Check your local drug formulary.</h3>
                                    </div> 
                                    <div class="treatment-box">
                                       <p>
                                          <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">heparin:</a> 
                                       </p>
                                       <p>For patients with renal impairment <a href="#" data-toggle="modal" data-target="#renal">see dose in the Renal Drug Handbook</a></p>
                                       <div class="modal fade" id="renal" tabindex="-1" role="dialog" aria-labelledby="renal" aria-hidden="true" style="display: none;">       
                                          <div class="modal-dialog" role="document" style="max-width: 50rem;">
                                             <div class="modal-content">
                                                <div class="modal-header" style="background: #fff; margin-top: 1rem;">
                                                   <h3 class="modal-title" id="exampleModalLabel" style="color:#c50084;margin: 0 0 1.5rem 0;text-align: center;">The Renal Handbook<br/></h3>
                                                </div>
                                                <iframe width="100%" height="700" src="../pdf/renalbook.pdf" title="Renal Book"></iframe>
                                             </div>
                                          </div>
                                       </div> 
                                       
                                    </div>                                            
                                    <p class="como_link mt-4 drug-title1"><a href="#">&#9664; Show drug doses for a patient with no comorbidities</a></p>
                                 </div>
                              </div>                                          
                           </div>                                 
                           <!-- DRUG CONTENT BOX ENDS -->
                                             
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group">
                                 <div class="panel-header">
                                    <p class="panel-title"> 
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_0_0" aria-controls="panel_0_0_0" aria-expanded="false">
                                       <span class="titles-wrap col-md-12">
                                       <span class="title-02 no-icon">
                                          <span class="title-03 col-md-1">
                                                Plus
                                          <span class="noShow">&nbsp;–&nbsp;</span>
                                          </span>
                                          <span class="title-04">
                                          <span class="material-icons"><span></span><span></span></span>
                                          <span class="txtwrap ">
                                                Thrombolysis     
                                          </span>
                                          </span>
                                          <span class="material-icons">
                                             <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                             <g>
                                                <g>
                                                   <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                      c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                   <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                      c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                   <g>
                                                      <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                   </g>
                                                </g>
                                                <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                   7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                             </g>
                                             </svg>
                                          </span>                
                                       </span>
                                       </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_0_0_0" id="panel_0_0_0" aria-expanded="false">
                                       <p><strong>Emergency primary reperfusion is indicated for any haemodynamically unstable patient with: [ESC]</strong></p>
                                       <li><strong>PE confirmed on CTPA </strong></li>
                                       <li><strong>Suspected PE and unequivocal signs of RV dysfunction on echocardiography</strong> (if CTPA is not immediately available and/or the patient is too unwell to undergo CTPA).</li>
                                       <li><strong>Thrombolysis is the first-line intervention for most patients. </strong>Surgical embolectomy or catheter-directed therapy are alternatives. [ESC]</li>
                                       <p><strong>Administer thrombolysis (unless contraindicated) to any patient with SBP &lt;90 mmHg or who has other signs of shock. </strong></p>
                                       <ul>
                                       <li>Systemic thrombolysis is associated with <strong>lower all-cause mortality</strong> in these patients when compared with UFH alone. [ESC] [CARDIO]</li>
                                       </ul>
                                       <p><strong>Give thrombolysis as soon as possible and certainly within 48 hours of symptom onset to ensure optimum benefit.</strong> [ESC]</p>
                                       <p><strong>Select an accelerated regimen administered over 2 hours.</strong></p>
                                       <p>These regimens are preferred to prolonged infusions over 12-24 hours. The European Society of Cardiology guideline recommends <strong>alteplase, streptokinase, and urokinase </strong>as approved thrombolytics for acute PE. [ESC] Alteplase and higher-dose streptokinase are administered over 2 hours; whereas, lower-dose streptokinase and urokinase are administered over 12 to 24 hours.</p>
   
                                       <div class="evidence-accordion">
                                          <div class="option">
                                             <input type="checkbox" id="toggle4" class="toggle" />
                                             <label class="title" for="toggle4">                                             
                                                <span class="material-icons"><span></span></span>
                                                <span class="title">Evidence: Most patients with high-risk PE respond to early thrombolysis</span>
                                          </label>
                                             <div class="content">
                                                <p><strong>Thrombolysis in the treatment of acute haemodynamically unstable PE has been shown to restore pulmonary perfusion more rapidly than anticoagulation with UFH alone.</strong></p>
                                                <ul>
                                                <li>An RCT of 36 patients concluded that use of alteplase, compared with heparin, resulted in a greater and faster improvement of angiographic and hemodynamic variables. However, the high frequency of bleeding observed with alteplase in this trial suggests that patients should be carefully selected before thrombolytic therapy is given. [PENGO]</li>
                                                </ul>
                                                <p><strong>Overall, &gt;90% of patients appear to respond favourably to thrombolysis</strong>.</p>
                                                <ul>
                                                <li>This was demonstrated in a prospective single-centre registry of 488 PE patients who underwent thrombolysis as judged by clinical and echocardiographic improvement within 36 hours. [BLONDE]</li>
                                                <li>Among the minority of patients with high-risk PE who did not respond to thrombolysis, rescue surgical embolectomy led to lower mortality rates and fewer recurrent PEs when compared with repeat thrombolysis.</li>
                                                </ul>
                                                <p><strong>Thrombolysis has greatest benefit when given early after symptom onset.</strong></p>
                                                <ul>
                                                   <li>An overview of 308 PE patients from 5 clinical trials who underwent thrombolysis for PE showed an inverse relation between duration of symptoms and improvement on post-treatment lung scan reperfusion scores. For each additional day of symptoms before thrombolysis, there was a decrease of 0.8% in lung tissue reperfusion. Similarly, on angiography, less clot lysis was observed immediately after thrombolysis in the group with the longest duration of symptoms compared with those with the shortest symptom duration.</li>
                                                   <li>However the authors concluded that thrombolysis may still have some benefit in patients who have had symptoms for 6 to 14 days. [AM]</li>
                                                   </ul>
                                             </div>
                                          </div>
                                       </div>
   
                                       <div id="tip_pitfall" class="card card-inverse mb-4">
                                          <div class="card-block">
                                             <svg version="1.1" id="pin" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 90 90" enable-background="new 0 0 90 90" xml:space="preserve">
                                             <g>
                                                <g>
                                                   <path fill="#333333" d="M42.694,51.942v30.413C42.694,83.816,44.174,85,46,85s3.306-1.184,3.306-2.645V51.942H42.694z"></path>
                                                </g>
                                                <g>
                                                   <ellipse fill="#333333" cx="46" cy="47.645" rx="19.835" ry="12.231"></ellipse>
                                                </g>
                                                <g id="cylinder">
                                                   <polygon fill="#333333" points="55.256,9.628 46,9.628 36.744,9.628 34.099,47.975 46,47.975 57.901,47.975 		"></polygon>
                                                </g>
                                                <g id="cylinder_highlight">
                                                   <polygon fill="#FFFFFF" points="54.595,46.653 50.628,47.975 49.306,13.595 53.273,13.595 		"></polygon>
                                                </g>
                                                <g>
                                                   <ellipse fill="#333333" cx="46" cy="13.595" rx="15.207" ry="8.595"></ellipse>
                                                </g>
                                                <g id="highlight">
                                                   <path fill="#FFFFFF" d="M47.982,18.929c-0.67,0-1.245-0.508-1.313-1.19c-0.073-0.727,0.456-1.375,1.183-1.448
                                                      c3.157-0.318,5.857-1.434,7.224-2.985c0.48-0.547,1.317-0.602,1.866-0.118c0.548,0.482,0.601,1.318,0.118,1.866
                                                      c-1.822,2.069-5.082,3.479-8.942,3.868C48.072,18.927,48.027,18.929,47.982,18.929z"></path>
                                                </g>
                                                <g>
                                                   <path fill="#333333" d="M46,49.54v-1.322c4.794,0,9.917-1.192,9.917-4.54h1.322C57.239,47.349,53.038,49.54,46,49.54z"></path>
                                                </g>
                                                <g id="highlight_lower">
                                                   <path fill="#FFFFFF" d="M48.011,56.926c-0.032,0-0.064,0-0.098,0c-0.73-0.003-1.319-0.598-1.316-1.328
                                                      c0.003-0.729,0.595-1.316,1.322-1.316c0.034,0,0.063,0,0.095,0c3.975,0,7.602-1.166,9.719-3.128
                                                      c0.533-0.496,1.37-0.467,1.868,0.071c0.496,0.535,0.465,1.372-0.071,1.868C56.937,55.496,52.637,56.926,48.011,56.926z"></path>
                                                </g>
                                                </g>
                                                </svg>
                                                <h3 class="card-title">Seek haematology advice if a patient with high-risk PE who is haemodynamically unstable has any contraindications to thrombolysis.</h3>
                                                <ul>
                                                   <li>In practice, almost any contraindication to thrombolysis should be considered only relative in high-risk patients who present with haemodynamic instability.</li>
                                                   <li>This is because the mortality risk from high-risk PE is so high that it is likely to outweigh any bleeding risk from thrombolysis in this patient group. [ESC]</li>
                                                   </ul>
                                                   <p><strong>Absolute contraindications: [ESC]</strong></p>
                                                   <ul>
                                                   <li>haemorrhagic stroke or stroke of unknown origin at any time</li>
                                                   <li>ischaemic stroke in the preceding 6 months</li>
                                                   <li>central nervous system damage or neoplasms</li>
                                                   <li>recent major trauma/surgery/head injury (in the preceding 3 weeks)</li>
                                                   <li>gastrointestinal bleeding within the last month</li>
                                                   <li>known bleeding risk.</li>
                                                   </ul>
                                                   <p><strong>Relative contraindications:</strong></p>
                                                   <ul>
                                                   <li>transient ischaemic attack in the preceding 6 months</li>
                                                   <li>oral anticoagulant therapy</li>
                                                   <li>pregnancy or within 1 week postnatally</li>
                                                   <li>traumatic resuscitation (in relation to this episode of PE)</li>
                                                   <li>refractory hypertension (SBP &gt;180 mmHg)</li>
                                                   <li>advanced liver disease</li>
                                                   <li>infective endocarditis</li>
                                                   <li>active peptic ulcer</li>
                                                   </ul>
                                             </div>
                                          </div>
   
                                          <div class="evidence-accordion">
                                             <div class="option">
                                                <input type="checkbox" id="toggle5" class="toggle" />
                                                <label class="title" for="toggle5">                                             
                                                   <span class="material-icons"><span></span></span>
                                                   <span class="title">Evidence: Thrombolysis carries a significant risk of major bleeding, including  intracranial bleeding</span>
                                             </label>
                                                <div class="content">
                                                   <ul>
                                                      <li>Analysis of pooled data from trials using various thrombolytic agents and regimens reported intracranial bleeding rates between 1.9% and 2.2%. [PARKER][CALIFF]</li>
                                                      <li>Increasing age and the presence of comorbidities have been associated with a higher risk of bleeding complications.[MIKKOLA]</li>
                                                      <li>The PEITHO trial showed a 2% incidence of haemorrhagic stroke after thrombolytic treatment with tenecteplase (versus 0.2% in the placebo arm) in patients with intermediate-high-risk PE. Major non-intracranial bleeding events were also increased in the tenecteplase group, compared with placebo (6.3% vs. 1.5%; <em>P &lt;</em> 0.001). [VICAUT] Note that tenecteplase is not licensed for use in PE.</li>
                                                      <li>These results underline the need to improve the safety of thrombolytic treatment in patients at increased risk of intracranial or other life-threatening bleeding.</li>
                                                      <li>A strategy using reduced-dose alteplase appeared to be safe in the setting of &lsquo;moderate&rsquo; PE in a study that included 121 patients,[SHARIFI] and another trial on 118 patients with haemodynamic instability or &lsquo;massive pulmonary obstruction&rsquo; reported similar results. [WU]</li>
                                                      <li>An alternative approach may consist of local, catheter-delivered, ultrasound-assisted thrombolysis using small doses of a thrombolytic agent. [ESC]</li>
                                                   </ul>
                                                </div>
                                             </div>
                                          </div>
                                          <p><strong>Do not give routine thrombolysis to patients who have SBP &gt;90 mmHg but have significant evidence of cardiopulmonary deterioration</strong>. [ESC] [SPRINGER]</p>
                                          <ul>
                                          <li><strong>Routine thrombolysis is not recommended in most major guidelines for this intermediate-risk group even if signs of both right ventricular dysfunction and myocardial injury (positive cardiac biomarkers) are initially present.</strong></li>
                                          <li>In these patients, use of systemic thrombolysis is associated with a <strong>mortality benefit</strong> but it significantly <strong>increases the risk of bleeding</strong>, including intracranial haemorrhage. [CARDIO]</li>
                                          <li>Patients in this intermediate risk group should receive anticoagulation and be monitored closely over at least 48 to 72 hours. Rescue thrombolysis should be considered if there are clinical signs of haemodynamic decompensation and the benefits/risks of thrombolysis have been weighed up by a specialist after taking account of the patient&rsquo;s comorbidities. [KONST][ESC][CHEST]</li>
                                          </ul>
   
   
                                          <div class="evidence-accordion">
                                             <div class="option">
                                                <input type="checkbox" id="toggle6" class="toggle" />
                                                <label class="title" for="toggle6">                                             
                                                   <span class="material-icons"><span></span></span>
                                                   <span class="title">Evidence does not support the routine use of thrombolysis in patients with intermediate-risk PE</span>
                                             </label>
                                                <div class="content">
                                                   <p>Current European guidelines do not recommend giving thrombolysis routinely in patients with intermediate-risk PE. Evidence suggests it carries an unacceptably high bleeding risk in this group.</p>
                                                   <p><strong>Current European guidelines do not recommend giving thrombolysis routinely in patients with intermediate-risk PE. Evidence suggests it carries an unacceptably high bleeding risk in this group. </strong>[ESC][CHEST] .</p>
                                                   <ul>
                                                   <li>The intermediate-risk group is defined by a PESI score of III-V or an sPESI score &ge;1. (see Risk Stratification below)</li>
                                                   <li>The international PEITHO (Pulmonary Embolism Thrombolysis) trial compared a single intravenous bolus of tenecteplase plus heparin with placebo plus heparin in 1,006 patients with confirmed PE, right ventricular dysfunction detected by echocardiography or CT, and a positive troponin I or T test.</li>
                                                   <li>In the thrombolysis group, haemodynamic decompensation/collapse or death within 7 days occurred less frequently than in the group receiving heparin alone.</li>
                                                   <li>However, in the thrombolysis group compared with the placebo group, there was also a higher incidence of haemorrhagic stroke (2.0% vs 0.2%) and major non-intracranial bleeding (6.3% vs 1.5%).</li>
                                                   </ul>
                                                </div>
                                             </div>
                                          </div>
                                          
                                          <div class="treatment-wrap">
                                             <h4>Primary options</h4>
                                             <div class="treatment-box">
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">alteplase</a>
                                                   <span>: </span>
                                                   <span>10 mg intravenous bolus over 1-2 minutes, followed by 90 mg intravenous infusion over 2 hours, maximum 1.5 mg/kg/total dose in patients &lt;65 kg body weight</span>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">streptokinase:</a>
                                                   <span>: </span>
                                                   <span>1,500,000 units by intravenous infusion over 1-2 hours; or 250,000 units by intravenous infusion over 30 minutes, followed by 100,000 units/hour for 24 hours</span> 
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p>
                                                   <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">urokinase</a>
                                                   <span>: </span>
                                                   <span>4400 units/kg by intravenous infusion over 10-20 minutes, followed by 4400 units/kg/hour for 12 hours</span>
                                                </p>
                                             </div>
                                          </div>
   
                                 </div>
                                 
                              </section>
                              <section class="panel-group">
                                 <div class="panel-header">
                                    <p class="panel-title"> 
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_0_1" aria-controls="panel_0_0_1" aria-expanded="false">
                                       <span class="titles-wrap col-md-12">
                                       <span class="title-02 no-icon">
                                          <span class="title-03 col-md-1">
                                          Plus
                                          <span class="noShow">&nbsp;–&nbsp;</span>
                                          </span>
                                          <span class="title-04">
                                          <span class="material-icons"><span></span><span></span></span>
                                          <span class="txtwrap">Switch to alternative anticoagulant</span>
                                          </span>
                                          <span class="material-icons">
                                             <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                             <g>
                                                <g>
                                                   <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                      c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                   <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                      c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                   <g>
                                                      <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                   </g>
                                                </g>
                                                <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                   7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                             </g>
                                             </svg>
                                          </span>
                                       </span>
                                       </span>
                                       </a>
                                    </p>
                                 </div>
   
                                 <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_0_0_1" id="panel_0_0_1" aria-expanded="false">
                                    
                                       <p><strong>Continue anticoagulation with UFH for several hours after the end of thrombolysis before switching to a low molecular weight heparin (LMWH), fondaparinux, apixaban, or rivaroxaban</strong>.[ESC] In the UK it is common practice to stop UFH within 24 hours.</p>
                                       <ul>
                                       <li><strong>If switching to LMWH  (e.g,.  dalteparin, enoxaparin) or fondaparinux, the total duration of treatment with UFH and then LMWH or fondaparinux should be at least 5 days.</strong>[NICE][ESC]</li>
                                       <ul>
                                       <li>If ongoing anticoagulation will be with warfarin, ensure overlap with UFH, LMWH, or fondaparinux for at least 5 days or until the INR is &ge;2 for at least 24 hours (whichever is the longer).[NICE] Seek specialist advice to decide when to start warfarin.</li>
                                       </ul>
                                       </ul>
                                       <p><strong>OR</strong></p>
                                       <ul>
                                       <ul>
                                       <li>If ongoing anticoagulation will be with edoxaban or dabigatran, at least 5 days of lead-in therapy with LMWH or fondaparinux is required first. Stop the LMWH or fondaparinux before starting dabigatran or edoxaban.[BTS]</li>
                                       </ul>
                                       <li><strong>If switching to rivaroxaban or apixaban, these drugs may be started after stopping UFH without the need for lead-in therapy with  LMWH or fondaparinux  first</strong>.</li>
                                       <ul>
                                       <li>Acute-phase treatment consists of an increased dose of the oral anticoagulant over the first 3 weeks (for rivaroxaban), or over the first 7 days (for apixaban).</li>
                                       </ul>
                                       </ul>
                                       <p><strong>Seek specialist advice when switching between anticoagulants</strong></p>
                                       <ul>
                                       <li>The protocol depends on which anticoagulant you are switching to and from. Haematology input is important.</li>
                                       </ul>
                                       <p><br /><strong>Be aware of special patient groups such as pregnancy, renal impairment, and active cancer</strong> as these groups will need a specific type/dose of anticoagulant. <strong>Seek haematology advice for all patients with hepatic impairment or who are at increased risk of bleeding.</strong></p>
   
                                       <div id="tip_pitfall" class="card card-inverse mb-4">
                                          <div class="card-block">
                                             <svg version="1.1" id="pin" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 90 90" enable-background="new 0 0 90 90" xml:space="preserve">
                                             <g>
                                             <g>
                                                <path fill="#333333" d="M42.694,51.942v30.413C42.694,83.816,44.174,85,46,85s3.306-1.184,3.306-2.645V51.942H42.694z"></path>
                                             </g>
                                             <g>
                                                <ellipse fill="#333333" cx="46" cy="47.645" rx="19.835" ry="12.231"></ellipse>
                                             </g>
                                             <g id="cylinder">
                                                <polygon fill="#333333" points="55.256,9.628 46,9.628 36.744,9.628 34.099,47.975 46,47.975 57.901,47.975 		"></polygon>
                                             </g>
                                             <g id="cylinder_highlight">
                                                <polygon fill="#FFFFFF" points="54.595,46.653 50.628,47.975 49.306,13.595 53.273,13.595 		"></polygon>
                                             </g>
                                             <g>
                                                <ellipse fill="#333333" cx="46" cy="13.595" rx="15.207" ry="8.595"></ellipse>
                                             </g>
                                             <g id="highlight">
                                                <path fill="#FFFFFF" d="M47.982,18.929c-0.67,0-1.245-0.508-1.313-1.19c-0.073-0.727,0.456-1.375,1.183-1.448
                                                   c3.157-0.318,5.857-1.434,7.224-2.985c0.48-0.547,1.317-0.602,1.866-0.118c0.548,0.482,0.601,1.318,0.118,1.866
                                                   c-1.822,2.069-5.082,3.479-8.942,3.868C48.072,18.927,48.027,18.929,47.982,18.929z"></path>
                                             </g>
                                             <g>
                                                <path fill="#333333" d="M46,49.54v-1.322c4.794,0,9.917-1.192,9.917-4.54h1.322C57.239,47.349,53.038,49.54,46,49.54z"></path>
                                             </g>
                                             <g id="highlight_lower">
                                                <path fill="#FFFFFF" d="M48.011,56.926c-0.032,0-0.064,0-0.098,0c-0.73-0.003-1.319-0.598-1.316-1.328
                                                   c0.003-0.729,0.595-1.316,1.322-1.316c0.034,0,0.063,0,0.095,0c3.975,0,7.602-1.166,9.719-3.128
                                                   c0.533-0.496,1.37-0.467,1.868,0.071c0.496,0.535,0.465,1.372-0.071,1.868C56.937,55.496,52.637,56.926,48.011,56.926z"></path>
                                             </g>
                                             </g>
                                             </svg>
                                             <h3 class="card-title">Never give a DOAC simultaneously with parenteral anticoagulation</h3>
                                             <ul>
                                                <li>While warfarin is started at the same time as a parenteral anticoagulant and overlapped for at least 5 days or until the INR is &ge;2 for at least 24 hours (whichever is the longer), DOACs should never be overlapped or given at the same time as a parenteral anticoagulant.</li>
                                                <li>Apixaban and rivaroxaban may be started without the need for lead-in therapy with a parenteral anticoagulant first. Either of these DOACs can be used as a single-drug approach; this is why BTS guidelines recommend them as the preferred DOAC options in any patient who might be suitable for early discharge. [BTS]</li>
                                                <li>However, dabigatran and edoxaban require at least 5 days lead-in therapy with a parenteral anticoagulant before starting treatment. The parenteral anticoagulant should be stopped before dabigatran or edoxaban are started.</li>
                                                </ul>
                                          </div>
                                       </div>
                                       <div class="treatment-wrap">
                                          <h4>Primary options</h4>
                                          <div class="treatment-box">
                                             <p><strong>[No special considerations]</strong></p>
                                             <p>
                                                <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">apixaban</a>
                                                <span>: </span>
                                                <span>10 mg orally twice daily for 7 days, followed by 5 mg twice daily</span>
                                             </p>
                                             <p class="small-or">OR</p>
                                             <p><strong>[No special considerations]</strong></p>
                                             <p>
                                                <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">rivaroxaban:</a>
                                                <span>: </span>
                                                <span>15 mg orally twice daily for 21 days, followed by 20 mg once daily</span> 
                                             </p>
                                             <p class="small-or">OR</p>
                                             <p><strong>[No special considerations]</strong></p>
                                             <p>
                                                <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">enoxaparin</a>
                                                <span>: </span>
                                                <span>1 mg/kg subcutaneously every 12 hours</span>
                                             </p>
                                             <p class="small-or">OR</p>                                          
                                             <p>
                                                <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">dalteparin</a>
                                                <span>: </span>
                                                <span>100 units/kg subcutaneously every 12 hours</span>
                                             </p>
                                             <p class="small-or">AND</p>                                       
                                             <p>
                                                <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">warfarin</a>
                                                <span>: </span>
                                                <span>5-10 mg orally once daily initially, adjust dose according to target INR</span>
                                             </p>
                                             <span class="reference">
                                                <a href="#referencePop-more8" data-trigger="click focus" data-toggle="popover" class="morePop" data-original-title="" title="" aria-describedby="popover621629">More</a>
                                                <span class="popTitle" aria-hidden="true"></span>
                                                <span class="popText" aria-hidden="true">
                                                   <p class="w-75">
                                                         Starting dose can be calculated using an online tool that takes patient characteristics and/or CYP2C9/VKORC1 genotype information (if available) into account. [ONLINE RESOURCE: Warfarin dosing http://www.warfarindosing.org/Source/Home.aspx]
                                                   </p>
                                                </span>
                                             </span>
                                             <p class="small-or">OR</p>  
                                             <p><strong>[No special considerations]</strong></p>                                         
                                             <p>
                                                <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">enoxaparin</a>
                                                <span>: </span>
                                                <span>1 mg/kg subcutaneously every 12 hours</span>
                                             </p>
                                             <p class="small-or">OR</p>  
                                             <p><strong>[No special considerations]</strong></p>                                        
                                             <p>
                                                <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">dalteparin</a>
                                                <span>: </span>
                                                <span>200 units/kg subcutaneously once daily for the first 30 days, followed by 150 units/kg once daily for 5 months, maximum 18,000 units/dose</span>
                                             </p>
                                             <span class="reference">
                                                <a href="#referencePop-more1" data-trigger="click focus" data-toggle="popover" class="morePop" data-original-title="" title="" aria-describedby="popover621629">More</a>
                                                <span class="popTitle" aria-hidden="true"></span>
                                                <span class="popText" aria-hidden="true">
                                                   <p class="w-75">Refer to local drug formulary for a table of recommended weight-based doses. Use fixed-dose syringes for this indication.</p>
                                                </span>
                                             </span>
                                             <p class="small-or">OR</p>  
                                             <p><strong>[No special considerations]</strong></p>                                        
                                             <p>
                                                <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">enoxaparin</a>
                                                <span>: </span>
                                                <span>body weight &lt;50 kg: 40 mg subcutaneously twice daily; body weight 50-69 kg: 60 mg subcutaneously twice daily; body weight 70-89 kg: 80 mg subcutaneously twice daily; body weight ≥90 kg: 100 mg subcutaneously twice daily </span>
                                             </p>
                                             
                                             <span class="reference">
                                                <a href="#referencePop-more2" data-trigger="click focus" data-toggle="popover" class="morePop" data-original-title="" title="" aria-describedby="popover621629">More</a>
                                                <span class="popTitle" aria-hidden="true"></span>
                                                <span class="popText" aria-hidden="true">
                                                   <p class="w-75">Dose based on early pregnancy body weight.</p>
                                                </span>
                                             </span>
                                             <p class="small-or">OR</p>  
                                             <p><strong>[No special considerations]</strong></p>                                        
                                             <p>
                                                <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">dalteparin</a>
                                                <span>: </span>
                                                <span>body weight &lt;50 kg: 5000 units subcutaneously twice daily; body weight 50-69 kg: 6000 units subcutaneously twice daily; body weight 70-89 kg: 8000 units subcutaneously twice daily; body weight ≥90 kg: 10,000 units subcutaneously twice daily </span>
                                             </p>
                                             <span class="reference">
                                                <a href="#referencePop-more3" data-trigger="click focus" data-toggle="popover" class="morePop" data-original-title="" title="" aria-describedby="popover621629">More</a>
                                                <span class="popTitle" aria-hidden="true">
                                                </span>
                                                <span class="popText" aria-hidden="true">
                                                   <p class="w-75">Dose based on early pregnancy body weight.</p>
                                                </span>
                                             </span>
                                             <p class="small-or">Secondary options</p>  
                                             <p><strong>[No special considerations]</strong></p>                                        
                                             <p>
                                                <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">fondaparinux</a>
                                                <span>: </span>
                                                <span>body weight &lt;50 kg: 5 mg subcutaneously once daily; body weight 50-100 kg: 7.5 mg subcutaneously once daily; body weight ≥100 kg: 10 mg subcutaneously once daily
                                                </span>
                                             </p>
                                             <span class="reference">
                                                <a href="#referencePop-more4" data-trigger="click focus" data-toggle="popover" class="morePop" data-original-title="" title="" aria-describedby="popover621629">More</a>
                                                <span class="popTitle" aria-hidden="true">
                                                </span>
                                                <span class="popText" aria-hidden="true">
                                                   <p class="w-75">Dose based on early pregnancy body weight.</p>
                                                </span>
                                             </span>
                                             <p class="small-or">AND</p>                                
                                             <p>
                                                <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">warfarin</a>
                                                <span>: </span>
                                                <span>5-10 mg orally once daily initially, adjust dose according to target INR</span>
                                             </p>
                                             <span class="reference">
                                                <a href="#referencePop-more5" data-trigger="click focus" data-toggle="popover" class="morePop" data-original-title="" title="" aria-describedby="popover621629">More</a>
                                                <span class="popTitle" aria-hidden="true">
                                                </span>
                                                <span class="popText" aria-hidden="true">
                                                   <p class="w-75">Starting dose can be calculated using an online tool that takes patient characteristics and/or CYP2C9/VKORC1 genotype information (if available) into account. [ONLINE RESOURCE: Warfarin dosing http://www.warfarindosing.org/Source/Home.aspx]
                                                      </p>
                                                </span>
                                             </span>
                                             <p class="small-or">OR</p>  
                                             <p><strong>[No special considerations]</strong></p>                                        
                                             <p>
                                                <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">edoxaban</a>
                                                <span>: </span>
                                                <span>start following initial use of a parenteral anticoagulant for at least 5 days; body weight &lt;60 kg: 30 mg orally once daily; body weight ≥60 kg: 60 mg orally once daily</span>
                                             </p>
                                             <p class="small-or">OR</p>  
                                             <p><strong>[No special considerations]</strong></p>                                        
                                             <p>
                                                <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">dabigatran</a>
                                                <span>: </span>
                                                <span>start following initial use of a parenteral anticoagulant for at least 5 days; 18-74 years of age: 150 mg orally twice daily; 75-79 years of age: 110-150 mg orally twice daily; ≥80 years of age: 110 mg orally twice daily</span>
                                             </p>
                                          </div>
                                       </div>
                                    
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group">
                                 <div class="panel-header">
                                    <p class="panel-title"> 
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_0_2" aria-controls="panel_0_0_2" aria-expanded="false">
                                       <span class="titles-wrap col-md-12">
                                       <span class="title-02 no-icon">
                                          <span class="title-03 col-md-1">
                                             Consider
                                          <span class="noShow">&nbsp;–&nbsp;</span>
                                          </span>
                                          <span class="title-04">
                                             <span class="material-icons"><span></span><span></span></span>
                                             <span class="txtwrap">
                                                   Vasoactive drug
                                             </span>
                                          </span>
                                          <span class="material-icons">
                                             <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                             <g>
                                                <g>
                                                   <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                      c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                   <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                      c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                   <g>
                                                      <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                   </g>
                                                </g>
                                                <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                   7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                             </g>
                                             </svg>
                                          </span>
                                       </span>
                                       </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_0_0_2" id="panel_0_0_2" aria-expanded="false">
                                    <!--  Consider/PLUS DISCLAIMER -->
                                    <p><strong>Give a vasopressor such as adrenaline (epinephrine) or noradrenaline (norepinephrine), or an inotrope such as dobutamine if SBP remains &lt;90 mmHg after thrombolysis </strong>[ESC]</p>
                                    <ul>
                                    <li>In haemodynamically unstable patients, use of a vasopressor or inotrope is often needed in parallel with reperfusion. [ESC]</li>
                                    </ul>
                           
                           
                           <div class="evidence-accordion">
                                 <div class="option">
                                    <input type="checkbox" id="toggle7" class="toggle" />
                                    <label class="title" for="toggle7">                                             
                                       <span class="material-icons"><span></span></span>
                                       <span class="title">Evidence: Choice of vasopressor is based on limited evidence</span>
                                 </label>
                                    <div class="content">
                                       <p><strong>Adrenaline combines the beneficial properties of noradrenaline (vasoconstriction with increased right ventricular perfusion, positive inotropy) and dobutamine (positive inotropy), but without the vasodilatory effects associated with the latter.</strong> [ESC]</p>
                                       <ul>
                                       <li>A small prospective descriptive study of patients with RV failure and shock demonstrated that during adrenaline infusion, mean arterial pressure (MAP), cardiac index (CI) and stroke volume index (SVI) were increased and right ventricular ejection fraction (RVEF) improved as well.</li>
                                       <li>Another small study showed that adrenaline improved cardiac output in patients with shock without having a detrimental effect on pulmonary vascular resistance. [BARRINGTON]</li>
                                       </ul>
                                       <p><strong>Evidence suggests that noradrenaline appears to improve RV function through its inotropic effect, as well as improving coronary perfusion by raising systemic pressure.</strong></p>
                                       <ul>
                                       <li>However, noradrenaline increases pulmonary vascular resistance and, in fact, no conclusive data are available regarding its potential use in PE. [PREWITT]</li>
                                       </ul>
                                       <p><strong>The use of dobutamine and/or dopamine may be considered for patients with PE, low cardiac index, and normal BP based on the results of some studies.</strong></p>
                                       <ul>
                                       <li>Dobutamine enhances contractility with an increase in stroke volume and cardiac output. However, raising the cardiac index above physiological values may aggravate the ventilation&ndash;perfusion mismatch by further redistributing ﬂow from (partly) obstructed to unobstructed vessels. [DIS][ESC]</li>
                                       </ul>
                                    </div>
                                 </div>
                              </div>                                       
                              <div class="treatment-wrap">
                                    <h4>Primary options</h4>
                                    <div class="treatment-box">
                                       <p>
                                          <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">adrenaline (epinephrine)</a>
                                          <span>: </span>
                                          <span>2-10 micrograms/minute by intravenous infusion initially, adjust dose according to response</span>
                                       </p>
                                       <p class="small-or">OR</p>
                                       <p>
                                          <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">noradrenaline (norepinephrine):</a>
                                          <span>: </span>
                                          <span> 0.4 to 0.8 mg/hour by intravenous infusion initially, adjust dose according to response</span> 
                                       </p>
                                       <span class="reference">
                                          <a href="#referencePop-more6" data-trigger="click focus" data-toggle="popover" class="morePop" data-original-title="" title="" aria-describedby="popover621629">More</a>
                                          <span class="popTitle" aria-hidden="true"></span>
                                          <span class="popText" aria-hidden="true">
                                             <p class="w-75">
                                                   Dose refers to noradrenaline base.
                                             </p>
                                          </span>
                                       </span>
                                       <p class="small-or">OR</p>
                                       <p>
                                          <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">dobutamine</a>
                                          <span>: </span>
                                          <span>2.5 to 10 micrograms/kg/minute by intravenous infusion initially, adjust dose according to response, maximum 40 micrograms/kg/minute</span>
                                       </p>
                                    </div>
                                 </div>                                  
                                    
                                 
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group">
                                 <div class="panel-header">
                                    <p class="panel-title"> 
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                       <span class="titles-wrap col-md-12">
                                       <span class="title-02 no-icon">
                                          <span class="title-03 col-md-1">
                                          Consider
                                          <span class="noShow">&nbsp;–&nbsp;</span>
                                          </span>
                                          <span class="title-04">
                                          <span class="material-icons"><span></span><span></span></span>
                                          <span class="txtwrap">Surgical embolectomy/percutaneous catheter-directed treatment</span>
                                          </span>
                                          <span class="material-icons">
                                             <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                             <g>
                                                <g>
                                                   <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                      c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                   <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                      c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                   <g>
                                                      <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                   </g>
                                                </g>
                                                <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                   7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                             </g>
                                             </svg>
                                          </span>
                                       </span>
                                       </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_0_0_3" id="panel_0_0_3" aria-expanded="false">
                                       <p><strong>If thrombolysis has failed the use of these interventions will depend on local expertise and availability.</strong></p>
                                       <p><strong>According to the European Society of Cardiology guidelines [ESC] [CTS], surgical embolectomy or percutaneous catheter-directed therapy may be indicated in the following circumstances: </strong></p>
                                       <ul>
                                       <li>Patients who are unable to receive thrombolytic therapy because of bleeding risk</li>
                                       <li>Insufficient time for effective systemic thrombolysis</li>
                                       <li>Failed thrombolysis</li>
                                       </ul>
                                       <p><strong>Surgical pulmonary embolectomy</strong></p>
                                       <ul>
                                       <li>Although this is rarely performed in the UK, the ESC guideline states that is technically a relatively simple operation although in practice it is normally only undertaken in specialist cardiothoracic centres. [ESC]</li>
                                       </ul>
                                       <p><strong>Catheter-directed therapy</strong></p>
                                       <ul>
                                       <li>Catheter-directed therapy uses a lower dose of thrombolytic drug (approximately one third of full-dose systemic thrombolysis) and is believed to reduce the risks of bleeding at remote sites(e.g. Intracranial or gastrointestinal). [KEARON]</li>
                                       <li>For patients with absolute contraindications to thrombolysis, interventional options include: [ESC]</li>
                                       <ul>
                                       <li>thrombus fragmentation with pigtail or balloon catheter,</li>
                                       <li>rheolytic thrombectomy with hydrodynamic catheter devices,</li>
                                       <li>suction thrombectomy with aspiration catheters</li>
                                       <li>rotational thrombectomy.</li>
                                       </ul>
                                       <li>For patients with relative contraindications to thrombolysis, interventional options include:[ESC]</li>
                                       <ul>
                                       <li>catheter-directed thrombolysis</li>
                                       <li>pharmacomechanical thrombolysis</li>
                                       </ul>
                                       </ul>
                                       
                                       <div class="evidence-accordion">
                                          <div class="option">
                                             <input type="checkbox" id="toggle8" class="toggle" />
                                             <label class="title" for="toggle8">                                             
                                                <span class="material-icons"><span></span></span>
                                                <span class="title">Evidence: Surgical pulmonary embolectomy and catheter-directed therapy outcomes</span>
                                          </label>
                                             <div class="content">
                                                <p><strong>There is no comparative data to guide the primary management of patients with high-risk (massive) PE and a strong contraindication to systemic thrombolysis and therefore management will depend on local options and expertise</strong>.</p>
                                                <ul>
                                                <li>However, some small studies have looked at outcomes from surgical pulmonary embolectomy and catheter-directed therapy.</li>
                                                <li>Mortality rates following pulmonary embolectomy range from 4% to 27%. [FUKUDA] In a small cohort of patients who underwent surgical pulmonary embolectomy for acute high-risk (massive) pulmonary thromboembolism, the 10-year survival rate was 84%. [FUKUI]</li>
                                                <li>A meta-analysis of non-randomised trials of catheter-directed therapies reported a clinical success rate of 87% with an associated risk of major and minor complications of 2% and 8%, respectively [KUO],</li>
                                                <li>The extent of early RV recovery after low-dose catheter-directed thrombolysis appears comparable to that after standard-dose systemic thrombolysis whereas anticoagulation with heparin alone has little effect on improvement of RV size and performance within the first 24&ndash;48 hours.</li>
                                                <li>In a randomized, controlled clinical trial of 59 intermediate-risk patients, when compared with treatment by heparin alone, catheter-directed ultrasound-accelerated thrombolysis&mdash;administering 10 mg alteplase per treated lung over 15 hours&mdash;significantly reduced the subannular RV/LV dimension ratio between baseline and 24-hour follow-up without an increase in bleeding complications [TIEDE] [BOLUS][KUCHER]</li>
                                                </ul>
                                             </div>
                                          </div>
                                       </div>
   
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Diabetes-como-content" style="display: none;">
                                 <div class="panel-header">
                                    <p class="panel-title"> 
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                       <span class="titles-wrap col-md-12">
                                       <span class="title-02 no-icon">
                                          <span class="title-03 col-md-1">
                                          Plus
                                          <span class="noShow">&nbsp;–&nbsp;</span>
                                          </span>
                                          <span class="title-04">
                                          <span class="material-icons"><span></span><span></span></span>
                                          <span class="txtwrap">Review diabetes medication (NEVER stop insulin in people with type 1 diabetes)</span>
                                          </span>
                                          <span class="material-icons">
                                             <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                             <g>
                                                <g>
                                                   <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                      c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                   <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                      c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                   <g>
                                                      <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                   </g>
                                                </g>
                                                <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                   7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                             </g>
                                             </svg>
                                          </span>
                                       </span>
                                       </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_0_0_3" id="panel_0_0_3" aria-expanded="false">
                                    <!-- CONDITIONAL COMO CONTENT -->
                                    <div class="Diabetes-como-content" style="display: block;">
                                          <div class="poce_drug_msg">
                                             <span class="material-icons">
                                                <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                <g>
                                                   <g>
                                                      <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                         c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                      <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                         c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                      <g>
                                                         <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                      </g>
                                                   </g>
                                                   <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                      7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                </g>
                                                </svg>
                                             </span> 
                                             <h3 class="poce_title"></h3>
                                             
                                             <p><strong>Never stop insulin in people with type 1 diabetes coming into hospital - insulin deficiency can rapidly precipitate ketoacidosis, particularly during illness. </strong></p>
                                             <ul>
                                             <li><strong>Always continue basal insulins</strong> (long-acting or background insulins e.g., determir or glargine) as this will <strong>prevent ketoacidosis</strong> if doses of rapid-acting insulin are inadvertently missed or delayed.</li>
                                             <li><strong>Dose adjustments</strong> up or down may be needed.</li>
                                             <ul>
                                             <li>For example, in the<strong> absence of significant hyperglycaemia </strong>consider <strong>reducing the evening basal insulin by 20% on admission</strong>, as most patients will have a <strong>smaller evening meal in hospital</strong> compared with at home.</li>
                                             </ul>
                                             </ul>
                                             <p><strong>If  a variable rate intravenous insulin infusion (VRIII) is started</strong>:</p>
                                             <ul>
                                             <li><strong>Continue the basal insulin </strong><em>(Joint British Diabetes Societies for inpatient care [JBDS-IP], 2014)</em> as this will reduce the risk of ketosis in the advent of the VRIII being <strong>accidentally interrupted </strong>(e.g., by cannula displacement or blockage) or <strong>switched off </strong>(e.g., during transfer to another ward or department)<strong>.</strong></li>
                                             <li>The patient&rsquo;s usual <strong>rapid-acting </strong>and <strong>mixed insulins</strong> can be <strong>stopped while on a VRIII</strong>. <em>Joint British Diabetes Societies for inpatient care [JBDS-IP], 2014)</em></li>
                                             <li>Use the VRIII for as <strong>short a time as possible</strong>, <em>(Joint British Diabetes Societies for inpatient care [JBDS-IP], 2014) </em>as incorrect use and insufficient monitoring can result in<strong> severe hypoglycaemia</strong> or<strong> ketoacidosis</strong>.</li>
                                             </ul>
                                             <p><strong>Indications for a VRIII include</strong>: <em>(Joint British Diabetes Societies for inpatient care [JBDS-IP], 2014)</em></p>
                                             <ul>
                                             <li>Patients with diabetes or hospital-related hyperglycaemia who <strong>can&rsquo;t take oral food or fluid </strong>and where it&rsquo;s <strong>not possible to adjust their insulin regimen</strong>, e.g., when:</li>
                                             <ul>
                                             <li>Vomiting</li>
                                             <li>Nil by mouth and patient will miss more than one meal</li>
                                             <li>There is severe illness with a need to achieve good glycaemic control (such as with sepsis).</li>
                                             </ul>
                                             <li>Most patients with diabetes <strong>requiring emergency surgery</strong>. <em>(Joint British Diabetes Societies for inpatient care [JBDS-IP], 2016)</em></li>
                                             <li><strong>Special circumstances</strong>, such as hyperglycaemia with <strong>acute coronary syndrome</strong>, when <strong>pregnant</strong>, or when receiving <strong>TPN or enteral feeding</strong>, or <strong>taking corticosteroids</strong>. <em>(Joint British Diabetes Societies for inpatient care., 2012) </em></li>
                                             <ul>
                                             <li><strong>Get specialist advice</strong> from the <strong>diabetes team</strong> in these circumstances.</li>
                                             </ul>
                                             </ul>
                                             <p><strong>People with type 2 diabetes on basal insulin should continue to take it, unless otherwise indicated</strong>.</p>
                                             <ul>
                                             <li>In the <strong>absence of significant hyperglycaemia</strong> consider <strong>reducing the evening basal insulin</strong> by <strong>20% on admission</strong>, as most patients will have a <strong>smaller evening meal in hospital </strong>compared with at home.</li>
                                             </ul>
                                             <p>Give<strong> oral hypoglycaemic</strong> medication<strong> with food</strong> to reduce the<strong> risk of hypoglycaemia</strong>.</p>
                                             <ul>
                                             <li><strong>Never give oral hypoglycaemic medication at bedtime </strong>and consider <strong>reducing the evening dose of sulphonylurea</strong>.</li>
                                             <ul>
                                             <li>This is because most patients have a <strong>smaller evening meal in hospital </strong>compared with their usual evening meal at home.</li>
                                             </ul>
                                             </ul>
                                             <p><strong>Withhold metformin in patients:</strong></p>
                                             <ul>
                                             <li>With <strong>contraindications</strong>, such as <strong>significant renal impairment</strong> (&lt;30 mL/minute/1.73 m2)</li>
                                             <li>With <strong>metabolic acidosis </strong>(including lactic acidosis and DKA)</li>
                                             <li>At<strong> risk of lactic acidosis</strong> with metformin, such as:</li>
                                             <ul>
                                             <li>With conditions associated with <strong>acute kidney injury </strong>or<strong> tissue hypoxia,</strong> including<strong> dehydration</strong></li>
                                             <li>With <strong>renal impairment</strong>and who have, or are to be <strong>fasted for a prolonged period</strong> or who are due to have a<strong> radio-opaque contrast injection</strong> as part of an imaging procedure. <strong>Follow local protocols </strong>for guidance on the specific eGFR levels indicating renal impairment for this to be applied.</li>
                                             </ul>
                                             </ul>
                                             <p><strong>Be aware that withholding metformin results in hyperglycemia</strong>.</p>
                                             <ul>
                                             <li>If your patient is taking <strong>other glucose-lowering medication</strong>, these may need to be<strong> increased in dose</strong> or an <strong>alternative hypoglycaemic medication to metformin</strong> prescribed.</li>
                                             <li>Some patients may need <strong>insulin as a temporary measure</strong>, but<strong> seek diabetes inpatient specialist team advice</strong>.</li>
                                             </ul>
                                             <p><strong>Stop sodium-glucose cotransporter-2 (SGLT-2) inhibitors in all acutely ill patients, particularly if dehydrated or with infection, as they are at risk of euglycaemic ketoacidosis.</strong></p>
                                             <ul>
                                             <li>SGLT-2 inhibitors (e.g., dapagliflozin) <strong>reduce blood glucose reabsorption</strong> in the kidneys (independently of insulin metabolism of glucose). <em>(Peters AL, et al, 2015) </em></li>
                                             <li>They can<strong> mask underlying ketoacidosis</strong> by patients having a normal (or near normal) serum glucose level <strong>(euglycaemic ketoacidosis)</strong>.</li>
                                             <li>Check <strong>blood ketones</strong> as urinary ketone measurement may be unreliable.</li>
                                             <li><strong>Treat for DKA</strong> if <strong>blood ketone level is &ge;3 mmol/L</strong>, blood<strong> pH &lt;7.3</strong> and <strong>bicarbonate &lt;15 mmol/L</strong>. (<em>JBDS-IP, 2013)</em></li>
                                             </ul>
                                             <p><strong>Reduce or omit the dose of gliclazide if the patient has impaired kidney function or is eating less than usual, to avoid hypoglycaemia at night. </strong></p>
                                             <p><strong>Inform the diabetic inpatient team of the admission of any patient with diabetes. They are available for advice and support.</strong></p>
                                             <p><strong>For a patient at the end of life</strong>: <em>(Rowles S, et al 2011)</em></p>
                                             <ul>
                                             <li><strong>Hypoglycaemic medication</strong> should be <strong>reduced </strong>to the minimum, <strong>but</strong></li>
                                             <li>The patient should be<strong> kept free from symptomatic hyperglycaemia</strong>, which can lead to <strong>dehydration</strong>, <strong>ketosis</strong> or <strong>hyperosmolar hyperglycaemia</strong>.</li>
                                             </ul>
                                             <p>Refer to <strong>local protocols </strong>or the Association of British Clinical Diabetologists (ABCD). <em>(Rowles S, et al 2011)</em></p>
                                             
                                             
                                          </div>
                                    </div>
                                    <!-- CONDITIONAL COMO CONTENT ENDS -->
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Diabetes-como-content" style="display: none;">
                                 <div class="panel-header">
                                    <p class="panel-title"> 
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                       <span class="titles-wrap col-md-12">
                                       <span class="title-02 no-icon">
                                          <span class="title-03 col-md-1">
                                          Plus
                                          <span class="noShow">&nbsp;–&nbsp;</span>
                                          </span>
                                          <span class="title-04">
                                          <span class="material-icons"><span></span><span></span></span>
                                          <span class="txtwrap">Monitor and manage blood glucose</span>
                                          </span>
                                          <span class="material-icons">
                                             <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                             <g>
                                                <g>
                                                   <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                      c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                   <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                      c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                   <g>
                                                      <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                   </g>
                                                </g>
                                                <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                   7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                             </g>
                                             </svg>
                                          </span>
                                       </span>
                                       </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_0_0_3" id="panel_0_0_3" aria-expanded="false">
                                    <!-- CONDITIONAL COMO CONTENT -->
                                    <div class="Diabetes-como-content" style="display: block;">
                                          <div class="poce_drug_msg">
                                             <span class="material-icons">
                                                <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                <g>
                                                   <g>
                                                      <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                         c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                      <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                         c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                      <g>
                                                         <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                      </g>
                                                   </g>
                                                   <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                      7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                </g>
                                                </svg>
                                             </span> 
                                             <h3 class="poce_title"></h3>
   
                                             
                                             <p><strong>Monitor blood glucose levels at least 4 times a day (pre-meal and before bedtime if eating) in all acutely unwell patients with diabetes mellitus (</strong><em>American Diabetes Association, 2019)</em></p>
                                             <ul>
                                             <li>The risk of<strong> hypo- and hyperglycaemia</strong> increases when people with diabetes are admitted to hospital with acute conditions. <em>(NHS Digital. National Diabetes Inpatient Audit (NaDIA) - 2017, 2018)</em></li>
                                             <li><strong>More frequent monitoring</strong> is needed after <strong>episodes of hyperglycaemia</strong> or <strong>hypoglycaemia</strong>.</li>
                                             <li>More <strong>frequent monitoring</strong> is needed after a <strong>change in hypoglycaemic medication</strong>.</li>
                                             <li>Patients on a<strong> variable rate intravenous insulin infusion (VRIII)</strong> need <strong>capillary blood glucose measurements every hour</strong>. <em>(Joint British Diabetes Societies for inpatient care [JBDS-IP], 2014)</em></li>
                                             <li>Support <strong>self-management</strong> (including monitoring blood glucose) if this conforms to local protocols, it is safe to do so, and the patient is willing. <em>(Joint British Diabetes Societies for inpatient care [JBDS-IP], 2012) </em></li>
                                             </ul>
                                             <p><strong>Prevent and manage hyperglycaemia if it occurs</strong></p>
                                             <ul>
                                             <li>There is <strong>no consensus on target blood glucose</strong> levels for people with diabetes in hospital.</li>
                                             <li><strong>The Joint British Diabetes Societies for Inpatient Care</strong> (JBDS-IP) recommend an<strong> ideal range</strong> of between<strong> 6 to 10 mmol/L</strong>, and an <strong>acceptable range</strong> of <strong>4 to 12 mmol/L</strong><em>(JBDS-IP, 2014)</em></li>
                                             <li><strong>The American Diabetes Association</strong> recommend a <strong>target blood glucose range</strong> of <strong>7.8 to 10.0 mmol/L</strong> (140-180 mg/dL) for most critically and noncritically ill patients. (<em>American Diabetes Association. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes&mdash;2019, 2019)</em></li>                                             
                                             <li><em>The <strong>National Institute for Health and Care Excellence</strong> recommends a target plasma glucose level of <strong>5 to 8 mmol/L</strong> in adults with type 1 diabetes in hospital undergoing surgery or with acute illness. <em>(NICE, 2017)</em></em></li>      
                                             <li><strong>More liberal blood glucose targets</strong> are appropriate for people at<strong> high risk of falls </strong>and who are<strong> frail </strong>or have <strong>dementia</strong>. <em>(JBDS-IP, 2014)</em></li>
                                             </ul>
                                             <div class="evidence-accordion">
                                                <div class="option">
                                                   <input type="checkbox" id="toggle9" class="toggle" />
                                                   <label class="title" for="toggle9">                                             
                                                      <span class="material-icons"><span></span></span>
                                                      <span class="title">Evidence: patient outcomes associated with hyperglycaemia</span>
                                                </label>
                                                   <div class="content">
                                                      <p><strong>Hyperglycaemia in patients in hospital is associated with adverse outcomes. (</strong><em>Moghissi, 2009)</em></p>
                                                      <p>Hyperglycaemia in patients in hospital, whether with known diabetes or not, has been shown by various observational studies to be associated with adverse patient outcomes, including increased mortality. <strong>(</strong><em>Moghissi, 2009)</em></p>
                                                   </div>
                                                </div>
                                             </div>
                                             <div class="evidence-accordion">
                                                <div class="option">
                                                   <input type="checkbox" id="toggle10" class="toggle" />
                                                   <label class="title" for="toggle10">                                             
                                                      <span class="material-icons"><span></span></span>
                                                      <span class="title">Evidence: blood glucose targets for people with diabetes in hospital</span>
                                                </label>
                                                   <div class="content">
                                                      <p><strong>Conflicting evidence for optimal blood glucose targets has led to variations in recommendations in different countries and settings. Follow your local protocol.</strong></p>
                                                      <ul>
                                                      <li>Intensive care setting</li>
                                                      <ul>
                                                      <li>A randomised controlled trial (RCT) of critically ill patients in a primarily surgical intensive care setting found lower patient mortality with tight glucose control - 80 to 110 mg/dL (4.4 to 6.1 mmol/L) compared with &lsquo;conventional&rsquo; more liberal glucose control. <em>(Van den Berghe G et al, 2001) </em></li>
                                                      <li>However, a subsequent multicentre RCT in critically ill medical and surgical patients in other intensive care settings found increased mortality with tighter glucose control, possibly due to increased episodes of hypoglycaemia. <em>(Finfer et al, 2009)</em></li>
                                                      </ul>
                                                      </ul>
                                                      <p>A 2010 systematic review of 6 RCTs and a meta-analysis investigating tight glucose control (80 to 110 mg/dL [4.4 to 6.1 mmol/L]) vs less strict glucose control in critically ill patients in the ICU setting found no significant improvement in mortality with tight glucose control, but it was associated with significantly more hypoglycaemic episodes compared with less strict glucose control. (<em>Marik, 2010)</em></p>
                                                   </div>
                                                </div>
                                             </div>
   
                                             <p><strong>Follow your local hospital protocol on steps to take if your patient&rsquo;s capillary blood glucose is &ge;15 mmol/L. Exclude diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS), both of which require specific urgent management.</strong></p>
                                             <ul>
                                             <li><strong>Treat hyperglycaemia</strong> to avoid <strong>DKA </strong>and<strong> HHS</strong>.</li>
                                             <li><strong>DKA</strong> and <strong>HHS</strong> are <strong>medical emergencies</strong>. Follow JBDS or local hospital guidelines for patients with DKA (<em>JBDS-IP, 2013) </em>or HHS (<em>JBDS-IP, 2012). </em></li>
                                             <li>The <strong>diabetes inpatient specialist team</strong> should be involved in the management of any patient with <strong>DKA</strong>. (<em>JBDS-IP, 2013)</em></li>
                                             <li><strong>Early senior review</strong> by a clinician who is familiar with the management of<strong> HHS</strong> is imperative. (<em>JBDS-IP, 2012) </em>Patients with <strong>other comorbidities</strong> may need to be on a <strong>high dependency unit. </strong>(<em>JBDS-IP, 2012)</em></li>
                                             </ul>
                                             <p><strong>Be aware that the following medication may be associated with hyperglycaemia and may need to be reviewed: </strong><em>(Abdur R, et al, 2011)</em></p>
                                             <ul>
                                             <li>Corticosteroids</li>
                                             <li>Some beta-blockers (e.g., propranolol, atenolol)</li>
                                             <li>Thiazide diuretics (e.g., hydrochlorozide)</li>
                                             <li>Some second-generation antipsychotics (e.g., olanzapine and clozaine)</li>
                                             <li>Certain fluoroquinolone antibiotics (e.g., gatifloxin)</li>
                                             <li>Calcineurin inhibitors (e.g., cyclosporine, tacrolimus)</li>
                                             <li>Protease inhibitors (e.g., as a component in antiretroviral therapy, such as ritonavir)</li>
                                             </ul>   
   
                                             <div id="tip_pitfall" class="card card-inverse mb-4">
                                                <div class="card-block">
                                                   <svg version="1.1" id="pin" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 90 90" enable-background="new 0 0 90 90" xml:space="preserve">
                                                   <g>
                                                   <g>
                                                      <path fill="#333333" d="M42.694,51.942v30.413C42.694,83.816,44.174,85,46,85s3.306-1.184,3.306-2.645V51.942H42.694z"></path>
                                                   </g>
                                                   <g>
                                                      <ellipse fill="#333333" cx="46" cy="47.645" rx="19.835" ry="12.231"></ellipse>
                                                   </g>
                                                   <g id="cylinder">
                                                      <polygon fill="#333333" points="55.256,9.628 46,9.628 36.744,9.628 34.099,47.975 46,47.975 57.901,47.975 		"></polygon>
                                                   </g>
                                                   <g id="cylinder_highlight">
                                                      <polygon fill="#FFFFFF" points="54.595,46.653 50.628,47.975 49.306,13.595 53.273,13.595 		"></polygon>
                                                   </g>
                                                   <g>
                                                      <ellipse fill="#333333" cx="46" cy="13.595" rx="15.207" ry="8.595"></ellipse>
                                                   </g>
                                                   <g id="highlight">
                                                      <path fill="#FFFFFF" d="M47.982,18.929c-0.67,0-1.245-0.508-1.313-1.19c-0.073-0.727,0.456-1.375,1.183-1.448
                                                         c3.157-0.318,5.857-1.434,7.224-2.985c0.48-0.547,1.317-0.602,1.866-0.118c0.548,0.482,0.601,1.318,0.118,1.866
                                                         c-1.822,2.069-5.082,3.479-8.942,3.868C48.072,18.927,48.027,18.929,47.982,18.929z"></path>
                                                   </g>
                                                   <g>
                                                      <path fill="#333333" d="M46,49.54v-1.322c4.794,0,9.917-1.192,9.917-4.54h1.322C57.239,47.349,53.038,49.54,46,49.54z"></path>
                                                   </g>
                                                   <g id="highlight_lower">
                                                      <path fill="#FFFFFF" d="M48.011,56.926c-0.032,0-0.064,0-0.098,0c-0.73-0.003-1.319-0.598-1.316-1.328
                                                         c0.003-0.729,0.595-1.316,1.322-1.316c0.034,0,0.063,0,0.095,0c3.975,0,7.602-1.166,9.719-3.128
                                                         c0.533-0.496,1.37-0.467,1.868,0.071c0.496,0.535,0.465,1.372-0.071,1.868C56.937,55.496,52.637,56.926,48.011,56.926z"></path>
                                                   </g>
                                                   </g>
                                                   </svg>
                                                   <h3 class="card-title"></h3>
                                                   <p>Ask for expert advice from the diabetes team in complex patients, or where hyperglycaemia is difficult to control.</p>
         
                                                </div>
                                             </div>
   
                                             <p><strong>Prevent and manage hypoglycaemia if it occurs</strong></p>
                                             <ul>
                                             <li><strong>Monitor blood glucose</strong> in people with diabetes in hospital and <strong>adjust medication </strong>in response to illness and hospital meal times, in order to <strong>reduce risk</strong> of <strong>hypoglycaemic episodes</strong>.</li>
                                             <li>1 in 5 inpatients with diabetes in England and Wales have a<strong> hypoglycaemic episode </strong>during their hospital stay. <em>(NHS Digital. National Diabetes Inpatient Audit (NaDIA) - 2017, 2018)</em></li>
                                             <li>Causes include:<em> (JBDS-IP, 2018)</em></li>
                                             <ul>
                                             <li>Recovery from an acute illness</li>
                                             <li>Insulin or oral hypoglycaemic medication error</li>
                                             <li>Wrong timing of insulin in relation to meals</li>
                                             <li>Patients eating less but taking the same amount of diabetes medication</li>
                                             <li>No bedtime snacks</li>
                                             <li>Reduced appetite or vomiting.</li>
                                             </ul>
                                             </ul>
   
                                             <div id="tip_pitfall" class="card card-inverse mb-4">
                                                <div class="card-block">
                                                   <svg version="1.1" id="pin" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 90 90" enable-background="new 0 0 90 90" xml:space="preserve">
                                                   <g>
                                                   <g>
                                                      <path fill="#333333" d="M42.694,51.942v30.413C42.694,83.816,44.174,85,46,85s3.306-1.184,3.306-2.645V51.942H42.694z"></path>
                                                   </g>
                                                   <g>
                                                      <ellipse fill="#333333" cx="46" cy="47.645" rx="19.835" ry="12.231"></ellipse>
                                                   </g>
                                                   <g id="cylinder">
                                                      <polygon fill="#333333" points="55.256,9.628 46,9.628 36.744,9.628 34.099,47.975 46,47.975 57.901,47.975 		"></polygon>
                                                   </g>
                                                   <g id="cylinder_highlight">
                                                      <polygon fill="#FFFFFF" points="54.595,46.653 50.628,47.975 49.306,13.595 53.273,13.595 		"></polygon>
                                                   </g>
                                                   <g>
                                                      <ellipse fill="#333333" cx="46" cy="13.595" rx="15.207" ry="8.595"></ellipse>
                                                   </g>
                                                   <g id="highlight">
                                                      <path fill="#FFFFFF" d="M47.982,18.929c-0.67,0-1.245-0.508-1.313-1.19c-0.073-0.727,0.456-1.375,1.183-1.448
                                                         c3.157-0.318,5.857-1.434,7.224-2.985c0.48-0.547,1.317-0.602,1.866-0.118c0.548,0.482,0.601,1.318,0.118,1.866
                                                         c-1.822,2.069-5.082,3.479-8.942,3.868C48.072,18.927,48.027,18.929,47.982,18.929z"></path>
                                                   </g>
                                                   <g>
                                                      <path fill="#333333" d="M46,49.54v-1.322c4.794,0,9.917-1.192,9.917-4.54h1.322C57.239,47.349,53.038,49.54,46,49.54z"></path>
                                                   </g>
                                                   <g id="highlight_lower">
                                                      <path fill="#FFFFFF" d="M48.011,56.926c-0.032,0-0.064,0-0.098,0c-0.73-0.003-1.319-0.598-1.316-1.328
                                                         c0.003-0.729,0.595-1.316,1.322-1.316c0.034,0,0.063,0,0.095,0c3.975,0,7.602-1.166,9.719-3.128
                                                         c0.533-0.496,1.37-0.467,1.868,0.071c0.496,0.535,0.465,1.372-0.071,1.868C56.937,55.496,52.637,56.926,48.011,56.926z"></path>
                                                   </g>
                                                   </g>
                                                   </svg>
                                                   <h3 class="card-title"></h3>
                                                   <p><strong>Bedtime snacks </strong>can reduce the risk of <strong>early morning hypoglycaemia</strong>. <em>(NHS Digital. National Diabetes Inpatient Audit (NaDIA) - 2017, 2018)</em></p>         
                                                </div>
                                             </div>
   
                                             <p><strong>Treat hypoglycaemia actively if the blood glucose falls below 4.0 mmol/L. </strong><em>(JBDS-IP, 2018)</em></p>
                                             <ul>
                                             <li>Follow hospital protocol. The JBDS-IP has guidelines on hospital management of hypoglycaemia in adults with diabetes. <em>(JBDS-IP, 2018)</em></li>
                                             </ul>
                                             
                                          </div>
                                    </div>
                                    <!-- CONDITIONAL COMO CONTENT ENDS -->
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group CKD-como-content" style="display: none;">
                                 <div class="panel-header">
                                    <p class="panel-title"> 
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                       <span class="titles-wrap col-md-12">
                                       <span class="title-02 no-icon">
                                          <span class="title-03 col-md-1">
                                          Plus
                                          <span class="noShow">&nbsp;–&nbsp;</span>
                                          </span>
                                          <span class="title-04">
                                          <span class="material-icons"><span></span><span></span></span>
                                          <span class="txtwrap">Check baseline kidney function</span>
                                          </span>
                                          <span class="material-icons">
                                             <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                             <g>
                                                <g>
                                                   <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                      c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                   <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                      c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                   <g>
                                                      <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                   </g>
                                                </g>
                                                <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                   7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                             </g>
                                             </svg>
                                          </span>
                                       </span>
                                       </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_0_0_3" id="panel_0_0_3" aria-expanded="false">
                                    <!-- CONDITIONAL COMO CONTENT -->
                                    <div class="CKD-como-content" style="display: block;">
                                          <div class="poce_drug_msg">
                                             <span class="material-icons">
                                                <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                <g>
                                                   <g>
                                                      <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                         c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                      <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                         c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                      <g>
                                                         <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                      </g>
                                                   </g>
                                                   <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                      7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                </g>
                                                </svg>
                                             </span> 
                                             <h3 class="poce_title"></h3>
   
                                             <p><strong>Check baseline serum kidney function on admission in all patients with a previous history of chronic kidney disease (CKD). </strong><em>[National Institute for Health and Care Excellence. 2013)</em></p>
                                          <ul>
                                          <li><strong>CKD</strong> is a significant<strong> risk factor</strong> for the development of <strong>acute kidney injury</strong>. <em>(Hsu CY, et al, 2008)</em></li>
                                          <li>Acute illness increases the risk of deterioration in renal function.</li>
                                          </ul>
                                             
                                          </div>
                                    </div>
                                    <!-- CONDITIONAL COMO CONTENT ENDS -->
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Dementia-como-content" style="display: none;">
                                 <div class="panel-header">
                                    <p class="panel-title"> 
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                       <span class="titles-wrap col-md-12">
                                       <span class="title-02 no-icon">
                                          <span class="title-03 col-md-1">
                                          Plus
                                          <span class="noShow">&nbsp;–&nbsp;</span>
                                          </span>
                                          <span class="title-04">
                                          <span class="material-icons"><span></span><span></span></span>
                                          <span class="txtwrap">Baseline cognitive assessment and collateral history</span>
                                          </span>
                                          <span class="material-icons">
                                             <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                             <g>
                                                <g>
                                                   <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                      c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                   <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                      c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                   <g>
                                                      <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                   </g>
                                                </g>
                                                <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                   7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                             </g>
                                             </svg>
                                          </span>
                                       </span>
                                       </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_0_0_3" id="panel_0_0_3" aria-expanded="false">
                                    <!-- CONDITIONAL COMO CONTENT -->
                                    <div class="Dementia-como-content" style="display: block;">
                                          <div class="poce_drug_msg">
                                             <span class="material-icons">
                                                <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                <g>
                                                   <g>
                                                      <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                         c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                      <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                         c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                      <g>
                                                         <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                      </g>
                                                   </g>
                                                   <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                      7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                </g>
                                                </svg>
                                             </span> 
                                             <h3 class="poce_title"></h3>
   
                                             <p><strong>Do a baseline cognitive assessment in all older patients, particularly those with a history of dementia. </strong><em>(Pendlebury ST, et al, 2015)</em></p>
                                             <ul>
                                             <li>Use a<strong> validated scoring system</strong> that is also feasible in the acute setting, such as:<em>(Pendlebury ST, et al, 2015)</em></li>
                                             <ul>
                                             <li>The <strong>abbreviated mental test score</strong> (AMTS/10) <em>(</em><em>Hodkinson,1972)</em></li>
                                             <li><strong>Montreal Cognitive Assessment</strong> (MoCA) <em>(Nasreddine, 2005).</em></li>
                                             </ul>
                                             </ul>
                                             <p><strong>Dementia increases the risk of delirium. </strong></p>
                                             <ul>
                                             <li>This can acutely reduce patients' cognitive assessment scores. <em>(George J, 2013)</em></li>
                                             </ul>
                                             <p><strong>Take a collateral history from family, friend or carer, to establish the patient&rsquo;s level of function and baseline cognition before this illness.</strong></p>
                                             <ul>
                                             <li>It&rsquo;s important to know if the <strong>decline</strong> in function and cognition has been <strong>gradual </strong>or <strong>acute</strong>.</li>
                                             </ul>
                                             <p>Use this information for <strong>monitoring clinical improvement</strong>, and for establishing <strong>needs on discharge</strong>.</p>
                                             
                                          </div>
                                    </div>
                                    <!-- CONDITIONAL COMO CONTENT ENDS -->
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Stroke-como-content" style="display: none;">
                                 <div class="panel-header">
                                    <p class="panel-title"> 
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                       <span class="titles-wrap col-md-12">
                                       <span class="title-02 no-icon">
                                          <span class="title-03 col-md-1">
                                          Plus
                                          <span class="noShow">&nbsp;–&nbsp;</span>
                                          </span>
                                          <span class="title-04">
                                          <span class="material-icons"><span></span><span></span></span>
                                          <span class="txtwrap">Baseline neurological assessment</span>
                                          </span>
                                          <span class="material-icons">
                                             <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                             <g>
                                                <g>
                                                   <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                      c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                   <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                      c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                   <g>
                                                      <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                   </g>
                                                </g>
                                                <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                   7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                             </g>
                                             </svg>
                                          </span>
                                       </span>
                                       </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_0_0_3" id="panel_0_0_3" aria-expanded="false">
                                    <!-- CONDITIONAL COMO CONTENT -->
                                    <div class="Stroke-como-content" style="display: block;">
                                          <div class="poce_drug_msg">
                                             <span class="material-icons">
                                                <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                <g>
                                                   <g>
                                                      <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                         c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                      <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                         c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                      <g>
                                                         <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                      </g>
                                                   </g>
                                                   <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                      7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                </g>
                                                </svg>
                                             </span> 
                                             <h3 class="poce_title"></h3>
   
                                             <p><strong>Do a baseline neurological assessment on admission for all patients with a history of stroke.</strong></p>
                                             <ul>
                                             <li>Patients with <strong>acute illness</strong> (including infections and causes of hypotension) are at <strong>increased risk of stroke</strong> (both ischaemic and haemorrhagic). <em>(Grau AJ, et al, 2010) (Eigenbrodt ML, et al, 2000)</em></li>
                                             <li>If there is a suspicion of a change in neurological status during admission, repeat the<strong>neurological assessment</strong> in case of a <strong>possible new stroke</strong>.</li>
                                             </ul>
                                             <p>Following assessment, consider appropriate level of <strong>patient supervision</strong> e.g., relating to possible <strong>confusion</strong> at night, <strong>falls</strong> related to <strong>frailty</strong>.</p>
                                             
                                          </div>
                                    </div>
                                    <!-- CONDITIONAL COMO CONTENT ENDS -->
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Dementia-como-content" style="display: none;">
                                 <div class="panel-header">
                                    <p class="panel-title"> 
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                       <span class="titles-wrap col-md-12">
                                       <span class="title-02 no-icon">
                                          <span class="title-03 col-md-1">
                                          Plus
                                          <span class="noShow">&nbsp;–&nbsp;</span>
                                          </span>
                                          <span class="title-04">
                                          <span class="material-icons"><span></span><span></span></span>
                                          <span class="txtwrap">Assess for and manage delirium</span>
                                          </span>
                                          <span class="material-icons">
                                             <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                             <g>
                                                <g>
                                                   <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                      c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                   <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                      c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                   <g>
                                                      <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                   </g>
                                                </g>
                                                <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                   7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                             </g>
                                             </svg>
                                          </span>
                                       </span>
                                       </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_0_0_3" id="panel_0_0_3" aria-expanded="false">
                                    <!-- CONDITIONAL COMO CONTENT -->
                                    <div class="Dementia-como-content" style="display: block;">
                                          <div class="poce_drug_msg">
                                             <span class="material-icons">
                                                <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                <g>
                                                   <g>
                                                      <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                         c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                      <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                         c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                      <g>
                                                         <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                      </g>
                                                   </g>
                                                   <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                      7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                </g>
                                                </svg>
                                             </span> 
                                             <h3 class="poce_title"></h3>
   
                                             
                                             <p><strong>Assess the patient with de mentia for delirium. </strong><em>(National Institute for Health and Clinical Excellence. 2010)</em></p>
                                             <ul>
                                             <li>People living with dementia are at increased risk of delirium when they are admitted to hospital. (<em>National Institute for Health and Clinical Excellence, 2018)</em></li>
                                             <li>Use a<strong> screening tool</strong>, such as:</li>
                                             <ul>
                                             <li>The <strong>4-AT</strong><em>(</em><em>Bellelli, 2014)</em></li>
                                             <li>The <strong>short confusion assessment method (S-CAM), </strong>as recommended by the National Institute of Health and Care Excellence (NICE). <em>(National Institute for Health and Clinical Excellence. 2010)</em></li>
                                             <li>Document the results clearly.</li>
                                             </ul>
                                             </ul>
                                             <p>&nbsp;</p>
                                             <p><strong>Assess the patient for any reversible causes of delirium</strong>. <em>(National Institute for Health and Clinical Excellence. 2010)</em>These include:</p>
                                             <ul>
                                             <li>Infection</li>
                                             <li>Pain</li>
                                             <li>Dehydration</li>
                                             <li>Constipation</li>
                                             <li>Hypoxia</li>
                                             <li>Immobility</li>
                                             <li>Medications</li>
                                             <li>Poor sleep</li>
                                             <li>Sensory impairment (e.g., ear wax or loss of glasses)</li>
                                             </ul>
                                             <p>&nbsp;</p>
                                             <p><strong>Investigations</strong> to help diagnose underlying causes include:</p>
                                             <ul>
                                             <li>Full blood count, electrolytes, renal function, liver function tests, calcium, glucose, CRP, folate and vitamin B12.</li>
                                             <li>Blood cultures (if bacteraemia is suspected)</li>
                                             <li>Urine microscopy and culture</li>
                                             <li>Chest x-ray</li>
                                             </ul>
                                             <p>&nbsp;</p>
                                             <p><strong>Manage according to the cause</strong>.</p>
                                             <p>&nbsp;</p>
                                             <p><strong>Manage patients with delirium initially with non-pharmacological treatment. </strong><em>(National Institute for Health and Clinical Excellence. 2010)</em></p>
                                             <p>&nbsp;</p>
                                             <ul>
                                             <li>Reduce <strong>disorientation</strong> by providing a <strong>well-lit room,</strong> with a <strong>clock</strong> and <strong>calendar </strong>visible (e.g., on the wall).</li>
                                             <li>Encourage and facilitate <strong>family, friends and carers</strong> visiting the patient.</li>
                                             <li>Use verbal and non-verbal techniques to<strong> de-escalate</strong> conflict and distress.</li>
                                             </ul>
                                             <p>&nbsp;</p>
                                             <p><strong>Where non-pharmacological treatments are ineffective, and the patient is distressed or considered a risk to themselves or others, short-term antipsychotic or sedative drugs may be used.</strong></p>
                                             <p>&nbsp;</p>
                                             <p><strong>Only use antipsychotics as a last resort and not in patients with Parkinson&rsquo;s disease or dementia with Lewy bodies.</strong><em>(National Institute for Health and Clinical Excellence. 2010)</em></p>
                                             <ul>
                                             <li><strong>Risperidone</strong> has the least anticholinergic effects. <em>(Tracy JI, et al, 1998)</em></li>
                                             <li><strong>Haloperidol</strong> is also licenced for this indication, but has the highest risk associated with its use. The UK National Institute for Health and Care Excellence recommends short-term use of haloperidol (usually for less than one week), starting at the <strong>lowest dose</strong> and <strong>titrating carefully</strong> according to the symptoms. <em>(National Institute for Health and Clinical Excellence. 2010)</em></li>
                                             <li>Consider sedation in significantly agitated patients who pose a risk to themselves or others.<strong> Lorazepam </strong>is a suitable choice, but it should only be given orally or intramuscularly (i.e., not intravenously).</li>
                                             <li>Lorazepam should only be used in the<strong> smallest possible dose</strong> for the <strong>shortest possible duration</strong>.</li>
                                             </ul>
                                             <p>&nbsp;</p>
                                             <p><strong>Avoid typical antipsychotics, particularly haloperidol in patients with Parkinson&rsquo;s disease or dementia with Lewy bodies. </strong><em>(National Institute for Health and Clinical Excellence. 2010)</em></p>
                                             <ul>
                                             <li>The dopamine receptor antagonistic effect of typical antipsychotics can <strong>dramatically worsen physical and cognitive symptoms</strong> in people with Parkinson&rsquo;s disease or with dementia with Lewy bodies.</li>
                                             <li>Consider a <strong>low-dose short-acting oral benzodiazepine,</strong> such as lorazepam, or l<strong>ow-dose quetiapine </strong>in patients with Parkinson&rsquo;s disease or dementia with Lewy bodies who require sedation to enable safe care because of delirium.</li>
                                             <li>Consult your local drug formulary for advice.</li>
                                             </ul>
                                             <p><strong><br /><strong>Document</strong> any episodes of current or resolved delirium in the<strong> discharge summary for the GP</strong>. <em>(National Institute for Health and Clinical Excellence. 2010)</em></strong></p>
   
   
                                             <div class="evidence-accordion">
                                                   <div class="option">
                                                      <input type="checkbox" id="toggle11" class="toggle" />
                                                      <label class="title" for="toggle11">                                             
                                                         <span class="material-icons"><span></span></span>
                                                         <span class="title">Evidence: risks and safe withdrawal of antipsychotics in the elderly</span>
                                                        </label>
                                                      <div class="content">
                                                            <p><strong>Short-term antipsychotics may be needed in people with dementia to enable safe care. However, antipsychotics have various adverse effects in the elderly and are associated with an increased risk of death in people with dementia.</strong></p>
                                                            <ul>
                                                            <li>A meta-analysis found that people with dementia who take atypical antipsychotics have an <strong>increased mortality risk </strong>compared with people taking placebo. <em>(</em><em>Ma H, et al, 2014)</em></li>
                                                            
                                                            <li><em>A large cohort study of elderly people found that <strong>higher doses</strong> of antipsychotics are generally associated with <strong>greater risk</strong>. <em>(Huybrechts K, 2012)</em></em></li>
                                                            
                                                            <li>It also found that of all the antipsychotics studied, <strong>haloperidol </strong>has the highest risk associated with its use. <em>(Huybrechts K, 2012)</em></li>
                                                            
                                                            <li>Contrary to popular belief, long-term antipsychotic prescriptions in people with dementia whose behaviour is now settled, can be <strong>withdrawn safely </strong>in the majority of cases. (<em>Van Leeuwen, 2018)</em></li>
                                                            </ul>
                                                      </div>
                                                   </div>
                                                </div>
   
                                                <div class="evidence-accordion">
                                                   <div class="option">
                                                      <input type="checkbox" id="toggle12" class="toggle" />
                                                      <label class="title" for="toggle12">                                             
                                                         <span class="material-icons"><span></span></span>
                                                         <span class="title">Evidence: primary prevention of delirium: this may be the most effective treatment strategy</span>
                                                        </label>
                                                      <div class="content">
                                                            <p><strong>A non-randomised trial studying how to reduce risk factors for delirium compared a multicomponent strategy with usual care in 852 elderly patients (over 70 years) in hospital. </strong><em>(Inouye, 1999)</em></p>
                                                            <ul>
                                                            <li>The multicomponent strategy targeted the following 6 risk factors:</li>
                                                            <ul>
                                                            <li>cognitive impairment</li>
                                                            <li>sleep deprivation</li>
                                                            <li>immobility</li>
                                                            <li>visual impairment</li>
                                                            <li>hearing impairment</li>
                                                            <li>dehydration.</li>
                                                            </ul>
                                                            </ul>
                                                            <p>It found: <em>(Inouye, 1999)</em></p>
                                                            <ul>
                                                            <li>There were <strong>significantly fewer first episodes of delirium</strong> with the <strong>multicomponent strategy </strong>vs usual care (44 [9.9%] vs 64 [15%] respectively)</li>
                                                            <li>Matched group analysis found an odds ratio (OR) of 0.60 (95%CI: 0.39-0.92; p=0.02)</li>
                                                            <li><strong>Total number of days with delirium</strong> was <strong>significantly lower </strong>with the <strong>multicomponent strategy</strong> vs usual care (105 vs. 161 days respectively, p=0.02)</li>
                                                            </ul>
                                                            <p><strong>Delirium severity and recurrence rates</strong> were <strong>not significantly different </strong>in the 2 groups.</p>
                                                      </div>
                                                   </div>
                                                </div>
                                             
                                          </div>
                                    </div>
                                    <!-- CONDITIONAL COMO CONTENT ENDS -->
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Diabetes-como-content" style="display: none;">
                                 <div class="panel-header">
                                    <p class="panel-title"> 
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                       <span class="titles-wrap col-md-12">
                                       <span class="title-02 no-icon">
                                          <span class="title-03 col-md-1">
                                          Plus
                                          <span class="noShow">&nbsp;–&nbsp;</span>
                                          </span>
                                          <span class="title-04">
                                          <span class="material-icons"><span></span><span></span></span>
                                          <span class="txtwrap">Set an escalation plan</span>
                                          </span>
                                          <span class="material-icons">
                                             <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                             <g>
                                                <g>
                                                   <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                      c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                   <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                      c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                   <g>
                                                      <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                   </g>
                                                </g>
                                                <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                   7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                             </g>
                                             </svg>
                                          </span>
                                       </span>
                                       </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_0_0_3" id="panel_0_0_3" aria-expanded="false">
                                    <!-- CONDITIONAL COMO CONTENT -->
                                    <div class="Diabetes-como-content" style="display: block;">
                                          <div class="poce_drug_msg">
                                             <span class="material-icons">
                                                <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                <g>
                                                   <g>
                                                      <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                         c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                      <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                         c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                      <g>
                                                         <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                      </g>
                                                   </g>
                                                   <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                      7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                </g>
                                                </svg>
                                             </span> 
                                             <h3 class="poce_title"></h3>
   
                                             <p><strong>Set an escalation plan for all patients with dementia as early as possible.</strong></p>
                                             <ul>
                                             <li>This should include: <em>(Fritz Z, et al, 2017):</em></li>
                                             <ul>
                                             <li><strong>Resuscitation status</strong> (i.e., do not attempt cardiopulmonary resuscitation [DNACPR] decision)</li>
                                             <li><strong>Ceiling of care</strong> (e.g., is the patient suitable for intubation or intensive care admission)</li>
                                             </ul>
                                             <li>Escalation plans should take account of<strong> advanced care planning</strong>, including legally-binding advanced directives. <em>(Fritz Z, et al, 2017)</em></li>
                                             </ul>
                                             <p><strong>Communicate</strong> all decisions regarding the escalation plan <strong>with the patient</strong>.<em>(Fritz Z, et al, 2017)</em></p>
                                             <ul>
                                             <li><strong>Assess mental capacity</strong> (the ability to make decisions at a specific time a decision needs to be made) and document. <em>(NICE, 2018)</em> Follow the appropriate legislation in your region.</li>
                                             <li>In England and Wales, health professionals must comply with the <strong>2005 Mental Capacity Act</strong>. <em>(Department of Health, 2005) </em>Assessments should follow the principles in the Act. <em>(Department of Health, 2005) </em></li>
                                             <li>If a patient is assessed to lack mental capacity, ensure decisions are made in the <strong>best interests of the patient</strong>. <em>(Department of Health, 2005) (NICE, 2018)</em></li>
                                             </ul>
                                             <p><strong>If the patient is assessed to lack mental capacity, consult with the patient&rsquo;s next of kin in order to make &lsquo;best interests&rsquo; decisions. </strong><em>(Department of Health, 2005) </em></p>
                                             <p>According to the 2005 Mental Capacity Act in England and Wales, if a patient is unbefriended and a decision is not time critical, an independent mental capacity advocate (IMCA) should be sought to perform this role instead. (<em>Social Care Institute for Excellence, 2011)</em></p>
                                          </div>
                                    </div>
                                    <!-- CONDITIONAL COMO CONTENT ENDS -->
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Asthma-como-content COPD-como-content" style="display: none;">
                                 <div class="panel-header">
                                    <p class="panel-title"> 
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                       <span class="titles-wrap col-md-12">
                                       <span class="title-02 no-icon">
                                          <span class="title-03 col-md-1">
                                          Plus
                                          <span class="noShow">&nbsp;–&nbsp;</span>
                                          </span>
                                          <span class="title-04">
                                          <span class="material-icons"><span></span><span></span></span>
                                          <span class="txtwrap">Remember to prescribe usual inhalers</span>
                                          </span>
                                          <span class="material-icons">
                                             <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                             <g>
                                                <g>
                                                   <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                      c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                   <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                      c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                   <g>
                                                      <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                   </g>
                                                </g>
                                                <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                   7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                             </g>
                                             </svg>
                                          </span>
                                       </span>
                                       </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_0_0_3" id="panel_0_0_3" aria-expanded="false">
                                    <!-- CONDITIONAL COMO CONTENT -->
                                    <div class="Asthma-como-content COPD-como-content" style="display: block;">
                                          <div class="poce_drug_msg">
                                             <span class="material-icons">
                                                <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                <g>
                                                   <g>
                                                      <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                         c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                      <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                         c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                      <g>
                                                         <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                      </g>
                                                   </g>
                                                   <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                      7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                </g>
                                                </svg>
                                             </span> 
                                             <h3 class="poce_title"></h3>
                                             <p><strong>Patients may not think to tell you about their usual inhalers when asked about their medication, so remember to check and prescribe these if appropriate</strong></p>
                                             <ul>
                                             <li>Patients with asthma should continue any inhaled corticosteroid medication they usually take. These should not be stopped without a clear medical reason.</li>
                                             <li>Many inhalers are combined medications, so check there is no dual prescribing</li>
                                             </ul>
                                             <p><strong>Temporarily stop inhaled long-acting muscarinic receptor antagonists if your patient with COPD or asthma usually takes this and develops acute kidney injury with an eGFR &lt;30.</strong></p>
                                          </div>
                                    </div>
                                    <!-- CONDITIONAL COMO CONTENT ENDS -->
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Asthma-como-content COPD-como-content" style="display: none;">
                                 <div class="panel-header">
                                    <p class="panel-title"> 
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                       <span class="titles-wrap col-md-12">
                                       <span class="title-02 no-icon">
                                          <span class="title-03 col-md-1">
                                             Consider
                                          <span class="noShow">&nbsp;–&nbsp;</span>
                                          </span>
                                          <span class="title-04">
                                          <span class="material-icons"><span></span><span></span></span>
                                          <span class="txtwrap">Nicotene replacement therapy in current smokers</span>
                                          </span>
                                          <span class="material-icons">
                                             <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                             <g>
                                                <g>
                                                   <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                      c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                   <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                      c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                   <g>
                                                      <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                   </g>
                                                </g>
                                                <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 7.707,19.5 7.707,16 11.207,16"></polygon>
                                             </g>
                                             </svg>
                                          </span>
                                       </span>
                                       </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_0_0_3" id="panel_0_0_3" aria-expanded="false">
                                    <!-- CONDITIONAL COMO CONTENT -->
                                    <div class="Asthma-como-content COPD-como-content" style="display: block;">
                                          <div class="poce_drug_msg">
                                             <span class="material-icons">
                                                <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                <g>
                                                   <g>
                                                      <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                         c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                      <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                         c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                      <g>
                                                         <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                      </g>
                                                   </g>
                                                   <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                      7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                </g>
                                                </svg>
                                             </span> 
                                             <h3 class="poce_title"></h3>
                                             <p><strong>All current smokers are nicotine dependent</strong></p>
                                             <ul>
                                             <li>Nicotine replacement therapy should be prescribed to prevent withdrawal regardless of a patient&rsquo;s intention regarding smoking cessation</li>
                                             <li>Please consult your local hospital guidance.</li>
                                             </ul>
                                             <p><br /><strong>Make every contact count:</strong></p>
                                             <ul>
                                             <li>Being in hospital with an acute illness is the ideal time to support someone to give up smoking</li>
                                             <li>Provide brief advice.</li>
                                             </ul>
                                          </div>
                                    </div>
                                    <!-- CONDITIONAL COMO CONTENT ENDS -->
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Asthma-como-content COPD-como-content" style="display: none;">
                                 <div class="panel-header">
                                    <p class="panel-title"> 
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                       <span class="titles-wrap col-md-12">
                                       <span class="title-02 no-icon">
                                          <span class="title-03 col-md-1">
                                             Plus
                                          <span class="noShow">&nbsp;–&nbsp;</span>
                                          </span>
                                          <span class="title-04">
                                          <span class="material-icons"><span></span><span></span></span>
                                          <span class="txtwrap">Monitor for and manage any acute exacerbation of asthma or COPD</span>
                                          </span>
                                          <span class="material-icons">
                                             <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                             <g>
                                                <g>
                                                   <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                      c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                   <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                      c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                   <g>
                                                      <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                   </g>
                                                </g>
                                                <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 7.707,19.5 7.707,16 11.207,16"></polygon>
                                             </g>
                                             </svg>
                                          </span>
                                       </span>
                                       </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_0_0_3" id="panel_0_0_3" aria-expanded="false">
                                    <!-- CONDITIONAL COMO CONTENT -->
                                    <div class="Asthma-como-content COPD-como-content" style="display: block;">
                                          <div class="poce_drug_msg">
                                             <span class="material-icons">
                                                <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                <g>
                                                   <g>
                                                      <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                         c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                      <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                         c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                      <g>
                                                         <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                      </g>
                                                   </g>
                                                   <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                      7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                </g>
                                                </svg>
                                             </span> 
                                             <h3 class="poce_title"></h3>
                                             <p><strong>Monitor patient for symptoms and signs of an acute exacerbation of their COPD or asthma.</strong></p>
                                             <ul>
                                             <li>A patient with airways disease may have an acute exacerbation while in hospital with a separate another medical or surgical condition.</li>
                                             </ul>
                                             <p><strong>Patients with comorbid COPD may be having an acute exacerbation if there is an acute worsening of respiratory symptoms that results in the need for additional therapy.</strong><em>(Global Initiative for Chronic Obstructive Lung Disease, 2019)</em></p>
                                             <ul>
                                             <li><strong>Differentiate</strong> from other conditions which may present very similarly, such as <strong>acute coronary syndrome</strong>, <strong>acute heart failure</strong> and <strong>pneumonia</strong>.</li>
                                             <li>Follow guideline recommendations on <strong>investigations</strong>, including:</li>
                                             <ul>
                                             <li><strong>ABG</strong> measurement</li>
                                             <li><strong>Chest x-ray.</strong> Generally, do a chest x-ray if a patient with COPD is admitted with breathlessness or cough, or has worse symptoms than usual.</li>
                                             </ul>
                                             <li>Follow <strong>COPD guideline </strong>recommendations on <strong>initial management</strong>, including:</li>
                                             <ul>
                                             <li><strong>Assessing severity</strong></li>
                                             <li>Increasing dose and/or frequency of <strong>bronchodilator therapy</strong>, using nebulisers (driven with air) or spacers</li>
                                             <li>Considering <strong>oral corticosteroids</strong>, <strong>antibiotics</strong> and need for <strong>noninvasive ventilation</strong>.</li>
                                             <li>See BMJ Best Practice topic on Acute exacerbation in COPD</li>
                                             </ul>
                                             </ul>
                                             <p><strong>Follow guideline recommendations for assessment of severity and management of an acute exacerbation of asthma in adults. </strong><em>(</em><em>British Thoracic Society; Scottish Intercollegiate Guidelines Network, 2016) </em></p>
                                             <ul>
                                             <li>Initial treatment of acute severe asthma includes:</li>
                                             <ul>
                                             <li><strong>Supplementary oxygen</strong> if hypoxaemic. Titrate to maintain an oxygen saturation level of <strong>94% to 98%</strong></li>
                                             <li><strong>High-dose inhaled beta2 agonists</strong> as early as possible, usually via nebuliser (oxygen-driven)</li>
                                             <li><strong>Ipratropium bromide</strong> via nebuliser (oxygen-driven) if needed</li>
                                             <li><strong>Corticosteroids</strong> in adequate doses (40 to 50 mg daily for at least 5 days)</li>
                                             <li>Other therapies may be required, <strong>follow guideline recommendations</strong></li>
                                             <li>See BMJ Best Practice topic on Acute exacerbation of asthma in adults.</li>
                                             </ul>
                                             </ul>
                                             <p><strong>Stop long-acting muscarinic receptor antagonists (LAMAs) e.g., tiotropium temporarily if short-acting muscarinic antagonists (SAMAs) e.g., ipratropium bromide are prescribed via nebuliser.</strong></p>
                                             <ul>
                                             <li>This is based on expert opinion due to concern over possible anticholinergic adverse effects.</li>
                                             </ul>
                                             <p><strong>Regular nebulisers should only be prescribed for 24 to 48 hours and then switched back to the patient&rsquo;s usual inhalers.</strong></p>
                                             
                                       <div class="evidence-accordion">
                                             <div class="option">
                                                <input type="checkbox" id="toggle13" class="toggle" />
                                                <label class="title" for="toggle13">                                             
                                                   <span class="material-icons"><span></span></span>
                                                   <span class="title">Evidence: cardiovascular harm with beta2- agonists.</span>
                                                  </label>
                                                <div class="content">
                                                      <p><strong>Beta2-agonists increase the risk of myocardial infarction and other adverse cardiovascular events</strong></p>
                                                      <p>Beta2-agonists increase heart rate and reduce potassium levels. <em>(Salpeter SR, et al, 2004) </em>They are absorbed into the systemic circulation and there is evidence they are associated with an increased risk of myocardial infarction, unable angina, congestive heart failure and arrhythmias. <em>(Au DH, et al, 2002) (Salpeter SR, et al, 2004) (Baker JG, 2017)</em></p>
                                                </div>
                                             </div>
                                          </div>
                                          
                                       <div class="evidence-accordion">
                                             <div class="option">
                                                <input type="checkbox" id="toggle14" class="toggle" />
                                                <label class="title" for="toggle14">                                             
                                                   <span class="material-icons"><span></span></span>
                                                   <span class="title">Evidence: short duration vs longer duration of corticosteroids for acute exacerbation of COPD</span>
                                                  </label>
                                                <div class="content">
                                                      <p><strong>A systematic review found no difference in outcomes (treatment failure, time to next exacerbation, time in hospital, lung function, adverse effects, mortality) between short courses (7 days or less) vs more conventional longer courses (longer than 7 days) of corticosteroids in people with acute exacerbation of COPD </strong><em>(Walters JAE, et al, 2018)</em></p>
                                                      <ul>
                                                      <li>The randomised controlled trials included in this Cochrane review were all in hospital settings and only included people with severe to very severe COPD<em> (Walters JAE, et al, 2018)</em></li>
                                                      <li>The review authors concluded that due to the addition of a new trial, they have increased confidence that a corticosteroid course of around 5 days is likely to be sufficient for the treatment of an acute exacerbation of COPD. <em>(Walters JAE, et al, 2018)</em></li>
                                                      </ul>
                                                </div>
                                             </div>
                                          </div>
                                          </div>
                                    </div>
                                    <!-- CONDITIONAL COMO CONTENT ENDS -->
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Diabetes-como-content" style="display: none;">
                                 <div class="panel-header">
                                    <p class="panel-title"> 
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                       <span class="titles-wrap col-md-12">
                                       <span class="title-02 no-icon">
                                          <span class="title-03 col-md-1">
                                          Plus
                                          <span class="noShow">&nbsp;–&nbsp;</span>
                                          </span>
                                          <span class="title-04">
                                          <span class="material-icons"><span></span><span></span></span>
                                          <span class="txtwrap">Check patient's feet</span>
                                          </span>
                                          <span class="material-icons">
                                             <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                             <g>
                                                <g>
                                                   <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                      c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                   <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                      c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                   <g>
                                                      <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                   </g>
                                                </g>
                                                <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                   7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                             </g>
                                             </svg>
                                          </span>
                                       </span>
                                       </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_0_0_3" id="panel_0_0_3" aria-expanded="false">
                                    <!-- CONDITIONAL COMO CONTENT -->
                                    <div class="Diabetes-como-content" style="display: block;">
                                          <div class="poce_drug_msg">
                                             <span class="material-icons">
                                                <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                <g>
                                                   <g>
                                                      <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                         c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                      <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                         c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                      <g>
                                                         <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                      </g>
                                                   </g>
                                                   <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                      7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                </g>
                                                </svg>
                                             </span> 
                                             <h3 class="poce_title"></h3>
                                             <p><strong>Check the feet of all adults with diabetes on admission to hospital and whenever there has been a change in their status. </strong><em>(NICE, 2016)</em></p>
                                             <ul>
                                             <li><strong>Why? </strong></li>
                                             <ul>
                                             <li>To detect <strong>new ulceration </strong>or<strong> infection, </strong>which may be<strong> unnoticed</strong> by the patient andmay even be the <strong>underlying cause </strong>of their illness (e.g., patient presenting with sepsis, spinal abscess or endocarditis where the original focus of infection is the foot lesion).</li>
                                             <li>To determine if patient is at<strong> high risk of pressure ulceration </strong>and <strong>requires pressure relief</strong>.</li>
                                             </ul>
                                             <li><strong>Take action </strong></li>
                                             <ul>
                                             <li>You must <strong>remove any foot dressings</strong> to see if any wound/ulcer is<strong> infected. </strong><em>(NICE NG19, 2016)</em></li>
                                             <li><strong>Inspect</strong> the foot for lesions and examine for loss of protective <strong>sensation</strong>. Follow your local guidelines, but a quick simple test is the <strong>Ipswich Touch Test&copy;️</strong>. (Rayman G, et al, 2011)</li>
                                             <li>If your patient has <strong>reduced sensation</strong>, they are at <strong>high risk of pressure ulceration</strong>. Inform the nursing staff and <strong>provide pressure relieving devices</strong>.</li>
                                             </ul>
                                             </ul>
                                             <p>A <strong>daily heel check</strong> for <strong>signs of pressure trauma</strong> should be undertaken by nursing or health care assistant staff.</p>
                                          </div>
                                    </div>
                                    <!-- CONDITIONAL COMO CONTENT ENDS -->
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group">
                                 <div class="panel-header">
                                    <p class="panel-title"> 
                                       <a href="#" role="tab header" id="nested-collapse_0_0_3" aria-controls="nested-collapse_0_0_3" aria-expanded="false" class="">
                                       <span class="title-01">
                                       <span>  
                                          Contraindication to thrombolysis; and no contraindication to anticoagulation                                                                                                                                                         
                                       </span>
                                       <span class="noShow">&nbsp;–&nbsp;</span>
                                       </span>
                                       <span class="titles-wrap col-md-12">
                                       <span class="title-02">
                                       <span class="title-03 col-md-1">
                                       1st line
                                       <span class="noShow">&nbsp;–&nbsp;</span>
                                       </span>
                                       <span class="title-04">
                                       <span class="material-icons"><span></span><span></span></span>
                                       <span class="txtwrap">Start unfractionated heparin</span>
                                       </span>
                                       </span>
                                       </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_0_0_3" id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">
                              
                                    <p><strong>Involve senior support and/or critical care in patients who are haemodynamically unstable (SBP &lt;90 mmHg or SBP drop of &ge;40 mmHg for &gt;15 minutes).</strong></p>
                                    <p><strong>Start UFH in haemodynamically unstable patients prior to primary reperfusion.</strong></p>
                                    <ul>
                                    <li>UFH has a short half-life, is easy to monitor, and is readily reversed by protamine. [ESC]</li>
                                    </ul>
                                    <p><br /><strong>Check local guidelines and seek specialist advice when deciding how long to continue UFH for</strong>.[ESC] In the UK it is common practice to stop UFH within 24 hours but this will depend on the stability of the patient.</p>

                                       <div id="tip_pitfall" class="card card-inverse mb-4">
                                       <div class="card-block">
                                          <svg version="1.1" id="pin" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 90 90" enable-background="new 0 0 90 90" xml:space="preserve">
                                          <g>
                                             <g>
                                                <path fill="#333333" d="M42.694,51.942v30.413C42.694,83.816,44.174,85,46,85s3.306-1.184,3.306-2.645V51.942H42.694z"></path>
                                             </g>
                                             <g>
                                                <ellipse fill="#333333" cx="46" cy="47.645" rx="19.835" ry="12.231"></ellipse>
                                             </g>
                                             <g id="cylinder">
                                                <polygon fill="#333333" points="55.256,9.628 46,9.628 36.744,9.628 34.099,47.975 46,47.975 57.901,47.975 		"></polygon>
                                             </g>
                                             <g id="cylinder_highlight">
                                                <polygon fill="#FFFFFF" points="54.595,46.653 50.628,47.975 49.306,13.595 53.273,13.595 		"></polygon>
                                             </g>
                                             <g>
                                                <ellipse fill="#333333" cx="46" cy="13.595" rx="15.207" ry="8.595"></ellipse>
                                             </g>
                                             <g id="highlight">
                                                <path fill="#FFFFFF" d="M47.982,18.929c-0.67,0-1.245-0.508-1.313-1.19c-0.073-0.727,0.456-1.375,1.183-1.448
                                                   c3.157-0.318,5.857-1.434,7.224-2.985c0.48-0.547,1.317-0.602,1.866-0.118c0.548,0.482,0.601,1.318,0.118,1.866
                                                   c-1.822,2.069-5.082,3.479-8.942,3.868C48.072,18.927,48.027,18.929,47.982,18.929z"></path>
                                             </g>
                                             <g>
                                                <path fill="#333333" d="M46,49.54v-1.322c4.794,0,9.917-1.192,9.917-4.54h1.322C57.239,47.349,53.038,49.54,46,49.54z"></path>
                                             </g>
                                             <g id="highlight_lower">
                                                <path fill="#FFFFFF" d="M48.011,56.926c-0.032,0-0.064,0-0.098,0c-0.73-0.003-1.319-0.598-1.316-1.328
                                                   c0.003-0.729,0.595-1.316,1.322-1.316c0.034,0,0.063,0,0.095,0c3.975,0,7.602-1.166,9.719-3.128
                                                   c0.533-0.496,1.37-0.467,1.868,0.071c0.496,0.535,0.465,1.372-0.071,1.868C56.937,55.496,52.637,56.926,48.011,56.926z"></path>
                                             </g>
                                             </g>
                                             </svg>
                                             <h3 class="card-title">In patients who are haemodynamically unstable, evidence of RV dysfunction on echocardiography is sufficient to warrant immediate anticoagulation.</h3>
                                             <p><strong></strong></p>
                                             <ul>
                                             <li><strong>These patients are normally too unstable to undergo CTPA.</strong></li>
                                             </ul>
                                          </div>
                                       </div>
                                       
                                       
   
                                       <div class="evidence-accordion">
                                             <div class="option">
                                                <input type="checkbox" id="toggle15" class="toggle" />
                                                <label class="title" for="toggle15">                                             
                                                   <span class="material-icons"><span></span></span>
                                                   <span class="title">Evidence: There is insufficient evidence to support use of LMWH in haemodynamically unstable (high-risk) PE</span>
                                             </label>
                                                <div class="content">
                                                   <p><strong>There is some evidence that LMWH has a similar safety profile to UFH when used prior to thrombolysis.</strong></p>
                                                   <ul>
                                                   <li>A prospective, observational multicentre trial showed similar bleeding rates following thrombolysis in patients who had UFH or LMWH. However this evidence remains limited.</li>
                                                   </ul>
                                                   <p><strong>There is not enough evidence to recommend LMWH as a first-line option for patients with PE who are haemodynamically unstable. </strong>[UCAR]</p>
                                                </div>
                                             </div>
                                          </div>
   
                                          <div id="tip_pitfall" class="card card-inverse mb-4">
                                             <div class="card-block">
                                                <svg version="1.1" id="pin" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 90 90" enable-background="new 0 0 90 90" xml:space="preserve">
                                                <g>
                                                   <g>
                                                      <path fill="#333333" d="M42.694,51.942v30.413C42.694,83.816,44.174,85,46,85s3.306-1.184,3.306-2.645V51.942H42.694z"></path>
                                                   </g>
                                                   <g>
                                                      <ellipse fill="#333333" cx="46" cy="47.645" rx="19.835" ry="12.231"></ellipse>
                                                   </g>
                                                   <g id="cylinder">
                                                      <polygon fill="#333333" points="55.256,9.628 46,9.628 36.744,9.628 34.099,47.975 46,47.975 57.901,47.975 		"></polygon>
                                                   </g>
                                                   <g id="cylinder_highlight">
                                                      <polygon fill="#FFFFFF" points="54.595,46.653 50.628,47.975 49.306,13.595 53.273,13.595 		"></polygon>
                                                   </g>
                                                   <g>
                                                      <ellipse fill="#333333" cx="46" cy="13.595" rx="15.207" ry="8.595"></ellipse>
                                                   </g>
                                                   <g id="highlight">
                                                      <path fill="#FFFFFF" d="M47.982,18.929c-0.67,0-1.245-0.508-1.313-1.19c-0.073-0.727,0.456-1.375,1.183-1.448
                                                         c3.157-0.318,5.857-1.434,7.224-2.985c0.48-0.547,1.317-0.602,1.866-0.118c0.548,0.482,0.601,1.318,0.118,1.866
                                                         c-1.822,2.069-5.082,3.479-8.942,3.868C48.072,18.927,48.027,18.929,47.982,18.929z"></path>
                                                   </g>
                                                   <g>
                                                      <path fill="#333333" d="M46,49.54v-1.322c4.794,0,9.917-1.192,9.917-4.54h1.322C57.239,47.349,53.038,49.54,46,49.54z"></path>
                                                   </g>
                                                   <g id="highlight_lower">
                                                      <path fill="#FFFFFF" d="M48.011,56.926c-0.032,0-0.064,0-0.098,0c-0.73-0.003-1.319-0.598-1.316-1.328
                                                         c0.003-0.729,0.595-1.316,1.322-1.316c0.034,0,0.063,0,0.095,0c3.975,0,7.602-1.166,9.719-3.128
                                                         c0.533-0.496,1.37-0.467,1.868,0.071c0.496,0.535,0.465,1.372-0.071,1.868C56.937,55.496,52.637,56.926,48.011,56.926z"></path>
                                                   </g>
                                                   </g>
                                                   </svg>
                                                   <h3 class="card-title">Seek haematology advice if a patient with high-risk PE who is haemodynamically unstable has any contraindications to thrombolysis.</h3>
                                                   <ul>
                                                      <li>In practice, almost any contraindication to thrombolysis should be considered only relative in high-risk patients who present with haemodynamic instability.</li>
                                                      <li>This is because the mortality risk from high-risk PE is so high that it is likely to outweigh any bleeding risk from thrombolysis in this patient group. [ESC]</li>
                                                      </ul>
                                                      <p><strong>Absolute contraindications: [ESC]</strong></p>
                                                      <ul>
                                                      <li>haemorrhagic stroke or stroke of unknown origin at any time</li>
                                                      <li>ischaemic stroke in the preceding 6 months</li>
                                                      <li>central nervous system damage or neoplasms</li>
                                                      <li>recent major trauma/surgery/head injury (in the preceding 3 weeks)</li>
                                                      <li>gastrointestinal bleeding within the last month</li>
                                                      <li>known bleeding risk.</li>
                                                      </ul>
                                                      <p><strong>Relative contraindications:</strong></p>
                                                      <ul>
                                                      <li>transient ischaemic attack in the preceding 6 months</li>
                                                      <li>oral anticoagulant therapy</li>
                                                      <li>pregnancy or within 1 week postnatally</li>
                                                      <li>traumatic resuscitation (in relation to this episode of PE)</li>
                                                      <li>refractory hypertension (SBP &gt;180 mmHg)</li>
                                                      <li>advanced liver disease</li>
                                                      <li>infective endocarditis</li>
                                                      <li>active peptic ulcer</li>
                                                      </ul>
                                                </div>
                                             </div>


                                          <div class="treatment-wrap">
                                             <h4>Primary options</h4>
                                             <div class="treatment-box">
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">heparin</a><span>: </span><span>10,000 units intravenously as a loading dose initially, followed by 18 units/kg/hour intravenous infusion, adjust dose according to aPTT</span>
                                                </p>
                                             </div>
                                          </div>
                                             
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group">
                                 <div class="panel-header">
                                    <p class="panel-title"> 
                                       <a href="#" role="tab header" id="nested-collapse_0_0_3" aria-controls="nested-collapse_0_0_3" aria-expanded="false" class="">
                                       <span class="titles-wrap col-md-12">
                                       <span class="title-02">
                                       <span class="title-03 col-md-1">
                                       Plus
                                       <span class="noShow">&nbsp;–&nbsp;</span>
                                       </span>
                                       <span class="title-04">
                                       <span class="material-icons"><span></span><span></span></span>
                                       <span class="txtwrap">Switch to alternative anticoagulant</span>
                                       </span>
                                       </span>
                                       </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_0_0_3" id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">
                              
                                    <p><strong>Continue anticoagulation with UFH before switching to LMWH, fondaparinux, apixaban, or rivaroxaban</strong>.[ESC] <strong>Check local guidelines and seek specialist advice when deciding how long to continue UFH for</strong>. [ESC] In the UK it is common practice to stop UFH within 24 hours but this will depend on the stability of the patient.</p>
                                    <ul>
                                    <li><strong>If switching to LMWH (e.g,. dalteparin, enoxaparin) or fondaparinux, the total duration of treatment with UFH and then LMWH or fondaparinux should be at least 5 days.</strong>[NICE][ESC]</li>
                                    <ul>
                                    <li>If ongoing anticoagulation will be with warfarin, ensure overlap with UFH, LMWH, or fondaparinux for at least 5 days or until the INR is &ge;2 for at least 24 hours (whichever is the longer).[NICE] Seek specialist advice to decide when to start warfarin.</li>
                                    </ul>
                                    </ul>
                                    <p><strong>OR</strong></p>
                                    <ul>
                                    <ul>
                                    <li>If ongoing anticoagulation will be with edoxaban or dabigatran, at least 5 days of lead-in therapy with LMWH or fondaparinux is required first. Stop the LMWH or fondaparinux before starting dabigatran or edoxaban.[BTS]</li>
                                    </ul>
                                    <li><strong>If switching to rivaroxaban or apixaban, these drugs may be started after stopping UFH without the need for lead-in therapywith LMWH or fondaparinux first</strong>.</li>
                                    <ul>
                                    <li>Acute-phase treatment consists of an increased dose of the oral anticoagulant over the first 3 weeks (for rivaroxaban), or over the first 7 days (for apixaban).</li>
                                    </ul>
                                    </ul>
                                    <p><strong>Seek specialist advice when switching between anticoagulants</strong></p>
                                    <ul>
                                    <li>The protocol depends on which anticoagulant you are switching to and from. Haematology input is important.</li>
                                    </ul>
                                    <p><br /><strong>Be aware of special patient groups such as pregnancy, renal impairment, and active cancer</strong> as these groups will need a specific type/dose of anticoagulant. <strong>Seek haematology advice for all patients with hepatic impairment or who are at increased risk of bleeding.</strong></p>

                                    <div id="tip_pitfall" class="card card-inverse mb-4">
                                    <div class="card-block">
                                       <svg version="1.1" id="pin" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 90 90" enable-background="new 0 0 90 90" xml:space="preserve">
                                       <g>
                                          <g>
                                             <path fill="#333333" d="M42.694,51.942v30.413C42.694,83.816,44.174,85,46,85s3.306-1.184,3.306-2.645V51.942H42.694z"></path>
                                          </g>
                                          <g>
                                             <ellipse fill="#333333" cx="46" cy="47.645" rx="19.835" ry="12.231"></ellipse>
                                          </g>
                                          <g id="cylinder">
                                             <polygon fill="#333333" points="55.256,9.628 46,9.628 36.744,9.628 34.099,47.975 46,47.975 57.901,47.975 		"></polygon>
                                          </g>
                                          <g id="cylinder_highlight">
                                             <polygon fill="#FFFFFF" points="54.595,46.653 50.628,47.975 49.306,13.595 53.273,13.595 		"></polygon>
                                          </g>
                                          <g>
                                             <ellipse fill="#333333" cx="46" cy="13.595" rx="15.207" ry="8.595"></ellipse>
                                          </g>
                                          <g id="highlight">
                                             <path fill="#FFFFFF" d="M47.982,18.929c-0.67,0-1.245-0.508-1.313-1.19c-0.073-0.727,0.456-1.375,1.183-1.448
                                                c3.157-0.318,5.857-1.434,7.224-2.985c0.48-0.547,1.317-0.602,1.866-0.118c0.548,0.482,0.601,1.318,0.118,1.866
                                                c-1.822,2.069-5.082,3.479-8.942,3.868C48.072,18.927,48.027,18.929,47.982,18.929z"></path>
                                          </g>
                                          <g>
                                             <path fill="#333333" d="M46,49.54v-1.322c4.794,0,9.917-1.192,9.917-4.54h1.322C57.239,47.349,53.038,49.54,46,49.54z"></path>
                                          </g>
                                          <g id="highlight_lower">
                                             <path fill="#FFFFFF" d="M48.011,56.926c-0.032,0-0.064,0-0.098,0c-0.73-0.003-1.319-0.598-1.316-1.328
                                                c0.003-0.729,0.595-1.316,1.322-1.316c0.034,0,0.063,0,0.095,0c3.975,0,7.602-1.166,9.719-3.128
                                                c0.533-0.496,1.37-0.467,1.868,0.071c0.496,0.535,0.465,1.372-0.071,1.868C56.937,55.496,52.637,56.926,48.011,56.926z"></path>
                                          </g>
                                          </g>
                                          </svg>
                                          <h3 class="card-title">Never give a DOAC simultaneously with parenteral anticoagulation</h3>
                                          <ul>
                                          <li>While warfarin is started at the same time as a parenteral anticoagulant and overlapped for at least 5 days or until the INR is &ge;2 for at least 24 hours (whichever is the longer), DOACs should never be overlapped or given at the same time as a parenteral anticoagulant.</li>
                                          <li>Apixaban and rivaroxaban may be started without the need for lead-in therapy with a parenteral anticoagulant first. Either of these DOACs can be used as a single-drug approach; this is why BTS guidelines recommend them as the preferred DOAC options in any patient who might be suitable for early discharge. [BTS]</li>
                                          <li>However, dabigatran and edoxaban require at least 5 days lead-in therapy with a parenteral anticoagulant before starting treatment. The parenteral anticoagulant should be stopped before dabigatran or edoxaban are started.</li>
                                          </ul>

                                       </div>
                                    </div>
                                                                            
   
                                       


                                    <div class="treatment-wrap">
                                       <h4>Primary options</h4>
                                       <div class="treatment-box">
                                          <p><strong>[No special considerations]</strong></p>
                                          <p>
                                             <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">apixaban</a><span>: </span><span>10 mg orally twice daily for 7 days, followed by 5 mg twice daily</span>
                                          </p>
                                          <p class="small-or">OR</p>
                                          <p><strong>[No special considerations]</strong></p>
                                          <p>
                                             <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">rivaroxaban</a>
                                             <span>: </span>
                                             <span>15 mg orally twice daily for 21 days, followed by 20 mg once daily</span>
                                          </p>
                                          <p class="small-or">OR</p>
                                          <p><strong>[No special considerations]</strong></p>
                                          <p>
                                             <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">enoxaparin:</a>
                                             <span>: </span>
                                             <span>1 mg/kg subcutaneously every 12 hours</span> 
                                          </p>
                                          <p class="small-or">-or-</p>
                                          <p>
                                             <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">dalteparin</a>
                                             <span>: </span>
                                             <span>100 units/kg subcutaneously every 12 hours</span>
                                          </p>
                                          <p class="small-or">-AND-</p>
                                          <p>
                                             <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">warfarin</a>
                                             <span>: </span>
                                             <span>5-10 mg orally once daily initially, adjust dose according to target INR</span>                 
            
                                          <span class="reference">
                                                <a href="#referencePop-more4" data-trigger="click focus" data-toggle="popover" class="morePop" data-original-title="" title="" aria-describedby="popover621629">More</a>
                                                <span class="popTitle" aria-hidden="true">
                                                </span>
                                                <span class="popText" aria-hidden="true">
                                                   <p class="w-75">Starting dose can be calculated using an online tool that takes patient characteristics and/or CYP2C9/VKORC1 genotype information (if available) into account. [http://www.warfarindosing.org/Source/Home.aspx ONLINE RESOURCE: Warfarin dosing]</p>
                                                </span>
                                             </span>
               
                                          </p><p class="small-or">OR</p>
                                          <p><strong>[Active cancer]</strong></p>
                                          <p>
                                             <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">enoxaparin:</a>
                                             <span>: </span>
                                             <span>1 mg/kg subcutaneously every 12 hours</span> 
                                          </p><p class="small-or">OR</p>
                                          <p><strong>[Active cancer]</strong></p>
                                          <p>
                                             <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">dalteparin:</a>
                                             <span>: </span>
                                             <span>200 units/kg subcutaneously once daily for the first 30 days, followed by 150 units/kg once daily for 5 months, maximum 18,000 units/dose 
                                                | 
                                                
                                             <span class="reference">
                                                <a href="#referencePop-more4" data-trigger="click focus" data-toggle="popover" class="morePop" data-original-title="" title="" aria-describedby="popover621629">More</a>
                                                <span class="popTitle" aria-hidden="true">
                                                </span>
                                                <span class="popText" aria-hidden="true">
                                                   <p class="w-75">Refer to local drug formulary for a table of recommended weight-based doses. Use fixed-dose syringes for this indication. </p>
                                                </span>
                                             </span>

                                          </span> 
                                          </p><p class="small-or">OR</p>
                                          <p><strong>[Pregnant women]</strong></p>
                              
                                          <p>
                                             <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">enoxaparin</a>
                                             <span>: </span>
                                             <span>  body weight &lt;50 kg: 40 mg subcutaneously twice daily; body weight 50-69 kg: 60 mg subcutaneously twice daily; body weight 70-89 kg: 80 mg subcutaneously twice daily; body weight ≥90 kg: 100 mg subcutaneously twice daily </span>
                                          </p>
                                          <span class="reference">
                                             <a href="#referencePop-more8" data-trigger="click focus" data-toggle="popover" class="morePop" data-original-title="" title="" aria-describedby="popover621629">More</a>
                                             <span class="popTitle" aria-hidden="true"></span>
                                             <span class="popText" aria-hidden="true">
                                                <p class="w-75">
                                                   Dose based on early pregnancy body weight.
                                                </p>
                                             </span>
                                          </span>

                                       </p><p class="small-or">OR</p>
                                       <p><strong>[Pregnant women]</strong></p>
                           
                                       <p>
                                          <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">dalteparin</a>
                                          <span>: </span>
                                          <span>body weight &lt;50 kg: 5000 units subcutaneously twice daily; body weight 50-69 kg: 6000 units subcutaneously twice daily; body weight 70-89 kg: 8000 units subcutaneously twice daily; body weight ≥90 kg: 10,000 units subcutaneously twice daily</span>
                                       </p>
                                       <span class="reference">
                                          <a href="#referencePop-more8" data-trigger="click focus" data-toggle="popover" class="morePop" data-original-title="" title="" aria-describedby="popover621629">More</a>
                                          <span class="popTitle" aria-hidden="true"></span>
                                          <span class="popText" aria-hidden="true">
                                             <p class="w-75">
                                                Dose based on early pregnancy body weight.
                                             </p>
                                          </span>
                                       </span>

                                       
                                    </p><p class="small-or">Secondary options</p>
                                    <p><strong>[No special considerations]</strong></p>
                        
                                    <p>
                                       <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">fondaparinux</a>
                                       <span>: </span>
                                       <span>body weight &lt;50 kg: 5 mg subcutaneously once daily; body weight 50-100 kg: 7.5 mg subcutaneously once daily; body weight ≥100 kg: 10 mg subcutaneously once daily</span>
                                    </p>

                                 </p><p class="small-or">AND</p>                           
                                 <p>
                                    <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">warfarin</a>
                                    <span>: </span>
                                    <span>5-10 mg orally once daily initially, adjust dose according to target INR</span>
                                 </p>
                                 <span class="reference">
                                    <a href="#referencePop-more8" data-trigger="click focus" data-toggle="popover" class="morePop" data-original-title="" title="" aria-describedby="popover621629">More</a>
                                    <span class="popTitle" aria-hidden="true"></span>
                                    <span class="popText" aria-hidden="true">
                                       <p class="w-75">
                                          Starting dose can be calculated using an online tool that takes patient characteristics and/or CYP2C9/VKORC1 genotype information (if available) into account. [ONLINE RESOURCE: Warfarin dosing http://www.warfarindosing.org/Source/Home.aspx]
                                       </p>
                                    </span>
                                 </span>
                              </p><p class="small-or">OR</p> 
                              <p><strong>[No special considerations]</strong></p>                 
                              <p>
                                 <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">edoxaban</a>
                                 <span>: </span>
                                 <span>start following initial use of a parenteral anticoagulant for at least 5 days; body weight &lt;60 kg: 30 mg orally once daily; body weight ≥60 kg: 60 mg orally once daily</span>
                              </p>
                           </p><p class="small-or">OR</p> 
                           <p><strong>[No special considerations]</strong></p>                 
                           <p>
                              <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">dabigatran</a>
                              <span>: </span>
                              <span>start following initial use of a parenteral anticoagulant for at least 5 days; 18-74 years of age: 150 mg orally twice daily; 75-79 years of age: 110-150 mg orally twice daily; ≥80 years of age: 110 mg orally twice daily</span>
                           </p>
                                       </div>
                                    </div>
                                             
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group">
                                 <div class="panel-header">
                                    <p class="panel-title"> 
                                       <a href="#" role="tab header" id="nested-collapse_0_0_3" aria-controls="nested-collapse_0_0_3" aria-expanded="false" class="">
                                       <span class="titles-wrap col-md-12">
                                       <span class="title-02">
                                       <span class="title-03 col-md-1">
                                          Consider
                                       <span class="noShow">&nbsp;–&nbsp;</span>
                                       </span>
                                       <span class="title-04">
                                       <span class="material-icons"><span></span><span></span></span>
                                       <span class="txtwrap">Vasoactive drug</span>
                                       </span>
                                       </span>
                                       </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_0_0_3" id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">
                              
                                    <p><strong>Give a vasopressor such as adrenaline (epinephrine) or noradrenaline (norepinephrine), or an inotrope such as dobutamine if SBP remains &lt;90 mmHg despite giving adequate intravenous fluids.</strong>[ESC]</p>
                              
   
                                    <div class="evidence-accordion">
                                       <div class="option">
                                          <input type="checkbox" id="toggle16" class="toggle" />
                                          <label class="title" for="toggle16">                                             
                                             <span class="material-icons"><span></span></span>
                                             <span class="title">Evidence: Choice of vasopressor is based on limited evidence</span>
                                       </label>
                                          <div class="content">
                                             <p><strong>Adrenaline combines the beneficial properties of noradrenaline (vasoconstriction with increased right ventricular perfusion, positive inotropy) and dobutamine (positive inotropy), but without the vasodilatory effects associated with the latter.</strong> [ESC]</p>
                                             <ul>
                                             <li>A small prospective descriptive study of patients with RV failure and shock demonstrated that during adrenaline infusion, mean arterial pressure (MAP), cardiac index (CI) and stroke volume index (SVI) were increased and right ventricular ejection fraction (RVEF) improved as well.</li>
                                             <li>Another small study showed that adrenaline improved cardiac output in patients with shock without having a detrimental effect on pulmonary vascular resistance. [BARRINGTON]</li>
                                             </ul>
                                             <p><strong>Evidence suggests that noradrenaline appears to improve RV function through its inotropic effect, as well as improving coronary perfusion by raising systemic pressure.</strong></p>
                                             <ul>
                                             <li>However, noradrenaline increases pulmonary vascular resistance and, in fact, no conclusive data are available regarding its potential use in PE. [PREWITT]</li>
                                             </ul>
                                             <p><strong>The use of dobutamine and/or dopamine may be considered for patients with PE, low cardiac index, and normal BP based on the results of some studies.</strong></p>
                                             <ul>
                                             <li>Dobutamine enhances contractility with an increase in stroke volume and cardiac output. However, raising the cardiac index above physiological values may aggravate the ventilation&ndash;perfusion mismatch by further redistributing ﬂow from (partly) obstructed to unobstructed vessels. [DIS][ESC]</li>
                                             </ul>
                                          </div>
                                       </div>
                                    </div>
                                            
                                    <div class="treatment-wrap">
                                       <h4>Primary options</h4>
                                       <div class="treatment-box">
                                          <p>
                                             <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">adrenaline (epinephrine)</a><span>: </span><span>2-10 micrograms/minute by intravenous infusion initially, adjust dose according to response</span>
                                          </p>
                                          <p class="small-or">OR</p>
                                          <p>
                                             <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">noradrenaline (norepinephrine)</a>
                                             <span>: </span>
                                             <span> 0.4 to 0.8 mg/hour by intravenous infusion initially, adjust dose according to response</span>
                                          </p>
                                          
                                 <span class="reference">
                                       <a href="#referencePop-more8" data-trigger="click focus" data-toggle="popover" class="morePop" data-original-title="" title="" aria-describedby="popover621629">More</a>
                                       <span class="popTitle" aria-hidden="true"></span>
                                       <span class="popText" aria-hidden="true">
                                          <p class="w-75">
                                                Dose refers to noradrenaline base.
                                          </p>
                                       </span>
                                    </span>
                                          <p class="small-or">OR</p>
                                          <p>
                                             <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">dobutamine:</a>
                                             <span>: </span>
                                             <span>2.5 to 10 micrograms/kg/minute by intravenous infusion initially, adjust dose according to response, maximum 40 micrograms/kg/minute</span> 
                                          </p>
                                       </div>
                                    </div>


                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group">
                                 <div class="panel-header">
                                    <p class="panel-title"> 
                                       <a href="#" role="tab header" id="nested-collapse_0_0_3" aria-controls="nested-collapse_0_0_3" aria-expanded="false" class="">
                                       <span class="titles-wrap col-md-12">
                                       <span class="title-02">
                                       <span class="title-03 col-md-1">
                                          Consider
                                       <span class="noShow">&nbsp;–&nbsp;</span>
                                       </span>
                                       <span class="title-04">
                                       <span class="material-icons"><span></span><span></span></span>
                                       <span class="txtwrap">Surgical embolectomy/percutaneous catheter-directed treatment</span>
                                       </span>
                                       </span>
                                       </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_0_0_3" id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">
                              
                                       <p><strong>According to the European Society of Cardiology (ESC) guidelines [ESC] [CTS], surgical embolectomy or percutaneous catheter-directed therapy may be indicated in the following circumstances: </strong></p>
                                       <ul>
                                       <li>Patients who are unable to receive thrombolytic therapy because of bleeding risk</li>
                                       <li>Insufficient time for effective systemic thrombolysis</li>
                                       <li>Failed thrombolysis</li>
                                       </ul>
                                       <p><strong>The use of these interventions will depend on local expertise and availability.</strong></p>
                                       <p><strong>Surgical pulmonary embolectomy</strong></p>
                                       <ul>
                                       <li>Although this is rarely performed in the UK, the ESC guideline states that is technically a relatively simple operation although in practice it is normally only undertaken in specialist cardiothoracic centres. [ESC]</li>
                                       </ul>
                                       <p><strong>Catheter-directed therapy</strong></p>
                                       <ul>
                                       <li>Catheter-directed therapy uses a lower dose of thrombolytic drug (approximately one third of full-dose systemic thrombolysis) and is believed to reduce the risks of bleeding at remote sites(e.g. Intracranial or gastrointestinal). [KEARON]</li>
                                       <li>For patients with absolute contraindications to thrombolysis, interventional options include: [ESC]</li>
                                       <ul>
                                       <li>thrombus fragmentation with pigtail or balloon catheter,</li>
                                       <li>rheolytic thrombectomy with hydrodynamic catheter devices,</li>
                                       <li>suction thrombectomy with aspiration catheters</li>
                                       <li>rotational thrombectomy.</li>
                                       </ul>
                                       <li>For patients with relative contraindications to thrombolysis, interventional options include:[ESC]</li>
                                       <ul>
                                       <li>catheter-directed thrombolysis</li>
                                       <li>pharmacomechanical thrombolysis</li>
                                       </ul>
                                       </ul>
                              
   
                                    <div class="evidence-accordion">
                                       <div class="option">
                                          <input type="checkbox" id="toggle17" class="toggle" />
                                          <label class="title" for="toggle17">                                             
                                             <span class="material-icons"><span></span></span>
                                             <span class="title">Evidence: Surgical pulmonary embolectomy and catheter-directed therapy outcomes</span>
                                       </label>
                                          <div class="content">
                                                <p><strong>There is no comparative data to guide the primary management of patients with high-risk (massive) PE and a strong contraindication to systemic thrombolysis and therefore management will depend on local options and expertise</strong>.</p>
                                                <ul>
                                                <li>However, some small studies have looked at outcomes from surgical pulmonary embolectomy and catheter-directed therapy.</li>
                                                <li>Mortality rates following pulmonary embolectomy range from 4% to 27%. [FUKUDA] In a small cohort of patients who underwent surgical pulmonary embolectomy for acute high-risk (massive) pulmonary thromboembolism, the 10-year survival rate was 84%. [FUKUI]</li>
                                                <li>A meta-analysis of non-randomised trials of catheter-directed therapies reported a clinical success rate of 87% with an associated risk of major and minor complications of 2% and 8%, respectively. [KUO]</li>
                                                <li>The extent of early RV recovery after low-dose catheter-directed thrombolysis appears comparable to that after standard-dose systemic thrombolysis whereas anticoagulation with heparin alone has little effect on improvement of RV size and performance within the first 24&ndash;48 hours.
                                                </li>
                                                <li>In a randomized, controlled clinical trial of 59 intermediate-risk patients, when compared with treatment by heparin alone, catheter-directed ultrasound-accelerated thrombolysis&mdash;administering 10 mg alteplase per treated lung over 15 hours&mdash;significantly reduced the subannular RV/LV dimension ratio between baseline and 24-hour follow-up without an increase in bleeding complications [TIEDE] [BOLUS][KUCHER]</li>
                                                </ul>
                                          </div>
                                       </div>
                                    </div>

                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Diabetes-como-content" style="display: none;">
                                 <div class="panel-header">
                                       <p class="panel-title"> 
                                          <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                          <span class="title-02">
                                             <span class="title-03 col-md-1">
                                             Plus
                                             <span class="noShow">&nbsp;–&nbsp;</span>
                                             </span>
                                             <span class="title-04">
                                             <span class="material-icons"><span></span><span></span></span>
                                             <span class="txtwrap">Review diabetes medication (NEVER stop insulin in people with type 1 diabetes)</span>
                                             </span>
                                             <span class="material-icons">
                                                   <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                   <g>
                                                      <g>
                                                         <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                            c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                         <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                            c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                         <g>
                                                            <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                         </g>
                                                      </g>
                                                      <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                         7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                   </g>
                                                   </svg>
                                                </span>
                                          </span>
                                          </span>
                                          </a>
                                       </p>
                                 </div>
                                 <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_0_0_3" id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">

                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                             <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                <g>
                                                   <g>
                                                      <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                         c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                      <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                         c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                      <g>
                                                         <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                      </g>
                                                   </g>
                                                   <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                      7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                </g>
                                                </svg>
                                       </span> 
                                       <h3 class="poce_title"></h3>
                              
                                       <p><strong>Never stop insulin in people with type 1 diabetes coming into hospital - insulin deficiency can rapidly precipitate ketoacidosis, particularly during illness. </strong></p>
                                       <ul>
                                       <li><strong>Always continue basal insulins</strong> (long-acting or background insulins e.g., determir or glargine) as this will <strong>prevent ketoacidosis</strong> if doses of rapid-acting insulin are inadvertently missed or delayed.</li>
                                       <li><strong>Dose adjustments</strong> up or down may be needed.</li>
                                       <ul>
                                       <li>For example, in the<strong> absence of significant hyperglycaemia </strong>consider <strong>reducing the evening basal insulin by 20% on admission</strong>, as most patients will have a <strong>smaller evening meal in hospital</strong> compared with at home.</li>
                                       </ul>
                                       </ul>
                                       <p><strong>If a variable rate intravenous insulin infusion (VRIII) is started</strong>:</p>
                                       <ul>
                                       <li><strong>Continue the basal insulin </strong><em>(Joint British Diabetes Societies for inpatient care [JBDS-IP], 2014)</em> as this will reduce the risk of ketosis in the advent of the VRIII being <strong>accidentally interrupted </strong>(e.g., by cannula displacement or blockage) or <strong>switched off </strong>(e.g., during transfer to another ward or department)<strong>.</strong></li>
                                       <li>The patient&rsquo;s usual <strong>rapid-acting </strong>and <strong>mixed insulins</strong> can be <strong>stopped while on a VRIII</strong>. <em>Joint British Diabetes Societies for inpatient care [JBDS-IP], 2014)</em></li>
                                       <li>Use the VRIII for as <strong>short a time as possible</strong>, <em>(Joint British Diabetes Societies for inpatient care [JBDS-IP], 2014) </em>as incorrect use and insufficient monitoring can result in<strong> severe hypoglycaemia</strong> or<strong> ketoacidosis</strong>.</li>
                                       </ul>
                                       <p><strong>Indications for a VRIII include</strong>: <em>(Joint British Diabetes Societies for inpatient care [JBDS-IP], 2014)</em></p>
                                       <ul>
                                       <li>Patients with diabetes or hospital-related hyperglycaemia who <strong>can&rsquo;t take oral food or fluid </strong>and where it&rsquo;s <strong>not possible to adjust their insulin regimen</strong>, e.g., when:</li>
                                       <ul>
                                       <li>Vomiting</li>
                                       <li>Nil by mouth and patient will miss more than one meal</li>
                                       <li>There is severe illness with a need to achieve good glycaemic control (such as with sepsis).</li>
                                       </ul>
                                       <li>Most patients with diabetes <strong>requiring emergency surgery</strong>. <em>(Joint British Diabetes Societies for inpatient care [JBDS-IP], 2016)</em></li>
                                       <li><strong>Special circumstances</strong>, such as hyperglycaemia with <strong>acute coronary syndrome</strong>, when <strong>pregnant</strong>, or when receiving <strong>TPN or enteral feeding</strong>, or <strong>taking corticosteroids</strong>. <em>(Joint British Diabetes Societies for inpatient care., 2012) </em></li>
                                       <ul>
                                       <li><strong>Get specialist advice</strong> from the <strong>diabetes team</strong> in these circumstances.</li>
                                       </ul>
                                       </ul>
                                       <p><strong>People with type 2 diabetes on basal insulin should continue to take it, unless otherwise indicated</strong>.</p>
                                       <ul>
                                       <li>In the <strong>absence of significant hyperglycaemia</strong> consider <strong>reducing the evening basal insulin</strong> by <strong>20% on admission</strong>, as most patients will have a <strong>smaller evening mealin hospital </strong>compared with at home.</li>
                                       </ul>
                                       <p>Give<strong> oral hypoglycaemic</strong> medication<strong> with food</strong> to reduce the<strong> risk of hypoglycaemia</strong>.</p>
                                       <ul>
                                       <li><strong>Never give oral hypoglycaemic medication at bedtime </strong>and consider <strong>reducing the evening dose of sulphonylurea</strong>.</li>
                                       <ul>
                                       <li>This is because most patients have a <strong>smaller evening meal in hospital </strong>compared with their usual evening meal at home.</li>
                                       </ul>
                                       </ul>
                                       <p><strong>Withhold metformin in patients:</strong></p>
                                       <ul>
                                       <li>With <strong>contraindications</strong>, such as <strong>significant renal impairment</strong> (&lt;30 mL/minute/1.73 m2)</li>
                                       <li>With <strong>metabolic acidosis </strong>(including lactic acidosis and DKA)</li>
                                       <li>At<strong> risk of lactic acidosis</strong> with metformin, such as:</li>
                                       <ul>
                                       <li>With conditions associated with <strong>acute kidney injury </strong>or<strong> tissue hypoxia,</strong> including<strong> dehydration</strong></li>
                                       <li>With <strong>renal impairment</strong>and who have, or are to be <strong>fasted for a prolonged period</strong> or who are due to have a<strong> radio-opaque contrast injection</strong> as part of an imaging procedure. <strong>Follow local protocols </strong>for guidance on the specific eGFR levels indicating renal impairment for this to be applied.</li>
                                       </ul>
                                       </ul>
                                       <p><strong>Be aware that withholding metformin results in hyperglycemia</strong>.</p>
                                       <ul>
                                       <li>If your patient is taking <strong>other glucose-lowering medication</strong>, these may need to be<strong> increased in dose</strong> or an <strong>alternative hypoglycaemic medication to metformin</strong> prescribed.</li>
                                       <li>Some patients may need <strong>insulin as a temporary measure</strong>, but<strong> seek diabetes inpatient specialist team advice</strong>.</li>
                                       </ul>
                                       <p><strong>Stop sodium-glucose cotransporter-2 (SGLT-2) inhibitors in all acutely ill patients, particularly if dehydrated or with infection, as they are at risk of euglycaemic ketoacidosis.</strong></p>
                                       <ul>
                                       <li>SGLT-2 inhibitors (e.g., dapagliflozin) <strong>reduce blood glucose reabsorption</strong> in the kidneys (independently of insulin metabolism of glucose). <em>(Peters AL, et al, 2015) </em></li>
                                       <li>They can<strong> mask underlying ketoacidosis</strong> by patients having a normal (or near normal) serum glucose level <strong>(euglycaemic ketoacidosis)</strong>.</li>
                                       <li>Check <strong>blood ketones</strong> as urinary ketone measurement may be unreliable.</li>
                                       <li><strong>Treat for DKA</strong> if <strong>blood ketone level is &ge;3 mmol/L</strong>, blood<strong> pH &lt;7.3</strong> and <strong>bicarbonate &lt;15 mmol/L</strong>. (<em>JBDS-IP, 2013)</em></li>
                                       </ul>
                                       <p><strong>Reduce or omit the dose of gliclazide if the patient has impaired kidney function or is eating less than usual, to avoid hypoglycaemia at night. </strong></p>
                                       <p><strong>Inform the diabetic inpatient team of the admission of any patient with diabetes. They are available for advice and support.</strong></p>
                                       <p><strong>For a patient at theend of life</strong>: <em>(Rowles S, et al 2011)</em></p>
                                       <ul>
                                       <li><strong>Hypoglycaemic medication</strong> should be <strong>reduced </strong>to the minimum, <strong>but</strong></li>
                                       <li>The patient should be<strong> kept free from symptomatic hyperglycaemia</strong>, which can lead to <strong>dehydration</strong>, <strong>ketosis</strong> or <strong>hyperosmolar hyperglycaemia</strong>.</li>
                                       </ul>
                                       <p>Refer to <strong>local protocols </strong>or the Association of British Clinical Diabetologists (ABCD). <em>(Rowles S, et al 2011)</em></p>
                                    </div>
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Diabetes-como-content" style="display: none;">
                                    <div class="panel-header">
                                          <p class="panel-title"> 
                                             <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                             <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1">
                                                Plus
                                                <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                <span class="material-icons"><span></span><span></span></span>
                                                <span class="txtwrap">Monitor and manage blood glucose</span>
                                                </span>
                                                <span class="material-icons">
                                                      <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                      <g>
                                                         <g>
                                                            <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                               c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                            <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                               c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                            <g>
                                                               <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                            </g>
                                                         </g>
                                                         <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                            7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                      </g>
                                                      </svg>
                                                   </span>
                                             </span>
                                             </span>
                                             </a>
                                          </p>
                                    </div>
                                    <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_0_0_3" id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">
                                       <div class="poce_drug_msg">
                                             <span class="material-icons">
                                                   <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                      <g>
                                                         <g>
                                                            <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                               c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                            <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                               c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                            <g>
                                                               <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                            </g>
                                                         </g>
                                                         <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                            7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                      </g>
                                                      </svg>
                                             </span> 
                                             <h3 class="poce_title"></h3>
   
                                             <p><strong>Monitor blood glucose levels at least 4 times a day (pre-meal and before bedtime if eating) in all acutely unwell patients with diabetes mellitus (</strong><em>American Diabetes Association, 2019)</em></p>
                                             <ul>
                                             <li>The risk of<strong> hypo- and hyperglycaemia</strong> increases when people with diabetes are admitted to hospital with acute conditions. <em>(NHS Digital. National Diabetes Inpatient Audit (NaDIA) - 2017, 2018)</em></li>
                                             <li><strong>More frequent monitoring</strong> is needed after <strong>episodes of hyperglycaemia</strong> or <strong>hypoglycaemia</strong>.</li>
                                             <li>More <strong>frequent monitoring</strong> is needed after a <strong>change in hypoglycaemic medication</strong>.</li>
                                             <li>Patients on a<strong> variable rate intravenous insulin infusion (VRIII)</strong> need <strong>capillary blood glucose measurements every hour</strong>. <em>(Joint British Diabetes Societies for inpatient care [JBDS-IP], 2014)</em></li>
                                             <li>Support <strong>self-management</strong> (including monitoring blood glucose) if this conforms to local protocols, it is safe to do so, and the patient is willing. <em>(Joint British Diabetes Societies for inpatient care [JBDS-IP], 2012) </em></li>
                                             </ul>
                                             <p><strong>Prevent and manage hyperglycaemia if it occurs</strong></p>
                                             <ul>
                                             <li>There is <strong>no consensus ontarget blood glucose</strong> levels for people with diabetes in hospital.</li>
                                             
                                             <li><strong>The Joint British Diabetes Societies for Inpatient Care</strong> (JBDS-IP) recommend an<strong> ideal range</strong> of between<strong> 6 to 10 mmol/L</strong>, and an <strong>acceptable range</strong> of <strong>4 to 12 mmol/L</strong><em>(JBDS-IP, 2014)</em></li>
                                             <li><strong>TheAmerican Diabetes Association</strong> recommend a <strong>target blood glucose range</strong> of <strong>7.8 to 10.0 mmol/L</strong> (140-180 mg/dL) for most critically and noncritically ill patients. (<em>American Diabetes Association. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes&mdash;2019, 2019)</em></li>
                                             
                                             <li><em>The <strong>National Institute for Health and Care Excellence</strong> recommends a target plasma glucose level of <strong>5 to 8 mmol/L</strong> in adults with type 1 diabetes in hospital undergoing surgery or with acute illness. <em>(NICE, 2017)</em></em></li>
                                             </ul>
                                             <p><strong>More liberal blood glucose targets</strong> are appropriate for people at<strong> high risk of falls </strong>and who are<strong> frail </strong>or have <strong>dementia</strong>. <em>(JBDS-IP, 2014)</em></p>
                                       </div>
   
                                    <div class="evidence-accordion">
                                          <div class="option">
                                             <input type="checkbox" id="toggle18" class="toggle" />
                                             <label class="title" for="toggle18">                                             
                                                <span class="material-icons"><span></span></span>
                                                <span class="title">Evidence: patient outcomes associated with hyperglycaemia</span>
                                          </label>
                                             <div class="content">
                                                   <p><strong>Hyperglycaemia in patients in hospital is associated with adverse outcomes. (</strong><em>Moghissi, 2009)</em></p>
                                                   <p>Hyperglycaemia in patients in hospital, whether with known diabetes or not, has been shown by various observational studies to be associated with adverse patient outcomes, including increased mortality. <strong>(</strong><em>Moghissi, 2009)</em></p>
                                             </div>
                                          </div>
                                       </div>

                                       
                                    <div class="evidence-accordion">
                                          <div class="option">
                                             <input type="checkbox" id="toggle19" class="toggle" />
                                             <label class="title" for="toggle19">                                             
                                                <span class="material-icons"><span></span></span>
                                                <span class="title">Evidence: blood glucose targets for people with diabetes in hospital</span>
                                          </label>
                                             <div class="content">
                                                   <p><strong>Conflicting evidence for optimal blood glucose targets has led to variations in recommendations in different countries and settings. Follow your local protocol.</strong></p>
                                                   <ul>
                                                   <li>Intensive care setting</li>
                                                   <ul>
                                                   <li>A randomised controlled trial (RCT) of critically ill patients in a primarily surgical intensive care setting found lower patient mortality with tight glucose control - 80 to 110 mg/dL (4.4 to 6.1 mmol/L) compared with &lsquo;conventional&rsquo; more liberal glucose control. <em>(Van den Berghe G et al, 2001) </em></li>
                                                   <li>However, a subsequent multicentre RCT in critically ill medical and surgical patients in other intensive care settings found increased mortality with tighter glucose control, possibly due to increased episodes of hypoglycaemia. <em>(Finfer et al, 2009)</em></li>
                                                   </ul>
                                                   </ul>
                                                   <p>A 2010 systematic review of 6 RCTs and a meta-analysis investigating tight glucose control (80 to 110 mg/dL [4.4 to 6.1 mmol/L]) vs less strict glucose control in critically ill patients in the ICU setting found no significant improvement in mortality with tight glucose control, but it was associated with significantly more hypoglycaemic episodes compared with less strict glucose control. (<em>Marik, 2010)</em></p>
                                             </div>
                                          </div>
                                       </div>


                                       
                                    <div id="tip_pitfall" class="card card-inverse mb-4">
                                          <div class="card-block">
                                             <svg version="1.1" id="pin" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 90 90" enable-background="new 0 0 90 90" xml:space="preserve">
                                             <g>
                                             <g>
                                                <path fill="#333333" d="M42.694,51.942v30.413C42.694,83.816,44.174,85,46,85s3.306-1.184,3.306-2.645V51.942H42.694z"></path>
                                             </g>
                                             <g>
                                                <ellipse fill="#333333" cx="46" cy="47.645" rx="19.835" ry="12.231"></ellipse>
                                             </g>
                                             <g id="cylinder">
                                                <polygon fill="#333333" points="55.256,9.628 46,9.628 36.744,9.628 34.099,47.975 46,47.975 57.901,47.975 		"></polygon>
                                             </g>
                                             <g id="cylinder_highlight">
                                                <polygon fill="#FFFFFF" points="54.595,46.653 50.628,47.975 49.306,13.595 53.273,13.595 		"></polygon>
                                             </g>
                                             <g>
                                                <ellipse fill="#333333" cx="46" cy="13.595" rx="15.207" ry="8.595"></ellipse>
                                             </g>
                                             <g id="highlight">
                                                <path fill="#FFFFFF" d="M47.982,18.929c-0.67,0-1.245-0.508-1.313-1.19c-0.073-0.727,0.456-1.375,1.183-1.448
                                                   c3.157-0.318,5.857-1.434,7.224-2.985c0.48-0.547,1.317-0.602,1.866-0.118c0.548,0.482,0.601,1.318,0.118,1.866
                                                   c-1.822,2.069-5.082,3.479-8.942,3.868C48.072,18.927,48.027,18.929,47.982,18.929z"></path>
                                             </g>
                                             <g>
                                                <path fill="#333333" d="M46,49.54v-1.322c4.794,0,9.917-1.192,9.917-4.54h1.322C57.239,47.349,53.038,49.54,46,49.54z"></path>
                                             </g>
                                             <g id="highlight_lower">
                                                <path fill="#FFFFFF" d="M48.011,56.926c-0.032,0-0.064,0-0.098,0c-0.73-0.003-1.319-0.598-1.316-1.328
                                                   c0.003-0.729,0.595-1.316,1.322-1.316c0.034,0,0.063,0,0.095,0c3.975,0,7.602-1.166,9.719-3.128
                                                   c0.533-0.496,1.37-0.467,1.868,0.071c0.496,0.535,0.465,1.372-0.071,1.868C56.937,55.496,52.637,56.926,48.011,56.926z"></path>
                                             </g>
                                             </g>
                                             </svg>
                                             <h3 class="card-title"></h3>
                                             <p><strong>Ask for expert advice from the diabetes team in complex patients, or where hyperglycaemia is difficult to control.</strong></p>
                                          </div>
                                       </div>

                                       <p><strong>Prevent and manage hypoglycaemia if it occurs</strong></p>
                                       <ul>
                                       <li><strong>Monitor blood glucose</strong> in people with diabetes in hospital and <strong>adjust medication </strong>in response to illness and hospital meal times, in order to <strong>reduce risk</strong> of <strong>hypoglycaemic episodes</strong>.</li>
                                       <li>1 in 5 inpatients with diabetes in England and Wales have a<strong> hypoglycaemic episode </strong>during their hospital stay. <em>(NHS Digital. National Diabetes Inpatient Audit (NaDIA) - 2017, 2018)</em></li>
                                       <li>Causes include:<em> (JBDS-IP, 2018)</em></li>
                                       <ul>
                                       <li>Recovery from an acute illness</li>
                                       <li>Insulin or oral hypoglycaemic medication error</li>
                                       <li>Wrong timing of insulin in relation to meals</li>
                                       <li>Patients eating less but taking the same amount of diabetes medication</li>
                                       <li>No bedtime snacks</li>
                                       <li>Reduced appetite or vomiting.</li>
                                       </ul>
                                       </ul>
                                    <div id="tip_pitfall" class="card card-inverse mb-4">
                                       <div class="card-block">
                                          <svg version="1.1" id="pin" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 90 90" enable-background="new 0 0 90 90" xml:space="preserve">
                                          <g>
                                          <g>
                                             <path fill="#333333" d="M42.694,51.942v30.413C42.694,83.816,44.174,85,46,85s3.306-1.184,3.306-2.645V51.942H42.694z"></path>
                                          </g>
                                          <g>
                                             <ellipse fill="#333333" cx="46" cy="47.645" rx="19.835" ry="12.231"></ellipse>
                                          </g>
                                          <g id="cylinder">
                                             <polygon fill="#333333" points="55.256,9.628 46,9.628 36.744,9.628 34.099,47.975 46,47.975 57.901,47.975 		"></polygon>
                                          </g>
                                          <g id="cylinder_highlight">
                                             <polygon fill="#FFFFFF" points="54.595,46.653 50.628,47.975 49.306,13.595 53.273,13.595 		"></polygon>
                                          </g>
                                          <g>
                                             <ellipse fill="#333333" cx="46" cy="13.595" rx="15.207" ry="8.595"></ellipse>
                                          </g>
                                          <g id="highlight">
                                             <path fill="#FFFFFF" d="M47.982,18.929c-0.67,0-1.245-0.508-1.313-1.19c-0.073-0.727,0.456-1.375,1.183-1.448
                                                c3.157-0.318,5.857-1.434,7.224-2.985c0.48-0.547,1.317-0.602,1.866-0.118c0.548,0.482,0.601,1.318,0.118,1.866
                                                c-1.822,2.069-5.082,3.479-8.942,3.868C48.072,18.927,48.027,18.929,47.982,18.929z"></path>
                                          </g>
                                          <g>
                                             <path fill="#333333" d="M46,49.54v-1.322c4.794,0,9.917-1.192,9.917-4.54h1.322C57.239,47.349,53.038,49.54,46,49.54z"></path>
                                          </g>
                                          <g id="highlight_lower">
                                             <path fill="#FFFFFF" d="M48.011,56.926c-0.032,0-0.064,0-0.098,0c-0.73-0.003-1.319-0.598-1.316-1.328
                                                c0.003-0.729,0.595-1.316,1.322-1.316c0.034,0,0.063,0,0.095,0c3.975,0,7.602-1.166,9.719-3.128
                                                c0.533-0.496,1.37-0.467,1.868,0.071c0.496,0.535,0.465,1.372-0.071,1.868C56.937,55.496,52.637,56.926,48.011,56.926z"></path>
                                          </g>
                                          </g>
                                          </svg>
                                          <h3 class="card-title"></h3>
                                          <p><strong>Bedtime snacks </strong>can reduce the risk of <strong>early morning hypoglycaemia</strong>. <em>(NHS Digital. National Diabetes Inpatient Audit (NaDIA) - 2017, 2018)</em></p>
                                       </div>
                                    </div>

                                    <p><strong>Treat hypoglycaemia actively if the blood glucose falls below 4.0 mmol/L. </strong><em>(JBDS-IP, 2018)</em></p>
                                    <ul>
                                    <li>Follow hospital protocol. The JBDS-IP has guidelines on hospital management of hypoglycaemia in adults with diabetes. <em>(JBDS-IP, 2018)</em></li>
                                    </ul>

                                    </div>
                                    <!--/.panel-body -->
                              </section>
                              <section class="panel-group CKD-como-content" style="display: none;">
                                 <div class="panel-header">
                                       <p class="panel-title"> 
                                          <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                          <span class="title-02">
                                             <span class="title-03 col-md-1">
                                             Plus
                                             <span class="noShow">&nbsp;–&nbsp;</span>
                                             </span>
                                             <span class="title-04">
                                             <span class="material-icons"><span></span><span></span></span>
                                             <span class="txtwrap">Check baseline kidney function</span>
                                             </span>
                                             <span class="material-icons">
                                                   <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                   <g>
                                                      <g>
                                                         <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                            c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                         <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                            c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                         <g>
                                                            <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                         </g>
                                                      </g>
                                                      <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                         7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                   </g>
                                                   </svg>
                                                </span>
                                          </span>
                                          </span>
                                          </a>
                                       </p>
                                 </div>
                                 <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_0_0_3" id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">

                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                             <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                <g>
                                                   <g>
                                                      <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                         c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                      <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                         c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                      <g>
                                                         <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                      </g>
                                                   </g>
                                                   <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                      7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                </g>
                                                </svg>
                                       </span> 
                                       <h3 class="poce_title"></h3>
                                       <p><strong>Check baseline serum kidney function on admission in all patients with a previous history of chronic kidney disease (CKD). </strong><em>[National Institute for Health and Care Excellence. 2013)</em></p>
                                       <ul>
                                       <li><strong>CKD</strong> is a significant<strong> risk factor</strong> for the development of <strong>acute kidney injury</strong>. <em>(Hsu CY, et al, 2008)</em></li>
                                       <li>Acute illness increases the risk of deterioration in renal function.</li>
                                       </ul>
                                    </div>

                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Stroke-como-content" style="display: none;">
                                 <div class="panel-header">
                                       <p class="panel-title"> 
                                          <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                          <span class="title-02">
                                             <span class="title-03 col-md-1">
                                             Plus
                                             <span class="noShow">&nbsp;–&nbsp;</span>
                                             </span>
                                             <span class="title-04">
                                             <span class="material-icons"><span></span><span></span></span>
                                             <span class="txtwrap">Baseline neurological assessment</span>
                                             </span>
                                             <span class="material-icons">
                                                   <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                   <g>
                                                      <g>
                                                         <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                            c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                         <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                            c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                         <g>
                                                            <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                         </g>
                                                      </g>
                                                      <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                         7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                   </g>
                                                   </svg>
                                                </span>
                                          </span>
                                          </span>
                                          </a>
                                       </p>
                                 </div>
                                 <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_0_0_3" id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">

                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                             <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                <g>
                                                   <g>
                                                      <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                         c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                      <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                         c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                      <g>
                                                         <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                      </g>
                                                   </g>
                                                   <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                      7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                </g>
                                                </svg>
                                       </span> 
                                       <h3 class="poce_title"></h3>
                                       <p><strong>Do a baseline neurological assessment on admission for all patients with a history of stroke.</strong></p>
                                       <ul>
                                       <li>Patients with <strong>acute illness</strong> (including infections and causes of hypotension) are at <strong>increased risk of stroke</strong> (both ischaemic and haemorrhagic). <em>(Grau AJ, et al, 2010) (Eigenbrodt ML, et al, 2000)</em></li>
                                       <li>If there is a suspicion of a change in neurological status during admission, repeat the<strong>neurological assessment</strong> in case of a <strong>possible new stroke</strong>.</li>
                                       <li>Following assessment, consider appropriate level of <strong>patient supervision</strong> e.g., relating to possible <strong>confusion</strong> at night, <strong>falls</strong> related to <strong>frailty</strong>.</li>
                                       </ul>
                                    </div>

                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Dementia-como-content" style="display: none;">
                                 <div class="panel-header">
                                       <p class="panel-title"> 
                                          <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                          <span class="title-02">
                                             <span class="title-03 col-md-1">
                                             Plus
                                             <span class="noShow">&nbsp;–&nbsp;</span>
                                             </span>
                                             <span class="title-04">
                                             <span class="material-icons"><span></span><span></span></span>
                                             <span class="txtwrap">Baseline cognitive assessment and collateral history</span>
                                             </span>
                                             <span class="material-icons">
                                                   <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                   <g>
                                                      <g>
                                                         <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                            c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                         <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                            c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                         <g>
                                                            <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                         </g>
                                                      </g>
                                                      <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                         7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                   </g>
                                                   </svg>
                                                </span>
                                          </span>
                                          </span>
                                          </a>
                                       </p>
                                 </div>
                                 <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_0_0_3" id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">

                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                             <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                <g>
                                                   <g>
                                                      <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                         c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                      <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                         c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                      <g>
                                                         <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                      </g>
                                                   </g>
                                                   <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                      7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                </g>
                                                </svg>
                                       </span> 
                                       <h3 class="poce_title"></h3>
                                       <p><strong>Do a baseline cognitive assessment in all older patients, particularly those with a history of dementia. </strong><em>(Pendlebury ST, et al, 2015)</em></p>
                                       <ul>
                                          <li>Use a<strong> validated scoring system</strong> that is also feasible in the acute setting, such as:<em>(Pendlebury ST, et al, 2015)</em>
                                             <ul>
                                                <li>The <strong>abbreviated mental test score</strong> (AMTS/10) <em>(</em><em>Hodkinson,1972)</em></li>
                                                <li><strong>Montreal Cognitive Assessment</strong> (MoCA) <em>(Nasreddine, 2005).</em></li>
                                             </ul>
                                          </li>
                                       </ul>
                                       <p><strong>Dementia increases the risk of delirium. </strong></p>
                                       <ul>
                                          <li>This can acutely reduce patients' cognitive assessment scores. <em>(George J, 2013)</em></li>
                                       </ul>
                                       <p><strong>Take a collateral history from family, friend or carer, to establish the patient&rsquo;s level of function and baseline cognition before this illness.</strong></p>
                                       <ul>
                                          <li>It&rsquo;s important to know if the <strong>decline</strong> in function and cognition has been <strong>gradual </strong>or <strong>acute</strong>.</li>
                                       </ul>
                                       <p>Use this information for <strong>monitoring clinical improvement</strong>, and for establishing <strong>needs on discharge</strong>.</p>
                                       <p>Read <a href="https://html-online.com/articles/" rel="nofollow noopener">HTML code related articles</a> on our blog to get the best tips on web content composing.</p>
                                    </div>

                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Dementia-como-content" style="display: none;">
                                 <div class="panel-header">
                                       <p class="panel-title"> 
                                          <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                          <span class="title-02">
                                             <span class="title-03 col-md-1">
                                             Plus
                                             <span class="noShow">&nbsp;–&nbsp;</span>
                                             </span>
                                             <span class="title-04">
                                             <span class="material-icons"><span></span><span></span></span>
                                             <span class="txtwrap">Assess for and manage delirium</span>
                                             </span>
                                             <span class="material-icons">
                                                   <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                   <g>
                                                      <g>
                                                         <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                            c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                         <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                            c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                         <g>
                                                            <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                         </g>
                                                      </g>
                                                      <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                         7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                   </g>
                                                   </svg>
                                                </span>
                                          </span>
                                          </span>
                                          </a>
                                       </p>
                                 </div>
                                 <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_0_0_3" id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">

                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                             <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                <g>
                                                   <g>
                                                      <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                         c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                      <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                         c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                      <g>
                                                         <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                      </g>
                                                   </g>
                                                   <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                      7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                </g>
                                                </svg>
                                       </span> 
                                       <h3 class="poce_title"></h3>
                                       <p><strong>Assess the patient with dementia for delirium. </strong><em>(National Institute for Health and Clinical Excellence. 2010)</em></p>
                                       <ul>
                                       <li>People living with dementia are at increased risk of delirium when they are admitted to hospital. (<em>National Institute for Health and Clinical Excellence, 2018)</em></li>
                                       <li>Use a<strong> screening tool</strong>, such as:
                                       <ul>
                                       <li>The <strong>4-AT</strong><em>(</em><em>Bellelli, 2014)</em></li>
                                       <li>The <strong>short confusion assessment method (S-CAM), </strong>as recommended by the National Institute of Health and Care Excellence (NICE). <em>(National Institute for Health and Clinical Excellence. 2010)</em></li>
                                       <li>Document the results clearly.</li>
                                       </ul></li>
                                       </ul>
                                       <p><strong>Assess the patient for any reversible causes of delirium</strong>. <em>(National Institute for Health and Clinical Excellence. 2010)</em>These include:</p>
                                       <ul>
                                       <li>Infection</li>
                                       <li>Pain</li>
                                       <li>Dehydration</li>
                                       <li>Constipation</li>
                                       <li>Hypoxia</li>
                                       <li>Immobility</li>
                                       <li>Medications</li>
                                       <li>Poor sleep</li>
                                       <li>Sensory impairment (e.g., ear wax or loss of glasses)</li>
                                       </ul>
                                       <p><strong>Investigations</strong> to help diagnose underlying causes include:</p>
                                       <ul>
                                       <li>Full blood count, electrolytes, renal function, liver function tests, calcium, glucose, CRP, folate and vitamin B12.</li>
                                       <li>Blood cultures (if bacteraemia is suspected)</li>
                                       <li>Urine microscopy and culture</li>
                                       <li>Chest x-ray</li>
                                       </ul>
                                       <p><strong>Manage according to the cause</strong>.</p>
                                       <p><strong>Manage patients with delirium initially with non-pharmacological treatment. </strong><em>(National Institute for Health and Clinical Excellence. 2010)</em></p>
                                       <ul>
                                       <li>Reduce <strong>disorientation</strong> by providing a <strong>well-lit room,</strong> with a <strong>clock</strong> and <strong>calendar </strong>visible (e.g., on the wall).</li>
                                       <li>Encourage and facilitate <strong>family, friends and carers</strong> visiting the patient.</li>
                                       <li>Use verbal and non-verbal techniques to<strong> de-escalate</strong> conflict and distress.</li>
                                       </ul>
                                       <p><strong>Where non-pharmacological treatments are ineffective, and the patient is distressed or considered a risk to themselves or others, short-term antipsychotic or sedative drugs may be used.</strong></p>
                                       <p><strong>Only use antipsychotics as a last resort and not in patients with Parkinson&rsquo;s disease or dementia with Lewy bodies.</strong><em>(National Institute for Health and Clinical Excellence. 2010)</em></p>
                                       <ul>
                                       <li><strong>Risperidone</strong> has the least anticholinergic effects. <em>(Tracy JI, et al, 1998)</em></li>
                                       <li><strong>Haloperidol</strong> is also licenced for this indication, but has the highest risk associated with its use. The UK National Institute for Health and Care Excellence recommends short-term use of haloperidol (usually for less than one week), starting at the <strong>lowest dose</strong> and <strong>titrating carefully</strong> according to the symptoms. <em>(National Institute for Health and Clinical Excellence. 2010)</em></li>
                                       <li>Consider sedation in significantly agitated patients who pose a risk to themselves or others.<strong> Lorazepam </strong>is a suitable choice, but it should only be given orally or intramuscularly (i.e., not intravenously).</li>
                                       <li>Lorazepam should only be used in the<strong> smallest possible dose</strong> for the <strong>shortest possible duration</strong>.</li>
                                       </ul>
                                       <p><strong>Avoid typical antipsychotics, particularly haloperidol in patients with Parkinson&rsquo;s disease or dementia with Lewy bodies. </strong><em>(National Institute for Health and Clinical Excellence. 2010)</em></p>
                                       <ul>
                                       <li>The dopamine receptor antagonistic effect of typical antipsychotics can <strong>dramatically worsen physical and cognitive symptoms</strong> in people with Parkinson&rsquo;s disease or with dementia with Lewy bodies.</li>
                                       <li>Consider a <strong>low-dose short-acting oral benzodiazepine,</strong> such as lorazepam, or l<strong>ow-dose quetiapine </strong>in patients with Parkinson&rsquo;s disease or dementia with Lewy bodies who require sedation to enable safe care because of delirium.</li>
                                       <li>Consult your local drug formulary for advice.</li>
                                       </ul>
                                       <p><br /><strong>Document</strong> any episodes of current or resolved delirium in the<strong> discharge summary for the GP</strong>. <em>(National Institute for Health and Clinical Excellence. 2010)</em></p>                                     

   
                                    <div class="evidence-accordion">
                                       <div class="option">
                                          <input type="checkbox" id="toggle20" class="toggle" />
                                          <label class="title" for="toggle20">                                             
                                             <span class="material-icons"><span></span></span>
                                             <span class="title">Evidence: risks and safe withdrawal of antipsychotics in the elderly</span>
                                       </label>
                                          <div class="content">
                                             <p><strong>Short-term antipsychotics may be needed in people with dementia to enable safe care. However, antipsychotics have various adverse effects in the elderly and are associated with an increased risk of death in people with dementia.</strong></p>
                                             <ul>
                                             <ul>
                                             <li>A meta-analysis found that people with dementia who take atypical antipsychotics have an <strong>increased mortality risk </strong>compared with people taking placebo. <em>(</em><em>Ma H, et al, 2014)</em></li>
                                             </ul>
                                             </ul>
                                             <ul>
                                             <li><em>A large cohort study of elderly people found that <strong>higher doses</strong> of antipsychotics are generally associated with <strong>greater risk</strong>. <em>(Huybrechts K, 2012)</em></em></li>
                                             </ul>
                                             <ul>
                                             <li>It also found that of all the antipsychotics studied, <strong>haloperidol </strong>has the highest risk associated with its use. <em>(Huybrechts K, 2012)</em></li>
                                             </ul>
                                             <ul>
                                             <li>Contrary to popular belief, long-term antipsychotic prescriptions in people with dementia whose behaviour is now settled, can be <strong>withdrawn safely </strong>in the majority of cases. (<em>Van Leeuwen, 2018)</em></li>
                                             </ul>
                                          </div>
                                       </div>
                                    </div>

                                    
   
                                    <div class="evidence-accordion">
                                       <div class="option">
                                          <input type="checkbox" id="toggle21" class="toggle" />
                                          <label class="title" for="toggle21">                                             
                                             <span class="material-icons"><span></span></span>
                                             <span class="title">Evidence: primary prevention of delirium: this may be the most effective treatment strategy</span>
                                       </label>
                                          <div class="content">
                                             <p><strong>A non-randomised trial studying how to reduce risk factors for delirium compared a multicomponent strategy with usual care in 852 elderly patients (over 70 years) in hospital. </strong><em>(Inouye, 1999)</em></p>
                                             <ul>
                                             <li>The multicomponent strategy targeted the following 6 risk factors:</li>
                                             <ul>
                                             <li>cognitive impairment</li>
                                             <li>sleep deprivation</li>
                                             <li>immobility</li>
                                             <li>visual impairment</li>
                                             <li>hearing impairment</li>
                                             <li>dehydration.</li>
                                             </ul>
                                             </ul>
                                             <p>It found: <em>(Inouye, 1999)</em></p>
                                             <ul>
                                             <li>There were <strong>significantly fewer first episodes of delirium</strong> with the <strong>multicomponent strategy </strong>vs usual care (44 [9.9%] vs 64 [15%] respectively)</li>
                                             <li>Matched group analysis found an odds ratio (OR) of 0.60 (95%CI: 0.39-0.92; p=0.02)</li>
                                             <li><strong>Total number of days with delirium</strong> was <strong>significantly lower </strong>with the <strong>multicomponent strategy</strong> vs usual care (105 vs. 161 days respectively, p=0.02)</li>
                                             </ul>
                                             <p><strong>Delirium severity and recurrence rates</strong> were <strong>not significantly different </strong>in the 2 groups.</p>
                                          </div>
                                       </div>
                                    </div>


                                    </div>


                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Dementia-como-content" style="display: none;">
                                 <div class="panel-header">
                                       <p class="panel-title"> 
                                          <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                          <span class="title-02">
                                             <span class="title-03 col-md-1">
                                             Plus
                                             <span class="noShow">&nbsp;–&nbsp;</span>
                                             </span>
                                             <span class="title-04">
                                             <span class="material-icons"><span></span><span></span></span>
                                             <span class="txtwrap">Set an escalation plan</span>
                                             </span>
                                             <span class="material-icons">
                                                   <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                   <g>
                                                      <g>
                                                         <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                            c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                         <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                            c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                         <g>
                                                            <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                         </g>
                                                      </g>
                                                      <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                         7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                   </g>
                                                   </svg>
                                                </span>
                                          </span>
                                          </span>
                                          </a>
                                       </p>
                                 </div>
                                 <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_0_0_3" id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">

                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                             <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                <g>
                                                   <g>
                                                      <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                         c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                      <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                         c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                      <g>
                                                         <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                      </g>
                                                   </g>
                                                   <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                      7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                </g>
                                                </svg>
                                       </span> 
                                       <h3 class="poce_title"></h3>
                                       <p><strong>Set an escalation plan for all patients with dementia as early as possible.</strong></p>
                                       <ul>
                                       <li>This should include: <em>(Fritz Z, et al, 2017):</em><ul>
                                       <li><strong>Resuscitation status</strong> (i.e., do not attempt cardiopulmonary resuscitation [DNACPR] decision)</li>
                                       <li><strong>Ceiling of care</strong> (e.g., is the patient suitable for intubation or intensive care admission)</li>
                                       </ul></li>
                                       
                                       <li>Escalation plans should take account of<strong> advanced care planning</strong>, including legally-binding advanced directives. <em>(Fritz Z, et al, 2017)</em></li>
                                       </ul>
                                       <p><strong>Communicate</strong> all decisions regarding the escalation plan <strong>with the patient</strong>.<em>(Fritz Z, et al, 2017)</em></p>
                                       <ul>
                                       <li><strong>Assess mental capacity</strong> (the ability to make decisions at a specific time a decision needs to be made) and document. <em>(NICE, 2018)</em> Follow the appropriate legislation in your region.</li>
                                       <li>In England and Wales, health professionals must comply with the <strong>2005 Mental Capacity Act</strong>. <em>(Department of Health, 2005) </em>Assessments should follow the principles in the Act. <em>(Department of Health, 2005) </em></li>
                                       <li>If a patient is assessed to lack mental capacity, ensure decisions are made in the <strong>best interests of the patient</strong>. <em>(Department of Health, 2005) (NICE, 2018)</em></li>
                                       </ul>
                                       <p><strong>If the patient is assessed to lack mental capacity, consult with the patient&rsquo;s next of kin in order to make &lsquo;best interests&rsquo; decisions. </strong><em>(Department of Health, 2005) </em></p>
                                       <p>According to the 2005 Mental Capacity Act in England and Wales, if a patient is unbefriended and a decision is not time critical, an independent mental capacity advocate (IMCA) should be sought to perform this role instead. (<em>Social Care Institute for Excellence, 2011)</em></p>
                                    </div>

                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group COPD-como-content Asthma-como-content" style="display: none;">
                                 <div class="panel-header">
                                       <p class="panel-title"> 
                                          <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                          <span class="title-02">
                                             <span class="title-03 col-md-1">
                                             Plus
                                             <span class="noShow">&nbsp;–&nbsp;</span>
                                             </span>
                                             <span class="title-04">
                                             <span class="material-icons"><span></span><span></span></span>
                                             <span class="txtwrap">Remember to prescribe usual inhalers</span>
                                             </span>
                                             <span class="material-icons">
                                                   <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                   <g>
                                                      <g>
                                                         <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                            c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                         <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                            c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                         <g>
                                                            <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                         </g>
                                                      </g>
                                                      <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                         7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                   </g>
                                                   </svg>
                                                </span>
                                          </span>
                                          </span>
                                          </a>
                                       </p>
                                 </div>
                                 <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_0_0_3" id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">

                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                             <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                <g>
                                                   <g>
                                                      <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                         c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                      <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                         c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                      <g>
                                                         <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                      </g>
                                                   </g>
                                                   <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                      7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                </g>
                                                </svg>
                                       </span> 
                                       <h3 class="poce_title"></h3>
                                       <p><strong>Patients may not think to tell you about their usual inhalers when asked about their medication, so remember to check and prescribe these if appropriate</strong></p>
                                       <ul>
                                       <li>Patients with asthma should continue any inhaled corticosteroid medication they usually take. These should not be stopped without a clear medical reason.</li>
                                       <li>Many inhalers are combined medications, so check there is no dual prescribing</li>
                                       </ul>
                                       <p><strong>Temporarily stop inhaled long-acting muscarinic receptor antagonists if your patient with COPD or asthma usually takes this and develops acute kidney injury with an eGFR &lt;30.</strong></p>

                                    </div>

                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group COPD-como-content Asthma-como-content" style="display: none;">
                                 <div class="panel-header">
                                       <p class="panel-title"> 
                                          <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                          <span class="title-02">
                                             <span class="title-03 col-md-1">
                                             Consider
                                             <span class="noShow">&nbsp;–&nbsp;</span>
                                             </span>
                                             <span class="title-04">
                                             <span class="material-icons"><span></span><span></span></span>
                                             <span class="txtwrap">Nicotene replacement therapy in current smokers</span>
                                             </span>
                                             <span class="material-icons">
                                                   <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                   <g>
                                                      <g>
                                                         <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                            c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                         <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                            c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                         <g>
                                                            <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                         </g>
                                                      </g>
                                                      <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                         7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                   </g>
                                                   </svg>
                                                </span>
                                          </span>
                                          </span>
                                          </a>
                                       </p>
                                 </div>
                                 <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_0_0_3" id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">

                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                             <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                <g>
                                                   <g>
                                                      <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                         c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                      <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                         c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                      <g>
                                                         <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                      </g>
                                                   </g>
                                                   <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                      7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                </g>
                                                </svg>
                                       </span> 
                                       <h3 class="poce_title"></h3>
                                       <p><strong>All current smokers are nicotine dependent</strong></p>
                                       <ul>
                                       <li>Nicotine replacement therapy should be prescribed to prevent withdrawal regardless of a patient&rsquo;s intention regarding smoking cessation</li>
                                       <li>Please consult your local hospital guidance.</li>
                                       </ul>
                                       <p><br /><strong>Make every contact count:</strong></p>
                                       <ul>
                                       <li>Being in hospital with an acute illness is the ideal time to support someone to give up smoking</li>
                                       <li>Provide brief advice.</li>
                                       </ul>
                                       
                                    </div>

                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group COPD-como-content Asthma-como-content" style="display: none;">
                                 <div class="panel-header">
                                       <p class="panel-title"> 
                                          <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                          <span class="title-02">
                                             <span class="title-03 col-md-1">
                                             Plus
                                             <span class="noShow">&nbsp;–&nbsp;</span>
                                             </span>
                                             <span class="title-04">
                                             <span class="material-icons"><span></span><span></span></span>
                                             <span class="txtwrap">Monitor for and manage any acute exacerbation of asthma or COPD</span>
                                             </span>
                                             <span class="material-icons">
                                                   <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                   <g>
                                                      <g>
                                                         <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                            c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                         <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                            c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                         <g>
                                                            <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                         </g>
                                                      </g>
                                                      <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                         7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                   </g>
                                                   </svg>
                                                </span>
                                          </span>
                                          </span>
                                          </a>
                                       </p>
                                 </div>
                                 <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_0_0_3" id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">

                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                             <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                <g>
                                                   <g>
                                                      <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                         c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                      <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                         c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                      <g>
                                                         <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                      </g>
                                                   </g>
                                                   <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                      7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                </g>
                                                </svg>
                                       </span> 
                                       <h3 class="poce_title"></h3>
                                       <p><strong>Monitor patient for symptoms and signs of an acute exacerbation of their COPD or asthma.</strong></p>
                                       <ul>
                                       <li>A patient with airways disease may have an acute exacerbation while in hospital with a separate another medical or surgical condition.</li>
                                       </ul>
                                       <p><strong>Patients with comorbid COPD may be having an acute exacerbation if there is an acute worsening of respiratory symptoms that results in the need for additional therapy.</strong><em>(Global Initiative for Chronic Obstructive Lung Disease, 2019)</em></p>
                                       <ul>
                                       <li><strong>Differentiate</strong> from other conditions which may present very similarly, such as <strong>acute coronary syndrome</strong>, <strong>acute heart failure</strong> and <strong>pneumonia</strong>.</li>
                                       <li>Follow guideline recommendations on <strong>investigations</strong>, including:</li>
                                       <ul>
                                       <li><strong>ABG</strong> measurement</li>
                                       <li><strong>Chest x-ray.</strong> Generally, do a chest x-ray if a patient with COPD is admitted with breathlessness or cough, or has worse symptoms than usual.</li>
                                       </ul>
                                       <li>Follow <strong>COPD guideline </strong>recommendations on <strong>initial management</strong>, including:</li>
                                       <ul>
                                       <li><strong>Assessingseverity</strong></li>
                                       <li>Increasing dose and/or frequency of <strong>bronchodilator therapy</strong>, using nebulisers (driven with air) or spacers</li>
                                       <li>Considering <strong>oral corticosteroids</strong>, <strong>antibiotics</strong> and need for <strong>noninvasive ventilation</strong>.</li>
                                       <li>See BMJ Best Practice topic on Acute exacerbation in COPD</li>
                                       </ul>
                                       </ul>
                                       <p><strong>Follow guideline recommendations for assessment of severity and management of an acute exacerbation of asthma in adults. </strong><em>(</em><em>British Thoracic Society; Scottish Intercollegiate Guidelines Network, 2016) </em></p>
                                       <ul>
                                       <li>Initial treatment of acute severe asthma includes:</li>
                                       <ul>
                                       <li><strong>Supplementary oxygen</strong> if hypoxaemic. Titrate to maintain an oxygen saturation level of <strong>94% to 98%</strong></li>
                                       <li><strong>High-dose inhaled beta2 agonists</strong> as early as possible, usually via nebuliser (oxygen-driven)</li>
                                       <li><strong>Ipratropium bromide</strong> via nebuliser (oxygen-driven) if needed</li>
                                       <li><strong>Corticosteroids</strong> in adequate doses (40 to 50 mg daily for at least 5 days)</li>
                                       <li>Other therapies may be required, <strong>follow guideline recommendations</strong></li>
                                       <li>See BMJ Best Practice topic on Acute exacerbation of asthma in adults.</li>
                                       </ul>
                                       </ul>
                                       <p><strong>Stop long-acting muscarinic receptor antagonists (LAMAs) e.g., tiotropium temporarily if short-acting muscarinic antagonists (SAMAs) e.g., ipratropium bromide are prescribed via nebuliser.</strong></p>
                                       <ul>
                                       <li>This is based on expert opinion due to concern over possible anticholinergic adverse effects.</li>
                                       </ul>
                                       <p><strong>Regular nebulisers should only be prescribed for 24 to 48 hours and then switched back to the patient&rsquo;s usual inhalers.</strong></p>
                                       
                                       
                                    <div class="evidence-accordion">
                                       <div class="option">
                                          <input type="checkbox" id="toggle22" class="toggle" />
                                          <label class="title" for="toggle22">                                             
                                             <span class="material-icons"><span></span></span>
                                             <span class="title">Evidence: cardiovascular harm with beta2- agonists.</span>
                                       </label>
                                          <div class="content">
                                             <p><strong>Beta2-agonists increase the risk of myocardial infarction and other adverse cardiovascular events</strong></p>
                                             <ul>
                                             <li>Beta2-agonists increase heart rate and reduce potassium levels. <em>(Salpeter SR, et al, 2004) </em>They are absorbed into the systemic circulation and there is evidence they are associated with an increased risk of myocardial infarction, unable angina, congestive heart failure and arrhythmias. <em>(Au DH, et al, 2002) (Salpeter SR, et al, 2004) (Baker JG, 2017)</em></li>
                                             </ul>
                                          </div>
                                       </div>
                                    </div>

                                    
                                    <div class="evidence-accordion">
                                       <div class="option">
                                          <input type="checkbox" id="toggle23" class="toggle" />
                                          <label class="title" for="toggle23">                                             
                                             <span class="material-icons"><span></span></span>
                                             <span class="title">Evidence: short duration vs longer duration of corticosteroids for acute exacerbation of COPD</span>
                                       </label>
                                          <div class="content">
                                             <p><strong>A systematic review found no difference in outcomes (treatment failure, time to next exacerbation, time in hospital, lung function, adverse effects, mortality) between short courses (7 days or less) vs more conventional longer courses (longer than 7 days) of corticosteroids in people with acute exacerbation of COPD </strong><em>(Walters JAE, et al, 2018)</em></p>
                                             <ul>
                                             <li>The randomised controlled trials included in this Cochrane review were all in hospital settings and only included people with severe to very severe COPD<em> (Walters JAE, et al, 2018)</em></li>
                                             <li>The review authors concluded that due to the addition of a new trial, they have increased confidence that a corticosteroid course of around 5 days is likely to be sufficient for the treatment of an acute exacerbation of COPD. <em>(Walters JAE, et al, 2018)</em></li>
                                             </ul>
                                          </div>
                                       </div>
                                    </div>


                                    </div>

                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Diabetes-como-content" style="display: none;">
                                 <div class="panel-header">
                                       <p class="panel-title"> 
                                          <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                          <span class="title-02">
                                             <span class="title-03 col-md-1">
                                             Plus
                                             <span class="noShow">&nbsp;–&nbsp;</span>
                                             </span>
                                             <span class="title-04">
                                             <span class="material-icons"><span></span><span></span></span>
                                             <span class="txtwrap">Check patient’s feet</span>
                                             </span>
                                             <span class="material-icons">
                                                   <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                   <g>
                                                      <g>
                                                         <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                            c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                         <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                            c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                         <g>
                                                            <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                         </g>
                                                      </g>
                                                      <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                         7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                   </g>
                                                   </svg>
                                                </span>
                                          </span>
                                          </span>
                                          </a>
                                       </p>
                                 </div>
                                 <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_0_0_3" id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">

                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                             <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                <g>
                                                   <g>
                                                      <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                         c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                      <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                         c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                      <g>
                                                         <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                      </g>
                                                   </g>
                                                   <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                      7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                </g>
                                                </svg>
                                       </span> 
                                       <h3 class="poce_title"></h3>
                                       <p><strong>Check the feet of all adults with diabetes on admission to hospital and whenever there has been a change in their status. </strong><em>(NICE, 2016)</em></p>
                                       <ul>
                                       <li><strong>Why? </strong>
                                          <ul>
                                          <li>To detect <strong>new ulceration </strong>or<strong> infection, </strong>which may be<strong> unnoticed</strong> by the patient andmay even be the <strong>underlying cause </strong>of their illness (e.g., patient presenting with sepsis, spinal abscess or endocarditis where the original focus of infection is the foot lesion).</li>
                                          <li>To determine if patient is at<strong> high risk of pressure ulceration </strong>and <strong>requires pressure relief</strong>.</li>
                                          </ul>
                                          <li><strong>Take action </strong></li>
                                          <ul>

                                          </li>
                                       <li>You must <strong>remove any foot dressings</strong> to see if any wound/ulcer is<strong> infected. </strong><em>(NICE NG19, 2016)</em></li>
                                       <li><strong>Inspect</strong> the foot for lesions and examine for loss of protective <strong>sensation</strong>. Follow your local guidelines, but a quick simple test is the <strong>Ipswich Touch Test&copy;️</strong>. (Rayman G, et al, 2011)</li>
                                       <li>If your patient has <strong>reduced sensation</strong>, they are at <strong>high risk of pressure ulceration</strong>. Inform the nursing staff and <strong>provide pressure relieving devices</strong>.</li>
                                       <li>A <strong>daily heel check</strong> for <strong>signs of pressure trauma</strong> should be undertaken by nursing or health care assistant staff.</li>
                                       </ul>


                                    </div>

                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group">
                                 <div class="panel-header">
                                    <p class="panel-title"> 
                                       <a href="#" role="tab header" id="nested-collapse_0_0_3" aria-controls="nested-collapse_0_0_3" aria-expanded="false" class="">
                                       <span class="title-01">
                                       <span>  
                                          Contraindication to anticoagulation                                                                                                                                                     
                                       </span>
                                       <span class="noShow">&nbsp;–&nbsp;</span>
                                       </span>
                                       <span class="titles-wrap col-md-12">
                                       <span class="title-02">
                                       <span class="title-03 col-md-1">
                                       1st line
                                       <span class="noShow">&nbsp;–&nbsp;</span>
                                       </span>
                                       <span class="title-04">
                                       <span class="material-icons"><span></span><span></span></span>
                                       <span class="txtwrap">Consider anticoagulation OR venous filter (wait for confirmation of diagnosis on CTPA)</span>
                                       </span>
                                       </span>
                                       </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_0_0_3" id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">
                              
                                    <p><strong>Consult a haematologist if a patient has a contraindication to anticoagulation.</strong></p>
                                    <ul>
                                    <li>Many patients with relative contraindications will still be able to have a different choice or altered dose of anticoagulation but a specialist opinion is needed to weigh up the benefit-risk balance.</li>
                                    <li><strong>Absolute contraindications are rare but include: [HOR]</strong>
                                       <ul>
                                          <li>active bleeding</li>
                                          <li>recent intracranial hemorrhage</li>
                                          <li>recent, planned, or emergent surgery or procedure with high bleeding risk</li>
                                          <li>platelet count &lt;50,000/uL</li>
                                          <li>severe bleeding diathesis.</li>
                                          </ul>
                                    </li>
                                    <li><strong>Relative contraindications include: [HOR]</strong>                                    
                                       <ul>
                                          <li>recurrent but inactive gastrointestinal bleeding</li>
                                          <li>intracranial or spinal tumor</li>
                                          <li>recent, planned, or emergent surgery or procedure with intermediate bleeding risk</li>
                                          <li>major trauma including cardiopulmonary resuscitation</li>
                                          <li>aortic dissection</li>
                                          <li>platelet count &lt;150,000/uL</li>
                                          </ul>
                                    </li>
                                    <li><strong>Remember too that each anticoagulant may have its own specific relative and absolute contraindications</strong> (e.g., heparin is contraindicated in patients with a history of heparin-induced thrombocytopenia), and these should be checked before starting treatment.</li>
                                    </ul>

                                       <div id="tip_pitfall" class="card card-inverse mb-4">
                                       <div class="card-block">
                                          <svg version="1.1" id="pin" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 90 90" enable-background="new 0 0 90 90" xml:space="preserve">
                                          <g>
                                             <g>
                                                <path fill="#333333" d="M42.694,51.942v30.413C42.694,83.816,44.174,85,46,85s3.306-1.184,3.306-2.645V51.942H42.694z"></path>
                                             </g>
                                             <g>
                                                <ellipse fill="#333333" cx="46" cy="47.645" rx="19.835" ry="12.231"></ellipse>
                                             </g>
                                             <g id="cylinder">
                                                <polygon fill="#333333" points="55.256,9.628 46,9.628 36.744,9.628 34.099,47.975 46,47.975 57.901,47.975 		"></polygon>
                                             </g>
                                             <g id="cylinder_highlight">
                                                <polygon fill="#FFFFFF" points="54.595,46.653 50.628,47.975 49.306,13.595 53.273,13.595 		"></polygon>
                                             </g>
                                             <g>
                                                <ellipse fill="#333333" cx="46" cy="13.595" rx="15.207" ry="8.595"></ellipse>
                                             </g>
                                             <g id="highlight">
                                                <path fill="#FFFFFF" d="M47.982,18.929c-0.67,0-1.245-0.508-1.313-1.19c-0.073-0.727,0.456-1.375,1.183-1.448
                                                   c3.157-0.318,5.857-1.434,7.224-2.985c0.48-0.547,1.317-0.602,1.866-0.118c0.548,0.482,0.601,1.318,0.118,1.866
                                                   c-1.822,2.069-5.082,3.479-8.942,3.868C48.072,18.927,48.027,18.929,47.982,18.929z"></path>
                                             </g>
                                             <g>
                                                <path fill="#333333" d="M46,49.54v-1.322c4.794,0,9.917-1.192,9.917-4.54h1.322C57.239,47.349,53.038,49.54,46,49.54z"></path>
                                             </g>
                                             <g id="highlight_lower">
                                                <path fill="#FFFFFF" d="M48.011,56.926c-0.032,0-0.064,0-0.098,0c-0.73-0.003-1.319-0.598-1.316-1.328
                                                   c0.003-0.729,0.595-1.316,1.322-1.316c0.034,0,0.063,0,0.095,0c3.975,0,7.602-1.166,9.719-3.128
                                                   c0.533-0.496,1.37-0.467,1.868,0.071c0.496,0.535,0.465,1.372-0.071,1.868C56.937,55.496,52.637,56.926,48.011,56.926z"></path>
                                             </g>
                                             </g>
                                             </svg>
                                             <h3 class="card-title"></h3>
                                             <p><strong></strong></p>
                                             <ul>
                                                <li>Peptic ulcer disease with no history of bleeding or faecal occult blood is not a contraindication to anticoagulation.[HOR]</li>
                                                <li>Anticoagulation is safe in most trauma and neurosurgical patients after the first or second postoperative week and in most stroke patients without haemorrhage. [HOR]</li>
                                                <li>Patients with spinal cord injury without haematomyelia may still be considered for anticoagulation [HOR]</li>
                                                </ul>
                                          </div>
                                       </div>
                                       
                                       <p><strong>Venous filters</strong></p>
                                       <p><strong>Consider a venous filter for any patient with confirmed PE who is deemed unsuitable for anticoagulation after discussion with a haematologist - in practice, they are rarely used outside the US. [BARCO] </strong></p>
                                       <ul>
                                       <li><strong>A retrievable venous filter should be used where possible</strong> and should be removed as soon as the reason for the absolute contraindication to anticoagulation has been resolved. [ESC][ACP][ACIR]</li>
                                       <li>The filter is normally placed in the infrarenal portion of the inferior vena cava (IVC). [BARCO]</li>
                                       </ul>

                                       <p><strong>The role of venous filters in PE remains controversial.</strong></p>
                                       <ul>
                                       <li>The European Society of Cardiology recommends venous filters in: [ESC]
                                          <ul>
                                       <li>patients with confirmed acute PE who have an absolute contraindication to anticoagulation.</li>
                                       <li>patients with confirmed recurrent PE despite adequate anticoagulation treatment.</li>
                                       </ul></li>
                                       <li>Their use is increasing rapidly in the US and the The American Society for Interventional Radiology has recommended a significantly longer list of indications for venous filter then the European Society of Cardiology. [ACRSIR]</li>
                                       </ul>

                                       <p><strong>Complications associated with permanent IVC filters are common and include: [HANN] [FAILLA]</strong></p>
                                       <ul>
                                       <li>Early<ul>
                                       <li>insertion site thrombosis (10%)</li>
                                       <li>pericardial tamponade (when placing filter in the superior vena cava.)</li>
                                       </ul></li>
                                       
                                       <li>Late (more common)
                                       <ul>
                                       <li>recurrent DVT (20%)</li>
                                       <li>post-thrombotic syndrome (40%)</li>
                                       <li>Occlusion of the IVC (regardless of use and duration of anticoagulation)                                          
                                       <ul>
                                             <li>22% at 5 years</li>
                                             <li>33% at 9 years</li>
                                             </ul>
                                       </li>
                                       <ul>

                                       </li>
                                       </ul>
   
                                       

                                       <div id="tip_pitfall" class="card card-inverse mb-4">
                                             <div class="card-block">
                                                <svg version="1.1" id="pin" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 90 90" enable-background="new 0 0 90 90" xml:space="preserve">
                                                <g>
                                                   <g>
                                                      <path fill="#333333" d="M42.694,51.942v30.413C42.694,83.816,44.174,85,46,85s3.306-1.184,3.306-2.645V51.942H42.694z"></path>
                                                   </g>
                                                   <g>
                                                      <ellipse fill="#333333" cx="46" cy="47.645" rx="19.835" ry="12.231"></ellipse>
                                                   </g>
                                                   <g id="cylinder">
                                                      <polygon fill="#333333" points="55.256,9.628 46,9.628 36.744,9.628 34.099,47.975 46,47.975 57.901,47.975 		"></polygon>
                                                   </g>
                                                   <g id="cylinder_highlight">
                                                      <polygon fill="#FFFFFF" points="54.595,46.653 50.628,47.975 49.306,13.595 53.273,13.595 		"></polygon>
                                                   </g>
                                                   <g>
                                                      <ellipse fill="#333333" cx="46" cy="13.595" rx="15.207" ry="8.595"></ellipse>
                                                   </g>
                                                   <g id="highlight">
                                                      <path fill="#FFFFFF" d="M47.982,18.929c-0.67,0-1.245-0.508-1.313-1.19c-0.073-0.727,0.456-1.375,1.183-1.448
                                                         c3.157-0.318,5.857-1.434,7.224-2.985c0.48-0.547,1.317-0.602,1.866-0.118c0.548,0.482,0.601,1.318,0.118,1.866
                                                         c-1.822,2.069-5.082,3.479-8.942,3.868C48.072,18.927,48.027,18.929,47.982,18.929z"></path>
                                                   </g>
                                                   <g>
                                                      <path fill="#333333" d="M46,49.54v-1.322c4.794,0,9.917-1.192,9.917-4.54h1.322C57.239,47.349,53.038,49.54,46,49.54z"></path>
                                                   </g>
                                                   <g id="highlight_lower">
                                                      <path fill="#FFFFFF" d="M48.011,56.926c-0.032,0-0.064,0-0.098,0c-0.73-0.003-1.319-0.598-1.316-1.328
                                                         c0.003-0.729,0.595-1.316,1.322-1.316c0.034,0,0.063,0,0.095,0c3.975,0,7.602-1.166,9.719-3.128
                                                         c0.533-0.496,1.37-0.467,1.868,0.071c0.496,0.535,0.465,1.372-0.071,1.868C56.937,55.496,52.637,56.926,48.011,56.926z"></path>
                                                   </g>
                                                   </g>
                                                   </svg>
                                                   <h3 class="card-title">In clinical practice venous filters are not commonly used in the UK or Europe. </h3>
                                                   <ul>
                                                      <li>It is common practice to seek advice from a haematologist in patients with contraindications to anticoagulation.</li>
                                                      <li>Many of these patients - even those with apparent absolute contraindications - may still be able to have a different or altered dose of anticoagulation with an acceptable risk-benefit balance and this is usually preferred to a venous filter.</li>
                                                      </ul>
                                                </div>
                                             </div>

                                             <div class="evidence-accordion">
                                                   <div class="option">
                                                      <input type="checkbox" id="toggle24" class="toggle" />
                                                      <label class="title" for="toggle24">                                             
                                                         <span class="material-icons"><span></span></span>
                                                         <span class="title">Evidence: The evidence shows varied outcomes from use of  venous filters in PE</span>
                                                   </label>
                                                      <div class="content">
                                                            <ul>
                                                                  <li>
                                                                  <p><strong>The use of venous filters is controversial and there is limited evidence to support recommendations about their use in clinical practice</strong>. <strong>For use in acute PE the evidence shows varied outcomes. </strong></p>
                                                                  <ul>
                                                                  <li>There have only been two RCTs performed in Europe.</li>
                                                                  <li>The first, PREPIC (Pr&eacute;vention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group), randomized 400 patients who suffered acute VTE to anticoagulation alone or anticoagulation and a permanent inferior vena cava filter (IVCF). Follow up at 8 years showed that while IVC filters reduced the risk of recurrent PE, they did not prevent death, and more DVTs occurred in patients who received these devices.</li>
                                                                  <li>The second study, PREPIC 2, randomised 399 patients with PE associated with DVT to anticoagulation alone or anticoagulation plus a retrievable IVCF. All the patients had at least one "high-risk" feature (age &gt;75 years old, active cancer, chronic cardiac or respiratory insufficiency, ischemic stroke with leg paralysis within 6 months, either iliocaval or bilateral DVT, or a sign of right ventricular strain or myocardial injury). Again, use of venous filter did not show any mortality benefit nor did they result in fewer symptomatic PEs during the first 3 months of follow-up.</li>
                                                                  </ul>
                                                                  On the other hand observational studies from the US, analyzing almost 298,000 filter implantations, &nbsp;suggest that insertion of a venous filter might reduce PE-related mortality rates in the acute phase, with benefit possibly coming at the cost of an increased risk of recurrence of VTE. [MURIEL]</li>
                                                                  </ul>
                                                      </div>
                                                   </div>
                                                </div>
   
                                                
                                             
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group">
                                    <div class="panel-header">
                                          <p class="panel-title"> 
                                             <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                             <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1">
                                                Plus
                                                <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                <span class="material-icons"><span></span><span></span></span>
                                                <span class="txtwrap">Risk assessment</span>
                                                </span>
                                             </span>
                                             </span>
                                             </a>
                                          </p>
                                    </div>
                                    <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_0_0_3" id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">
   
                                          <p><strong>Risk stratify stable patients using the Pulmonary Embolism Severity Index (PESI) score or the simplified Pulmonary Embolism Severity Index (sPESI) score</strong>.</p>
                                          <p><strong>[LINK TO PESI scoring calculator AND sPESI scoring calculator EBM calc] </strong></p>
                                          <ul>
                                          <li>The PESI/sPESI risk score can be used to risk stratify haemodynamically stable patients to <strong>identify an intermediate-risk group</strong> who need close monitoring (PESI III-IV or sPESI &ge;1)[ESC] [BTS]</li>
                                          <li>The <strong>sPESI is non-inferior to the PESI </strong>in predicting 30-day mortality. [BTS]</li>
                                          </ul>
                                          
                                          <p><strong>Do not use PESI/sPESI scoring in:</strong></p>
                                          <ul>
                                          <li><strong>Patients with hypotension or shock. </strong>All such patients are high-risk and must be managed accordingly.</strong></li>
                                          <li><strong>Pregnant women</strong></li>
                                          </ul>
                                          <p><strong>Monescue thrombolysis. </strong>&nbsp;[KONST][ESC][CHEST]</p>
                                          <ul>
                                          <li><strong>Rescue thrombolysis may be indicated in </strong>intermediate-risk patients, and in patients with other clinical features of cardiopulmonary impairment (e.g., elevated heart rate, respiratory rate, jugular venous pressure) who have started anticoagulant therapy, and:</li>
                                          </ul>

                                          <p>are clinically d<strong>itor intermediate-risk patients (PESI score &ge; III or sPESI &ge;I) patients closely over at least 48-72 hours as they are at risk of deterioration and may need r</strong>eteriorating, but have not yet developed hypotension</p>
                                          <ul>
                                          <li>are exhibiting signs of haemodynamic decompensation (e.g. systolic BP &lt;90 mmHg for at least 15 minutes, or drop of systolic BP by at least 40 mmHg for at least 15 minutes with signs of end organ hypoperfusion). [ESC]</li>                                          
                                          <li><strong>Routine thrombolysis is not recommended in most major guidelines for this intermediate-risk group </strong>even if signs of both right ventricular dysfunction and myocardial injury (positive cardiac biomarkers) are initially present.</li>
                                          </ul>
                                          
                                          <p>In these patients, use of systemic thrombolysis is associated with a <strong>mortality benefit</strong> but it significantly <strong>increases the risk of bleeding</strong>, including intracranial haemorrhage. [CARDIO]</p>
   

                                          <div class="evidence-accordion">
                                                <div class="option">
                                                   <input type="checkbox" id="toggle25" class="toggle" />
                                                   <label class="title" for="toggle25">                                             
                                                      <span class="material-icons"><span></span></span>
                                                      <span class="title">Evidence: Evidence does not support the routine use of thrombolysis in patients with intermediate-risk PE</span>
                                                </label>
                                                   <div class="content">
                                                         <ul>
                                                         <li>The intermediate-risk group is defined by a PESI score of III-V or an sPESI score &ge;1.</li>
                                                         <li>The international PEITHO (Pulmonary Embolism Thrombolysis) trial compared a single intravenous bolus of tenecteplase plus heparin with placebo plus heparin in 1,006 patients with confirmed PE, right ventricular dysfunction detected by echocardiography or CT, and a positive troponin I or T test.</li>
                                                         <li>In the thrombolysis group, haemodynamic decompensation/collapse or death within 7 days occurred less frequently than in the group receiving heparin alone.</li>
                                                         <li>However, in the thrombolysis group compared with the placebo group, there was also a higher incidence of haemorrhagic stroke (2.0% vs 0.2%) and major non-intracranial bleeding (6.3% vs 1.5%).</li>
                                                         </ul>
                                                   </div>
                                                </div>
                                             </div>


                                    </div>
                                    <!--/.panel-body -->
                              </section>
                              <section class="panel-group Diabetes-como-content" style="display: none;">
                                 <div class="panel-header">
                                       <p class="panel-title"> 
                                          <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                          <span class="title-02">
                                             <span class="title-03 col-md-1">
                                             Plus
                                             <span class="noShow">&nbsp;–&nbsp;</span>
                                             </span>
                                             <span class="title-04">
                                             <span class="material-icons"><span></span><span></span></span>
                                             <span class="txtwrap">Review diabetes medication (NEVER stop insulin in people with type 1 diabetes)</span>
                                             </span>
                                             <span class="material-icons">
                                                   <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                   <g>
                                                      <g>
                                                         <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                            c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                         <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                            c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                         <g>
                                                            <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                         </g>
                                                      </g>
                                                      <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                         7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                   </g>
                                                   </svg>
                                                </span>
                                          </span>
                                          </span>
                                          </a>
                                       </p>
                                 </div>
                                 <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_0_0_3" id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">

                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                             <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                <g>
                                                   <g>
                                                      <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                         c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                      <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                         c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                      <g>
                                                         <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                      </g>
                                                   </g>
                                                   <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                      7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                </g>
                                                </svg>
                                       </span> 
                                       <h3 class="poce_title"></h3>
                                       <p><strong>Never stop insulin in people with type 1 diabetes coming into hospital - insulin deficiency can rapidly precipitate ketoacidosis, particularly during illness. </strong></p>
                                       <ul>
                                       <li><strong>Always continue basal insulins</strong> (long-acting or background insulins e.g., determir or glargine) as this will <strong>prevent ketoacidosis</strong> if doses of rapid-acting insulin are inadvertently missed or delayed.</li>
                                       <li><strong>Dose adjustments</strong> up or down may be needed.
                                       <ul>
                                       <li>For example, in the<strong> absence of significant hyperglycaemia </strong>consider <strong>reducing the evening basal insulin by 20% on admission</strong>, as most patients will have a <strong>smaller evening meal in hospital</strong> compared with at home.</li>
                                       </ul>
                                       </li>
                                       </ul>

                                       <p><strong>If a variable rate intravenous insulin infusion (VRIII) is started</strong>:</p>
                                       <ul>
                                       <li><strong>Continue the basal insulin </strong><em>(Joint British Diabetes Societies for inpatient care [JBDS-IP], 2014)</em> as this will reduce the risk of ketosis in the advent of the VRIII being <strong>accidentally interrupted </strong>(e.g., by cannula displacement or blockage) or <strong>switched off </strong>(e.g., during transfer to another ward or department)<strong>.</strong></li>
                                       <li>The patient&rsquo;s usual <strong>rapid-acting </strong>and <strong>mixed insulins</strong> can be <strong>stopped while on a VRIII</strong>. <em>Joint British Diabetes Societies for inpatient care [JBDS-IP], 2014)</em></li>
                                       <li>Use the VRIII for as <strong>short a time as possible</strong>, <em>(Joint British Diabetes Societies for inpatient care [JBDS-IP], 2014) </em>as incorrect use and insufficient monitoring can result in<strong> severe hypoglycaemia</strong> or<strong> ketoacidosis</strong>.</li>
                                       </ul>
                                       <p><strong>Indications for a VRIII include</strong>: <em>(Joint British Diabetes Societies for inpatient care [JBDS-IP], 2014)</em></p>
                                       <ul>
                                       <li>Patients with diabetes or hospital-related hyperglycaemia who <strong>can&rsquo;t take oral food or fluid </strong>and where it&rsquo;s <strong>not possible to adjust their insulin regimen</strong>, e.g., when:</li>
                                       <ul>
                                       <li>Vomiting</li>
                                       <li>Nil by mouth and patient will miss more than one meal</li>
                                       <li>There is severe illness with a need to achieve good glycaemic control (such as with sepsis).</li>
                                       </ul>
                                       <li>Most patients with diabetes <strong>requiring emergency surgery</strong>. <em>(Joint British Diabetes Societies for inpatient care [JBDS-IP], 2016)</em></li>
                                       <li><strong>Special circumstances</strong>, such as hyperglycaemia with <strong>acute coronary syndrome</strong>, when <strong>pregnant</strong>, or when receiving <strong>TPN or enteral feeding</strong>, or <strong>taking corticosteroids</strong>. <em>(Joint British Diabetes Societies for inpatient care., 2012) </em></li>
                                       <ul>
                                       <li><strong>Get specialist advice</strong> from the <strong>diabetes team</strong> in these circumstances.</li>
                                       </ul>
                                       </ul>
                                       <p><strong>People with type 2 diabetes on basal insulin should continue to take it, unless otherwise indicated</strong>.</p>
                                       <ul>
                                       <li>In the <strong>absence of significant hyperglycaemia</strong> consider <strong>reducing the evening basal insulin</strong> by <strong>20% on admission</strong>, as most patients will have a <strong>smaller evening mealin hospital </strong>compared with at home.</li>
                                       </ul>
                                       <p>Give<strong> oral hypoglycaemic</strong> medication<strong> with food</strong> to reduce the<strong> risk of hypoglycaemia</strong>.</p>
                                       <ul>
                                       <li><strong>Never give oral hypoglycaemic medication at bedtime </strong>and consider <strong>reducing the evening dose of sulphonylurea</strong>.
                                       <ul>
                                       <li>This is because most patients have a <strong>smaller evening meal in hospital </strong>compared with their usual evening meal at home.</li>
                                       </ul></li>
                                       </ul>
                                       <p><strong>Withhold metformin in patients:</strong></p>
                                       <ul>
                                       <li>With <strong>contraindications</strong>, such as <strong>significant renal impairment</strong> (&lt;30 mL/minute/1.73 m2)</li>
                                       <li>With <strong>metabolic acidosis </strong>(including lactic acidosis and DKA)</li>
                                       <li>At<strong> risk of lactic acidosis</strong> with metformin, such as:</li>
                                       <ul>
                                       <li>With conditions associated with <strong>acute kidney injury </strong>or<strong> tissue hypoxia,</strong> including<strong> dehydration</strong></li>
                                       <li>With <strong>renal impairment</strong>and who have, or are to be <strong>fasted for a prolonged period</strong> or who are due to have a<strong> radio-opaque contrast injection</strong> as part of an imaging procedure. <strong>Follow local protocols </strong>for guidance on the specific eGFR levels indicating renal impairment for this to be applied.</li>
                                       </ul>
                                       <p><strong>Be aware that withholding metformin results in hyperglycemia</strong>.</p>
                                       <ul>
                                       <li>If your patient is taking <strong>other glucose-lowering medication</strong>, these may need to be<strong> increased in dose</strong> or an <strong>alternative hypoglycaemic medication to metformin</strong> prescribed.</li>
                                       <li>Some patients may need <strong>insulin as a temporary measure</strong>, but<strong> seek diabetes inpatient specialist team advice</strong>.</li>
                                       </ul>
                                       <p><strong>Stop sodium-glucose cotransporter-2 (SGLT-2) inhibitors in all acutely ill patients, particularly if dehydrated or with infection, as they are at risk of euglycaemic ketoacidosis.</strong></p>
                                       <ul>
                                       <li>SGLT-2 inhibitors (e.g., dapagliflozin) <strong>reduce blood glucose reabsorption</strong> in the kidneys (independently of insulin metabolism of glucose). <em>(Peters AL, et al, 2015) </em></li>
                                       <li>They can<strong> mask underlying ketoacidosis</strong> by patients having a normal (or near normal) serum glucose level <strong>(euglycaemic ketoacidosis)</strong>.</li>
                                       <li>Check <strong>blood ketones</strong> as urinary ketone measurement may be unreliable.</li>
                                       <li><strong>Treat for DKA</strong> if <strong>blood ketone level is &ge;3 mmol/L</strong>, blood<strong> pH &lt;7.3</strong> and <strong>bicarbonate &lt;15 mmol/L</strong>. (<em>JBDS-IP, 2013)</em></li>
                                       </ul>
                                       <p><strong>Reduce or omit the dose of gliclazide if the patient has impaired kidney function or is eating less than usual, to avoid hypoglycaemia at night. </strong></p>
                                       <p><strong>Inform the diabetic inpatient team of the admission of any patient with diabetes. They are available for advice and support.</strong></p>
                                       <p><strong>For a patient at theend of life</strong>: <em>(Rowles S, et al 2011)</em></p>
                                       <ul>
                                       <li><strong>Hypoglycaemic medication</strong> should be <strong>reduced </strong>to the minimum, <strong>but</strong></li>
                                       <li>The patient should be<strong> kept free from symptomatic hyperglycaemia</strong>, which can lead to <strong>dehydration</strong>, <strong>ketosis</strong> or <strong>hyperosmolar hyperglycaemia</strong>.</li>
                                       </ul>
                                       <p>Refer to <strong>local protocols </strong>or the Association of British Clinical Diabetologists (ABCD). <em>(Rowles S, et al 2011)</em></p>


                                    </div>

                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Diabetes-como-content" style="display: none;">
                                 <div class="panel-header">
                                       <p class="panel-title"> 
                                          <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                          <span class="title-02">
                                             <span class="title-03 col-md-1">
                                             Plus
                                             <span class="noShow">&nbsp;–&nbsp;</span>
                                             </span>
                                             <span class="title-04">
                                             <span class="material-icons"><span></span><span></span></span>
                                             <span class="txtwrap">Monitor and manage blood glucose</span>
                                             </span>
                                             <span class="material-icons">
                                                   <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                   <g>
                                                      <g>
                                                         <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                            c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                         <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                            c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                         <g>
                                                            <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                         </g>
                                                      </g>
                                                      <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                         7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                   </g>
                                                   </svg>
                                                </span>
                                          </span>
                                          </span>
                                          </a>
                                       </p>
                                 </div>
                                 <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_0_0_3" id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">

                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                             <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                <g>
                                                   <g>
                                                      <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                         c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                      <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                         c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                      <g>
                                                         <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                      </g>
                                                   </g>
                                                   <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                      7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                </g>
                                                </svg>
                                       </span> 
                                       <h3 class="poce_title"></h3>
                                       <p><strong>Monitor blood glucose levels at least 4 times a day (pre-meal and before bedtime if eating) in all acutely unwell patients with diabetes mellitus (</strong><em>American Diabetes Association, 2019)</em></p>
                                       <ul>
                                       <li>The risk of<strong> hypo- and hyperglycaemia</strong> increases when people with diabetes are admitted to hospital with acute conditions. <em>(NHS Digital. National Diabetes Inpatient Audit (NaDIA) - 2017, 2018)</em></li>
                                       <li><strong>More frequent monitoring</strong> is needed after <strong>episodes of hyperglycaemia</strong> or <strong>hypoglycaemia</strong>.</li>
                                       <li>More <strong>frequent monitoring</strong> is needed after a <strong>change in hypoglycaemic medication</strong>.</li>
                                       <li>Patients on a<strong> variable rate intravenous insulin infusion (VRIII)</strong> need <strong>capillary blood glucose measurements every hour</strong>. <em>(Joint British Diabetes Societies for inpatient care [JBDS-IP], 2014)</em></li>
                                       <li>Support <strong>self-management</strong> (including monitoring blood glucose) if this conforms to local protocols, it is safe to do so, and the patient is willing. <em>(Joint British Diabetes Societies for inpatient care [JBDS-IP], 2012) </em></li>
                                       </ul>
                                       
                                       <p><strong>Prevent and manage hyperglycaemia if it occurs</strong></p>
                                       <ul>
                                       <li>There is <strong>no consensus ontarget blood glucose</strong> levels for people with diabetes in hospital.
                                          <ul>
                                          <li><strong>The Joint British Diabetes Societies for Inpatient Care</strong> (JBDS-IP) recommend an<strong> ideal range</strong> of between<strong> 6 to 10 mmol/L</strong>, and an <strong>acceptable range</strong> of <strong>4 to 12 mmol/L</strong><em>(JBDS-IP, 2014)</em></li>
                                          <li><strong>The American Diabetes Association</strong> recommend a <strong>target blood glucose range</strong> of <strong>7.8 to 10.0 mmol/L</strong> (140-180 mg/dL) for most critically and noncritically ill patients. (<em>American Diabetes Association. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes&mdash;2019, 2019)</em></li>
                                          <li><em>The <strong>National Institute for Health and Care Excellence</strong> recommends a target plasma glucose level of <strong>5 to 8 mmol/L</strong> in adults with type 1 diabetes in hospital undergoing surgery or with acute illness. <em>(NICE, 2017)</em></em></li>
                                          </ul>
                                       </li>
                                       <li><strong>More liberal blood glucose targets</strong> are appropriate for people at<strong> high risk of falls </strong>and who are<strong> frail </strong>or have <strong>dementia</strong>. <em>(JBDS-IP, 2014)</em></li>



                                       <div class="evidence-accordion">
                                             <div class="option">
                                                <input type="checkbox" id="toggle26" class="toggle" />
                                                <label class="title" for="toggle26">                                             
                                                   <span class="material-icons"><span></span></span>
                                                   <span class="title">Evidence: patient outcomes associated with hyperglycaemia</span>
                                             </label>
                                                <div class="content">
                                                      <p><strong>Hyperglycaemia in patients in hospital is associated with adverse outcomes. (</strong><em>Moghissi, 2009)</em></p>
                                                      <ul>
                                                      <li>Hyperglycaemia in patients in hospital, whether with known diabetes or not, has been shown by various observational studies to be associated with adverse patient outcomes, including increased mortality. <strong>(</strong><em>Moghissi, 2009)</em></li>
                                                      </ul>
                                                </div>
                                             </div>
                                          </div>

                                          

                                          <div class="evidence-accordion">
                                                <div class="option">
                                                   <input type="checkbox" id="toggle27" class="toggle" />
                                                   <label class="title" for="toggle27">                                             
                                                      <span class="material-icons"><span></span></span>
                                                      <span class="title">Evidence: blood glucose targets for people with diabetes in hospital</span>
                                                </label>
                                                   <div class="content">
                                                         <p><strong>Conflicting evidence for optimal blood glucose targets has led to variations in recommendations in different countries and settings. Follow your local protocol.</strong></p>
                                                         <ul>
                                                         <li>Intensive care setting
                                                         <ul>
                                                         <li>A randomised controlled trial (RCT) of critically ill patients in a primarily surgical intensive care setting found lower patient mortality with tight glucose control - 80 to 110 mg/dL (4.4 to 6.1 mmol/L) compared with &lsquo;conventional&rsquo; more liberal glucose control. <em>(Van den Berghe G et al, 2001) </em></li>
                                                         <li>However, a subsequent multicentre RCT in critically ill medical and surgical patients in other intensive care settings found increased mortality with tighter glucose control, possibly due to increased episodes of hypoglycaemia. <em>(Finfer et al, 2009)</em></li>
                                                         <li>A 2010 systematic review of 6 RCTs and a meta-analysis investigating tight glucose control (80 to 110 mg/dL [4.4 to 6.1 mmol/L]) vs less strict glucose control in critically ill patients in the ICU setting found no significant improvement in mortality with tight glucose control, but it was associated with significantly more hypoglycaemic episodes compared with less strict glucose control. (<em>Marik, 2010)</em></li>
                                                         </ul>
                                                      </li>
                                                         </ul>
                                                   </div>
                                                </div>
                                             </div>

                                             <p><strong>Follow your local hospital protocol on steps to take if your patient&rsquo;s capillary blood glucose is &ge;15 mmol/L. Exclude diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS), both of which require specific urgent management.</strong></p>
                                             <ul>
                                             <li><strong>Treat hyperglycaemia</strong> to avoid <strong>DKA </strong>and<strong> HHS</strong>.</li>
                                             <li><strong>DKA</strong> and <strong>HHS</strong> are <strong>medical emergencies</strong>. Follow JBDS or local hospital guidelines for patients with DKA (<em>JBDS-IP, 2013) </em>or HHS (<em>JBDS-IP, 2012). </em></li>
                                             <li>The <strong>diabetes inpatient specialist team</strong> should be involved in the management of any patient with <strong>DKA</strong>. (<em>JBDS-IP, 2013)</em></li>
                                             <li><strong>Early senior review</strong> by a clinician who is familiar with the management of<strong> HHS</strong> is imperative. (<em>JBDS-IP, 2012) </em>Patients with <strong>other comorbidities</strong> may need to be on a <strong>high dependency unit. </strong>(<em>JBDS-IP, 2012)</em></li>
                                             </ul>
                                             <p><strong>Be aware that the following medication may be associated with hyperglycaemia and may need to be reviewed: </strong><em>(Abdur R, et al, 2011)</em></p>
                                             <ul>
                                             <li>Corticosteroids</li>
                                             <li>Some beta-blockers (e.g., propranolol, atenolol)</li>
                                             <li>Thiazide diuretics (e.g., hydrochlorozide)</li>
                                             <li>Some second-generation antipsychotics (e.g., olanzapine and clozaine)</li>
                                             <li>Certain fluoroquinolone antibiotics (e.g., gatifloxin)</li>
                                             <li>Calcineurin inhibitors (e.g., cyclosporine, tacrolimus)</li>
                                             <li>Protease inhibitors (e.g., as a component in antiretroviral therapy, such as ritonavir)</li>
                                             </ul>

                                             <div id="tip_pitfall" class="card card-inverse mb-4">
                                                <div class="card-block">
                                                   <svg version="1.1" id="pin" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 90 90" enable-background="new 0 0 90 90" xml:space="preserve">
                                                   <g>
                                                      <g>
                                                         <path fill="#333333" d="M42.694,51.942v30.413C42.694,83.816,44.174,85,46,85s3.306-1.184,3.306-2.645V51.942H42.694z"></path>
                                                      </g>
                                                      <g>
                                                         <ellipse fill="#333333" cx="46" cy="47.645" rx="19.835" ry="12.231"></ellipse>
                                                      </g>
                                                      <g id="cylinder">
                                                         <polygon fill="#333333" points="55.256,9.628 46,9.628 36.744,9.628 34.099,47.975 46,47.975 57.901,47.975 		"></polygon>
                                                      </g>
                                                      <g id="cylinder_highlight">
                                                         <polygon fill="#FFFFFF" points="54.595,46.653 50.628,47.975 49.306,13.595 53.273,13.595 		"></polygon>
                                                      </g>
                                                      <g>
                                                         <ellipse fill="#333333" cx="46" cy="13.595" rx="15.207" ry="8.595"></ellipse>
                                                      </g>
                                                      <g id="highlight">
                                                         <path fill="#FFFFFF" d="M47.982,18.929c-0.67,0-1.245-0.508-1.313-1.19c-0.073-0.727,0.456-1.375,1.183-1.448
                                                            c3.157-0.318,5.857-1.434,7.224-2.985c0.48-0.547,1.317-0.602,1.866-0.118c0.548,0.482,0.601,1.318,0.118,1.866
                                                            c-1.822,2.069-5.082,3.479-8.942,3.868C48.072,18.927,48.027,18.929,47.982,18.929z"></path>
                                                      </g>
                                                      <g>
                                                         <path fill="#333333" d="M46,49.54v-1.322c4.794,0,9.917-1.192,9.917-4.54h1.322C57.239,47.349,53.038,49.54,46,49.54z"></path>
                                                      </g>
                                                      <g id="highlight_lower">
                                                         <path fill="#FFFFFF" d="M48.011,56.926c-0.032,0-0.064,0-0.098,0c-0.73-0.003-1.319-0.598-1.316-1.328
                                                            c0.003-0.729,0.595-1.316,1.322-1.316c0.034,0,0.063,0,0.095,0c3.975,0,7.602-1.166,9.719-3.128
                                                            c0.533-0.496,1.37-0.467,1.868,0.071c0.496,0.535,0.465,1.372-0.071,1.868C56.937,55.496,52.637,56.926,48.011,56.926z"></path>
                                                      </g>
                                                      </g>
                                                      </svg>
                                                      <h3 class="card-title">Ask for expert advice from the diabetes team in complex patients, or where hyperglycaemia is difficult to control.</h3>
                                                </div>
                                             </div>
                                             <p><strong>Prevent and manage hypoglycaemia if it occurs</strong></p>
                                             <ul>
                                                <li><strong>Monitor blood glucose</strong> in people with diabetes in hospital and <strong>adjust medication </strong>in response to illness and hospital meal times, in order to <strong>reduce risk</strong> of <strong>hypoglycaemic episodes</strong>.</li>
                                                <li>1 in 5 inpatients with diabetes in England and Wales have a<strong> hypoglycaemic episode </strong>during their hospital stay. <em>(NHS Digital. National Diabetes Inpatient Audit (NaDIA) - 2017, 2018)</em></li>
                                                <li>Causes include:<em> (JBDS-IP, 2018)</em>
                                                <ul>
                                                <li>Recovery from an acute illness</li>
                                                <li>Insulin or oral hypoglycaemic medication error</li>
                                                <li>Wrong timing of insulin in relation to meals</li>
                                                <li>Patients eating less but taking the same amount of diabetes medication</li>
                                                <li>No bedtime snacks</li>
                                                <li>Reduced appetite or vomiting.</li>
                                                </ul></li>
                                             </ul>

                                             <div id="tip_pitfall" class="card card-inverse mb-4">
                                                <div class="card-block">
                                                   <svg version="1.1" id="pin" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 90 90" enable-background="new 0 0 90 90" xml:space="preserve">
                                                   <g>
                                                      <g>
                                                         <path fill="#333333" d="M42.694,51.942v30.413C42.694,83.816,44.174,85,46,85s3.306-1.184,3.306-2.645V51.942H42.694z"></path>
                                                      </g>
                                                      <g>
                                                         <ellipse fill="#333333" cx="46" cy="47.645" rx="19.835" ry="12.231"></ellipse>
                                                      </g>
                                                      <g id="cylinder">
                                                         <polygon fill="#333333" points="55.256,9.628 46,9.628 36.744,9.628 34.099,47.975 46,47.975 57.901,47.975 		"></polygon>
                                                      </g>
                                                      <g id="cylinder_highlight">
                                                         <polygon fill="#FFFFFF" points="54.595,46.653 50.628,47.975 49.306,13.595 53.273,13.595 		"></polygon>
                                                      </g>
                                                      <g>
                                                         <ellipse fill="#333333" cx="46" cy="13.595" rx="15.207" ry="8.595"></ellipse>
                                                      </g>
                                                      <g id="highlight">
                                                         <path fill="#FFFFFF" d="M47.982,18.929c-0.67,0-1.245-0.508-1.313-1.19c-0.073-0.727,0.456-1.375,1.183-1.448
                                                            c3.157-0.318,5.857-1.434,7.224-2.985c0.48-0.547,1.317-0.602,1.866-0.118c0.548,0.482,0.601,1.318,0.118,1.866
                                                            c-1.822,2.069-5.082,3.479-8.942,3.868C48.072,18.927,48.027,18.929,47.982,18.929z"></path>
                                                      </g>
                                                      <g>
                                                         <path fill="#333333" d="M46,49.54v-1.322c4.794,0,9.917-1.192,9.917-4.54h1.322C57.239,47.349,53.038,49.54,46,49.54z"></path>
                                                      </g>
                                                      <g id="highlight_lower">
                                                         <path fill="#FFFFFF" d="M48.011,56.926c-0.032,0-0.064,0-0.098,0c-0.73-0.003-1.319-0.598-1.316-1.328
                                                            c0.003-0.729,0.595-1.316,1.322-1.316c0.034,0,0.063,0,0.095,0c3.975,0,7.602-1.166,9.719-3.128
                                                            c0.533-0.496,1.37-0.467,1.868,0.071c0.496,0.535,0.465,1.372-0.071,1.868C56.937,55.496,52.637,56.926,48.011,56.926z"></path>
                                                      </g>
                                                      </g>
                                                      </svg>
                                                      <h3 class="card-title"><p><strong>Bedtime snacks </strong>can reduce the risk of <strong>early morning hypoglycaemia</strong>. <em>(NHS Digital. National Diabetes Inpatient Audit (NaDIA) - 2017, 2018)</em></p></h3>
                                                </div>
                                             </div>

                                             <p><strong>Treat hypoglycaemia actively if the blood glucose falls below 4.0 mmol/L. </strong><em>(JBDS-IP, 2018)</em></p>
                                             <ul>
                                             <li>Follow hospital protocol. The JBDS-IP has guidelines on hospital management of hypoglycaemia in adults with diabetes. <em>(JBDS-IP, 2018)</em></li>
                                             </ul>
                                                
                                    </div>

                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group CKD-como-content" style="display: none;">
                                 <div class="panel-header">
                                       <p class="panel-title"> 
                                          <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                          <span class="title-02">
                                             <span class="title-03 col-md-1">
                                             Plus
                                             <span class="noShow">&nbsp;–&nbsp;</span>
                                             </span>
                                             <span class="title-04">
                                             <span class="material-icons"><span></span><span></span></span>
                                             <span class="txtwrap">Check baseline kidney function</span>
                                             </span>
                                             <span class="material-icons">
                                                   <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                   <g>
                                                      <g>
                                                         <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                            c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                         <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                            c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                         <g>
                                                            <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                         </g>
                                                      </g>
                                                      <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                         7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                   </g>
                                                   </svg>
                                                </span>
                                          </span>
                                          </span>
                                          </a>
                                       </p>
                                 </div>
                                 <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_0_0_3" id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">

                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                             <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                <g>
                                                   <g>
                                                      <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                         c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                      <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                         c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                      <g>
                                                         <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                      </g>
                                                   </g>
                                                   <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                      7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                </g>
                                                </svg>
                                       </span> 
                                       <h3 class="poce_title"></h3>
                                       <p><strong>Check baseline serum kidney function on admission in all patients with a previous history of chronic kidney disease (CKD). </strong><em>[National Institute for Health and Care Excellence. 2013)</em></p>
                                       <ul>
                                       <li><strong>CKD</strong> is a significant<strong> risk factor</strong> for the development of <strong>acute kidney injury</strong>. <em>(Hsu CY, et al, 2008)</em></li>
                                       <li>Acute illness increases the risk of deterioration in renal function.</li>
                                       </ul>
                                                
                                    </div>

                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Stroke-como-content" style="display: none;">
                                 <div class="panel-header">
                                       <p class="panel-title"> 
                                          <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                          <span class="title-02">
                                             <span class="title-03 col-md-1">
                                             Plus
                                             <span class="noShow">&nbsp;–&nbsp;</span>
                                             </span>
                                             <span class="title-04">
                                             <span class="material-icons"><span></span><span></span></span>
                                             <span class="txtwrap">Baseline neurological assessment</span>
                                             </span>
                                             <span class="material-icons">
                                                   <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                   <g>
                                                      <g>
                                                         <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                            c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                         <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                            c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                         <g>
                                                            <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                         </g>
                                                      </g>
                                                      <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                         7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                   </g>
                                                   </svg>
                                                </span>
                                          </span>
                                          </span>
                                          </a>
                                       </p>
                                 </div>
                                 <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_0_0_3" id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">

                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                             <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                <g>
                                                   <g>
                                                      <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                         c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                      <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                         c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                      <g>
                                                         <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                      </g>
                                                   </g>
                                                   <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                      7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                </g>
                                                </svg>
                                       </span> 
                                       <h3 class="poce_title"></h3>
                                       <p><strong>Do a baseline neurological assessment on admission for all patients with a history of stroke.</strong></p>
                                       <ul>
                                       <li>Patients with <strong>acute illness</strong> (including infections and causes of hypotension) are at <strong>increased risk of stroke</strong> (both ischaemic and haemorrhagic). <em>(Grau AJ, et al, 2010) (Eigenbrodt ML, et al, 2000)</em></li>
                                       <li>If there is a suspicion of a change in neurological status during admission, repeat the<strong>neurological assessment</strong> in case of a <strong>possible new stroke</strong>.</li>
                                       </ul>
                                       <p>Following assessment, consider appropriate level of <strong>patient supervision</strong> e.g., relating to possible <strong>confusion</strong> at night, <strong>falls</strong> related to <strong>frailty</strong>.</p>
                                                
                                    </div>

                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Dementia-como-content" style="display: none;">
                                 <div class="panel-header">
                                       <p class="panel-title"> 
                                          <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                          <span class="title-02">
                                             <span class="title-03 col-md-1">
                                             Plus
                                             <span class="noShow">&nbsp;–&nbsp;</span>
                                             </span>
                                             <span class="title-04">
                                             <span class="material-icons"><span></span><span></span></span>
                                             <span class="txtwrap">Baseline cognitive assessment and collateral history</span>
                                             </span>
                                             <span class="material-icons">
                                                   <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                   <g>
                                                      <g>
                                                         <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                            c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                         <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                            c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                         <g>
                                                            <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                         </g>
                                                      </g>
                                                      <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                         7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                   </g>
                                                   </svg>
                                                </span>
                                          </span>
                                          </span>
                                          </a>
                                       </p>
                                 </div>
                                 <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_0_0_3" id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">

                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                             <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                <g>
                                                   <g>
                                                      <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                         c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                      <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                         c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                      <g>
                                                         <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                      </g>
                                                   </g>
                                                   <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                      7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                </g>
                                                </svg>
                                       </span> 
                                       <h3 class="poce_title"></h3>
                                       <p><strong>Do a baseline cognitive assessment in all older patients, particularly those with a history of dementia. </strong><em>(Pendlebury ST, et al, 2015)</em></p>
                                       <ul>
                                       <li>Use a<strong> validated scoring system</strong> that is also feasible in the acute setting, such as:<em>(Pendlebury ST, et al, 2015)</em>
                                          <ul>
                                          <li>The <strong>abbreviated mental test score</strong> (AMTS/10) <em>(Hodkinson,1972)</em></li>
                                          <li><strong>Montreal Cognitive Assessment</strong> (MoCA) <em>(Nasreddine, 2005).</em></li>
                                          </ul>
                                       </li>                                       
                                       </ul>
                                       <p><strong>Dementia increases the risk of delirium. </strong></p>
                                       <ul>
                                       <li>This can acutely reduce patients' cognitive assessment scores. <em>(George J, 2013)</em></li>
                                       </ul>
                                       <p><strong>Take a collateral history from family, friend or carer, to establish the patient&rsquo;s level of function and baseline cognition before this illness.</strong></p>
                                       <ul>
                                       <li>It&rsquo;s important to know if the <strong>decline</strong> in function and cognition has been <strong>gradual </strong>or <strong>acute</strong>.</li>
                                       </ul>
                                       <p>Use this information for <strong>monitoring clinical improvement</strong>, and for establishing <strong>needs on discharge</strong>.</p>
                                                
                                    </div>

                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Dementia-como-content" style="display: none;">
                                 <div class="panel-header">
                                       <p class="panel-title"> 
                                          <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                          <span class="title-02">
                                             <span class="title-03 col-md-1">
                                             Plus
                                             <span class="noShow">&nbsp;–&nbsp;</span>
                                             </span>
                                             <span class="title-04">
                                             <span class="material-icons"><span></span><span></span></span>
                                             <span class="txtwrap">Assess for and manage delirium</span>
                                             </span>
                                             <span class="material-icons">
                                                   <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                   <g>
                                                      <g>
                                                         <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                            c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                         <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                            c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                         <g>
                                                            <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                         </g>
                                                      </g>
                                                      <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                         7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                   </g>
                                                   </svg>
                                                </span>
                                          </span>
                                          </span>
                                          </a>
                                       </p>
                                 </div>
                                 <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_0_0_3" id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">

                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                             <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                <g>
                                                   <g>
                                                      <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                         c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                      <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                         c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                      <g>
                                                         <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                      </g>
                                                   </g>
                                                   <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                      7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                </g>
                                                </svg>
                                       </span> 
                                       <h3 class="poce_title"></h3>
                                       <p><strong>Assess the patient with dementia for delirium. </strong><em>(National Institute for Health and Clinical Excellence. 2010)</em></p>
                                       <ul>
                                       <li>People living with dementia are at increased risk of delirium when they are admitted to hospital. (<em>National Institute for Health and Clinical Excellence, 2018)</em></li>
                                       <li>Use a<strong> screening tool</strong>, such as:
                                       <ul>
                                       <li>The <strong>4-AT</strong><em>(</em><em>Bellelli, 2014)</em></li>
                                       <li>The <strong>short confusion assessment method (S-CAM), </strong>as recommended by the National Institute of Health and Care Excellence (NICE). <em>(National Institute for Health and Clinical Excellence. 2010)</em></li>
                                       <li>Document the results clearly.</li>
                                       </ul></li>
                                       </ul>
                                       <p><strong>Assess the patient for any reversible causes of delirium</strong>. <em>(National Institute for Health and Clinical Excellence. 2010)</em>These include:</p>
                                       <ul>
                                       <li>Infection</li>
                                       <li>Pain</li>
                                       <li>Dehydration</li>
                                       <li>Constipation</li>
                                       <li>Hypoxia</li>
                                       <li>Immobility</li>
                                       <li>Medications</li>
                                       <li>Poor sleep</li>
                                       <li>Sensory impairment (e.g., ear wax or loss of glasses)</li>
                                       </ul>
                                       <p><strong>Investigations</strong> to help diagnose underlying causes include:</p>
                                       <ul>
                                       <li>Full blood count, electrolytes, renal function, liver function tests, calcium, glucose, CRP, folate and vitamin B12.</li>
                                       <li>Blood cultures (if bacteraemia is suspected)</li>
                                       <li>Urine microscopy and culture</li>
                                       <li>Chest x-ray</li>
                                       </ul>
                                       <p><strong>Manage according to the cause</strong>.</p>
                                       <p><strong>Manage patients with delirium initially with non-pharmacological treatment. </strong><em>(National Institute for Health and Clinical Excellence. 2010)</em></p>
                                       <ul>
                                       <li>Reduce <strong>disorientation</strong> by providing a <strong>well-lit room,</strong> with a <strong>clock</strong> and <strong>calendar </strong>visible (e.g., on the wall).</li>
                                       <li>Encourage and facilitate <strong>family, friends and carers</strong> visiting the patient.</li>
                                       <li>Use verbal and non-verbal techniques to<strong> de-escalate</strong> conflict and distress.</li>
                                       </ul>
                                       <p><strong>Where non-pharmacological treatments are ineffective, and the patient is distressed or considered a risk to themselves or others, short-term antipsychotic or sedative drugs may be used.</strong></p>
                                       <p><strong>Only use antipsychotics as a last resort and not in patients with Parkinson&rsquo;s disease or dementia with Lewy bodies.</strong><em>(National Institute for Health and Clinical Excellence. 2010)</em></p>
                                       <ul>
                                       <li><strong>Risperidone</strong> has the least anticholinergic effects. <em>(Tracy JI, et al, 1998)</em></li>
                                       <li><strong>Haloperidol</strong> is also licenced for this indication, but has the highest risk associated with its use. The UK National Institute for Health and Care Excellence recommends short-term use of haloperidol (usually for less than one week), starting at the <strong>lowest dose</strong> and <strong>titrating carefully</strong> according to the symptoms. <em>(National Institute for Health and Clinical Excellence. 2010)</em></li>
                                       <li>Consider sedation in significantly agitated patients who pose a risk to themselves or others.<strong> Lorazepam </strong>is a suitable choice, but it should only be given orally or intramuscularly (i.e., not intravenously).</li>
                                       <li>Lorazepam should only be used in the<strong> smallest possible dose</strong> for the <strong>shortest possible duration</strong>.</li>
                                       </ul>
                                       <p><strong>Avoid typical antipsychotics, particularly haloperidol in patients with Parkinson&rsquo;s disease or dementia with Lewy bodies. </strong><em>(National Institute for Health and Clinical Excellence. 2010)</em></p>
                                       <ul>
                                       <li>The dopamine receptor antagonistic effect of typical antipsychotics can <strong>dramatically worsen physical and cognitive symptoms</strong> in people with Parkinson&rsquo;s disease or with dementia with Lewy bodies.</li>
                                       <li>Consider a <strong>low-dose short-acting oral benzodiazepine,</strong> such as lorazepam, or l<strong>ow-dose quetiapine </strong>in patients with Parkinson&rsquo;s disease or dementia with Lewy bodies who require sedation to enable safe care because of delirium.</li>
                                       <li>Consult your local drug formulary for advice.</li>
                                       </ul>
                                       <p><br /><strong>Document</strong> any episodes of current or resolved delirium in the<strong> discharge summary for the GP</strong>. <em>(National Institute for Health and Clinical Excellence. 2010)</em></p>
                                                
                                       

                                       <div class="evidence-accordion">
                                             <div class="option">
                                                <input type="checkbox" id="toggle28" class="toggle" />
                                                <label class="title" for="toggle28">                                             
                                                   <span class="material-icons"><span></span></span>
                                                   <span class="title">Evidence: risks and safe withdrawal of antipsychotics in the elderly</span>
                                             </label>
                                                <div class="content">
                                                      <p><strong>Short-term antipsychotics may be needed in people with dementia to enable safe care. However, antipsychotics have various adverse effects in the elderly and are associated with an increased risk of death in people with dementia.</strong></p>
                                                      <ul>
                                                      <li>A meta-analysis found that people with dementia who take atypical antipsychotics have an <strong>increased mortality risk </strong>compared with people taking placebo. <em>(Ma H, et al, 2014)</em></li>
                                                      
                                                      <li>A large cohort study of elderly people found that <strong>higher doses</strong> of antipsychotics are generally associated with <strong>greater risk</strong>. <em>(Huybrechts K, 2012)</em></li>
                                                      
                                                      <li>It also found that of all the antipsychotics studied, <strong>haloperidol </strong>has the highest risk associated with its use. <em>(Huybrechts K, 2012)</em></li>
                                                      
                                                      <li>Contrary to popular belief, long-term antipsychotic prescriptions in people with dementia whose behaviour is now settled, can be <strong>withdrawn safely </strong>in the majority of cases. <em>(Van Leeuwen, 2018)</em></li>
                                                      </ul>
                                                </div>
                                             </div>
                                          </div>

                                          

                                          <div class="evidence-accordion">
                                             <div class="option">
                                                <input type="checkbox" id="toggle29" class="toggle" />
                                                <label class="title" for="toggle29">                                             
                                                   <span class="material-icons"><span></span></span>
                                                   <span class="title">Evidence: primary prevention of delirium: this may be the most effective treatment strategy</span>
                                             </label>
                                                <div class="content">
                                                      <p><strong>A non-randomised trial studying how to reduce risk factors for delirium compared a multicomponent strategy with usual care in 852 elderly patients (over 70 years) in hospital. </strong><em>(Inouye, 1999)</em></p>
                                                      <ul>
                                                      <li>The multicomponent strategy targeted the following 6 risk factors:
                                                      <ul>
                                                      <li>cognitive impairment</li>
                                                      <li>sleep deprivation</li>
                                                      <li>immobility</li>
                                                      <li>visual impairment</li>
                                                      <li>hearing impairment</li>
                                                      <li>dehydration.</li>
                                                      </ul></li>
                                                      </ul>
                                                      <p>It found: <em>(Inouye, 1999)</em></p>
                                                      <ul>
                                                      <li>There were <strong>significantly fewer first episodes of delirium</strong> with the <strong>multicomponent strategy </strong>vs usual care (44 [9.9%] vs 64 [15%] respectively)</li>
                                                      <li>Matched group analysis found an odds ratio (OR) of 0.60 (95%CI: 0.39-0.92; p=0.02)</li>
                                                      <li><strong>Total number of days with delirium</strong> was <strong>significantly lower </strong>with the <strong>multicomponent strategy</strong> vs usual care (105 vs. 161 days respectively, p=0.02)</li>
                                                      </ul>
                                                      <p><strong>Delirium severity and recurrence rates</strong> were <strong>not significantly different </strong>in the 2 groups.</p>
                                                </div>
                                             </div>
                                          </div>

                                    </div>

                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Dementia-como-content" style="display: none;">
                                 <div class="panel-header">
                                       <p class="panel-title"> 
                                          <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                          <span class="title-02">
                                             <span class="title-03 col-md-1">
                                             Plus
                                             <span class="noShow">&nbsp;–&nbsp;</span>
                                             </span>
                                             <span class="title-04">
                                             <span class="material-icons"><span></span><span></span></span>
                                             <span class="txtwrap">Set an escalation plan</span>
                                             </span>
                                             <span class="material-icons">
                                                   <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                   <g>
                                                      <g>
                                                         <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                            c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                         <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                            c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                         <g>
                                                            <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                         </g>
                                                      </g>
                                                      <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                         7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                   </g>
                                                   </svg>
                                                </span>
                                          </span>
                                          </span>
                                          </a>
                                       </p>
                                 </div>
                                 <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_0_0_3" id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">

                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                             <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                <g>
                                                   <g>
                                                      <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                         c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                      <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                         c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                      <g>
                                                         <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                      </g>
                                                   </g>
                                                   <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                      7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                </g>
                                                </svg>
                                       </span> 
                                       <h3 class="poce_title"></h3>
                                       <p><strong>Set an escalation plan for all patients with dementia as early as possible.</strong></p>
                                       <ul>
                                       <li>This should include: <em>(Fritz Z, et al, 2017):</em> <ul>
                                       <li><strong>Resuscitation status</strong> (i.e., do not attempt cardiopulmonary resuscitation [DNACPR] decision)</li>
                                       <li><strong>Ceiling of care</strong> (e.g., is the patient suitable for intubation or intensive care admission)</li>
                                       </ul></li>
                                      
                                       <li>Escalation plans should take account of<strong> advanced care planning</strong>, including legally-binding advanced directives. <em>(Fritz Z, et al, 2017)</em></li>
                                       </ul>
                                       <p><strong>Communicate</strong> all decisions regarding the escalation plan <strong>with the patient</strong>.<em>(Fritz Z, et al, 2017)</em></p>
                                       <ul>
                                       <li><strong>Assess mental capacity</strong> (the ability to make decisions at a specific time a decision needs to be made) and document. <em>(NICE, 2018)</em> Follow the appropriate legislation in your region.</li>
                                       <li>In England and Wales, health professionals must comply with the <strong>2005 Mental Capacity Act</strong>. <em>(Department of Health, 2005) </em>Assessments should follow the principles in the Act. <em>(Department of Health, 2005) </em></li>
                                       <li>If a patient is assessed to lack mental capacity, ensure decisions are made in the <strong>best interests of the patient</strong>. <em>(Department of Health, 2005) (NICE, 2018)</em></li>
                                       </ul>
                                       <p><strong>If the patient is assessed to lack mental capacity, consult with the patient&rsquo;s next of kin in order to make &lsquo;best interests&rsquo; decisions. </strong><em>(Department of Health, 2005) </em></p>
                                       <p>According to the 2005 Mental Capacity Act in England and Wales, if a patient is unbefriended and a decision is not time critical, an independent mental capacity advocate (IMCA) should be sought to perform this role instead. (<em>Social Care Institute for Excellence, 2011)</em></p>
                                    </div>

                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group COPD-como-content Asthma-como-content" style="display: none;">
                                 <div class="panel-header">
                                       <p class="panel-title"> 
                                          <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                          <span class="title-02">
                                             <span class="title-03 col-md-1">
                                             Plus
                                             <span class="noShow">&nbsp;–&nbsp;</span>
                                             </span>
                                             <span class="title-04">
                                             <span class="material-icons"><span></span><span></span></span>
                                             <span class="txtwrap">Remember to prescribe usual inhalers </span>
                                             </span>
                                             <span class="material-icons">
                                                   <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                   <g>
                                                      <g>
                                                         <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                            c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                         <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                            c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                         <g>
                                                            <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                         </g>
                                                      </g>
                                                      <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                         7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                   </g>
                                                   </svg>
                                                </span>
                                          </span>
                                          </span>
                                          </a>
                                       </p>
                                 </div>
                                 <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_0_0_3" id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">

                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                             <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                <g>
                                                   <g>
                                                      <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                         c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                      <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                         c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                      <g>
                                                         <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                      </g>
                                                   </g>
                                                   <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                      7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                </g>
                                                </svg>
                                       </span> 
                                       <h3 class="poce_title"></h3>
                                       <p><strong>Patients may not think to tell you about their usual inhalers when asked about their medication, so remember to check and prescribe these if appropriate</strong></p>
                                       <ul>
                                       <li>Patients with asthma should continue any inhaled corticosteroid medication they usually take. These should not be stopped without a clear medical reason.</li>
                                       <li>Many inhalers are combined medications, so check there is no dual prescribing</li>
                                       </ul>
                                       <p><strong>Temporarily stop inhaled long-acting muscarinic receptor antagonists if your patient with COPD or asthma usually takes this and develops acute kidney injury with an eGFR &lt;30.</strong></p>
                                    </div>

                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group COPD-como-content Asthma-como-content" style="display: none;">
                                 <div class="panel-header">
                                       <p class="panel-title"> 
                                          <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                          <span class="title-02">
                                             <span class="title-03 col-md-1">
                                             Plus
                                             <span class="noShow">&nbsp;–&nbsp;</span>
                                             </span>
                                             <span class="title-04">
                                             <span class="material-icons"><span></span><span></span></span>
                                             <span class="txtwrap">Nicotene replacement therapy in current smokers</span>
                                             </span>
                                             <span class="material-icons">
                                                   <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                   <g>
                                                      <g>
                                                         <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                            c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                         <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                            c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                         <g>
                                                            <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                         </g>
                                                      </g>
                                                      <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                         7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                   </g>
                                                   </svg>
                                                </span>
                                          </span>
                                          </span>
                                          </a>
                                       </p>
                                 </div>
                                 <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_0_0_3" id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">

                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                             <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                <g>
                                                   <g>
                                                      <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                         c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                      <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                         c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                      <g>
                                                         <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                      </g>
                                                   </g>
                                                   <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                      7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                </g>
                                                </svg>
                                       </span> 
                                       <h3 class="poce_title"></h3>
                                       <p><strong>All current smokers are nicotine dependent</strong></p>
                                       <ul>
                                       <li>Nicotine replacement therapy should be prescribed to prevent withdrawal regardless of a patient&rsquo;s intention regarding smoking cessation</li>
                                       <li>Please consult your local hospital guidance.</li>
                                       </ul>
                                       <p><br /><strong>Make every contact count:</strong></p>
                                       <ul>
                                       <li>Being in hospital with an acute illness is the ideal time to support someone to give up smoking</li>
                                       <li>Provide brief advice.</li>
                                       </ul>
                                    </div>

                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group COPD-como-content Asthma-como-content" style="display: none;">
                                 <div class="panel-header">
                                       <p class="panel-title"> 
                                          <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                          <span class="title-02">
                                             <span class="title-03 col-md-1">
                                             Plus
                                             <span class="noShow">&nbsp;–&nbsp;</span>
                                             </span>
                                             <span class="title-04">
                                             <span class="material-icons"><span></span><span></span></span>
                                             <span class="txtwrap">Monitor for and manage any acute exacerbation of asthma or COPD</span>
                                             </span>
                                             <span class="material-icons">
                                                   <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                   <g>
                                                      <g>
                                                         <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                            c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                         <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                            c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                         <g>
                                                            <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                         </g>
                                                      </g>
                                                      <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                         7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                   </g>
                                                   </svg>
                                                </span>
                                          </span>
                                          </span>
                                          </a>
                                       </p>
                                 </div>
                                 <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_0_0_3" id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">

                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                             <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                <g>
                                                   <g>
                                                      <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                         c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                      <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                         c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                      <g>
                                                         <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                      </g>
                                                   </g>
                                                   <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                      7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                </g>
                                                </svg>
                                       </span> 
                                       <h3 class="poce_title"></h3>
                                       <p><strong>Monitor patient for symptoms and signs of an acute exacerbation of their COPD or asthma.</strong></p>
                                       <ul>
                                       <li>A patient with airways disease may have an acute exacerbation while in hospital with a separate another medical or surgical condition.</li>
                                       </ul>
                                       <p><strong>Patients with comorbid COPD may be having an acute exacerbation if there is an acute worsening of respiratory symptoms that results in the need for additional therapy.</strong><em>(Global Initiative for Chronic Obstructive Lung Disease, 2019)</em></p>
                                       <ul>
                                       <li><strong>Differentiate</strong> from other conditions which may present very similarly, such as <strong>acute coronary syndrome</strong>, <strong>acute heart failure</strong> and <strong>pneumonia</strong>.</li>
                                       <li>Follow guideline recommendations on <strong>investigations</strong>, including:
                                       <ul>
                                       <li><strong>ABG</strong> measurement</li>
                                       <li><strong>Chest x-ray.</strong> Generally, do a chest x-ray if a patient with COPD is admitted with breathlessness or cough, or has worse symptoms than usual.</li>
                                       </ul></li>
                                       <li>Follow <strong>COPD guideline </strong>recommendations on <strong>initial management</strong>, including:<ul>
                                       <li><strong>Assessing severity</strong></li>
                                       <li>Increasing dose and/or frequency of <strong>bronchodilator therapy</strong>, using nebulisers (driven with air) or spacers</li>
                                       <li>Considering <strong>oral corticosteroids</strong>, <strong>antibiotics</strong> and need for <strong>noninvasive ventilation</strong>.</li>
                                       <li>See BMJ Best Practice topic on Acute exacerbation in COPD</li>
                                       </ul></li>                                       
                                       </ul>
                                       <p><strong>Follow guideline recommendations for assessment of severity and management of an acute exacerbation of asthma in adults. </strong><em>(</em><em>British Thoracic Society; Scottish Intercollegiate Guidelines Network, 2016) </em></p>
                                       <ul>
                                       <li>Initial treatment of acute severe asthma includes:<ul>
                                       <li><strong>Supplementary oxygen</strong> if hypoxaemic. Titrate to maintain an oxygen saturation level of <strong>94% to 98%</strong></li>
                                       <li><strong>High-dose inhaled beta2 agonists</strong> as early as possible, usually via nebuliser (oxygen-driven)</li>
                                       <li><strong>Ipratropium bromide</strong> via nebuliser (oxygen-driven) if needed</li>
                                       <li><strong>Corticosteroids</strong> in adequate doses (40 to 50 mg daily for at least 5 days)</li>
                                       <li>Other therapies may be required, <strong>follow guideline recommendations</strong></li>
                                       <li>See BMJ Best Practice topic on Acute exacerbation of asthma in adults.</li>
                                       </ul></li>                                       
                                       </ul>
                                       <p><strong>Stop long-acting muscarinic receptor antagonists (LAMAs) e.g., tiotropium temporarily if short-acting muscarinic antagonists (SAMAs) e.g., ipratropium bromide are prescribed via nebuliser.</strong></p>
                                       <ul>
                                       <li>This is based on expert opinion due to concern over possible anticholinergic adverse effects.</li>
                                       </ul>
                                       <p><strong>Regular nebulisers should only be prescribed for 24 to 48 hours and then switched back to the patient&rsquo;s usual inhalers.</strong></p>


                                          <div class="evidence-accordion">
                                             <div class="option">
                                                <input type="checkbox" id="toggle30" class="toggle" />
                                                <label class="title" for="toggle30">                                             
                                                   <span class="material-icons"><span></span></span>
                                                   <span class="title">Evidence: cardiovascular harm with beta2- agonists.</span>
                                             </label>
                                                <div class="content">
                                                      <p><strong>Beta2-agonists increase the risk of myocardial infarction and other adverse cardiovascular events</strong></p>
                                                      <ul>
                                                      <li>Beta2-agonists increase heart rate and reduce potassium levels. <em>(Salpeter SR, et al, 2004) </em>They are absorbed into the systemic circulation and there is evidence they are associated with an increased risk of myocardial infarction, unable angina, congestive heart failure and arrhythmias. <em>(Au DH, et al, 2002) (Salpeter SR, et al, 2004) (Baker JG, 2017)</em></li>
                                                      </ul>
                                                </div>
                                             </div>
                                          </div>


                                          <div class="evidence-accordion">
                                             <div class="option">
                                                <input type="checkbox" id="toggle31" class="toggle" />
                                                <label class="title" for="toggle31">                                             
                                                   <span class="material-icons"><span></span></span>
                                                   <span class="title">Evidence: short duration vs longer duration of corticosteroids for acute exacerbation of COPD</span>
                                             </label>
                                                <div class="content">
                                                      <p><strong>A systematic review found no difference in outcomes (treatment failure, time to next exacerbation, time in hospital, lung function, adverse effects, mortality) between short courses (7 days or less) vs more conventional longer courses (longer than 7 days) of corticosteroids in people with acute exacerbation of COPD </strong><em>(Walters JAE, et al, 2018)</em></p>
                                                      <ul>
                                                      <li>The randomised controlled trials included in this Cochrane review were all in hospital settings and only included people with severe to very severe COPD<em> (Walters JAE, et al, 2018)</em></li>
                                                      <li>The review authors concluded that due to the addition of a new trial, they have increased confidence that a corticosteroid course of around 5 days is likely to be sufficient for the treatment of an acute exacerbation of COPD. <em>(Walters JAE, et al, 2018)</em></li>
                                                      </ul>
                                                </div>
                                             </div>
                                          </div>
                                          
                                    </div>
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Diabetes-como-content" style="display: none;">
                                 <div class="panel-header">
                                       <p class="panel-title"> 
                                          <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                          <span class="title-02">
                                             <span class="title-03 col-md-1">
                                             Plus
                                             <span class="noShow">&nbsp;–&nbsp;</span>
                                             </span>
                                             <span class="title-04">
                                             <span class="material-icons"><span></span><span></span></span>
                                             <span class="txtwrap">Check patient’s feet</span>
                                             </span>
                                             <span class="material-icons">
                                                   <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                   <g>
                                                      <g>
                                                         <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                            c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                         <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                            c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                         <g>
                                                            <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                         </g>
                                                      </g>
                                                      <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                         7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                   </g>
                                                   </svg>
                                                </span>
                                          </span>
                                          </span>
                                          </a>
                                       </p>
                                 </div>
                                 <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_0_0_3" id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">

                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                             <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                <g>
                                                   <g>
                                                      <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                         c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                      <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                         c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                      <g>
                                                         <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                      </g>
                                                   </g>
                                                   <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                      7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                </g>
                                                </svg>
                                       </span> 
                                       <h3 class="poce_title"></h3>
                                       <p><strong>Check</strong><strong> the feet of all adults with diabetes on admission to hospital and whenever there has been a change in their status. </strong><em>(NICE, 2016)</em></p>
                                       <ul>
                                       <li><strong>Why? </strong>
                                       <ul>
                                       <li>To detect <strong>new ulceration </strong>or<strong> infection, </strong>which may be<strong> unnoticed</strong> by the patient andmay even be the <strong>underlying cause </strong>of their illness (e.g., patient presenting with sepsis, spinal abscess or endocarditis where the original focus of infection is the foot lesion).</li>
                                       <li>To determine if patient is at<strong> high risk of pressure ulceration </strong>and <strong>requires pressure relief</strong>.</li>
                                       </ul></li>
                                       <li><strong>Take action </strong>
                                       <ul>
                                       <li>You must <strong>remove any foot dressings</strong> to see if any wound/ulcer is<strong> infected. </strong><em>(NICE NG19, 2016)</em></li>
                                       <li><strong>Inspect</strong> the foot for lesions and examine for loss of protective <strong>sensation</strong>. Follow your local guidelines, but a quick simple test is the <strong>Ipswich Touch Test&copy;️</strong>. (Rayman G, et al, 2011)</li>
                                       <li>If your patient has <strong>reduced sensation</strong>, they are at <strong>high risk of pressure ulceration</strong>. Inform the nursing staff and <strong>provide pressure relieving devices</strong>.</li>
                                       <li>A <strong>daily heel check</strong> for <strong>signs of pressure trauma</strong> should be undertaken by nursing or health care assistant staff.</li>
                                       </ul></li>
                                       </ul>
                                          
                                    </div>
                                 </div>
                                 <!--/.panel-body -->
                              </section>

                           </div>
                           <!--/.panel-body -->
                        </div>
                        <!-- /.panel-group -->
                     </div>
                  </div>
               </div>
         </div>
         <div class="card-block disclaimer">
            <p><span>Use of this content is subject to our <a href="https://bestpractice.bmj.com/info/disclaimer/" target="_blank">disclaimer</a> </span></p>
         </div>
         <script type="text/javascript">//<![CDATA[
            var drugDatabases = ["AHFS","BNF","BNFC","MARTINDALE","MICROMEDEX"];
            var drugMappings = {"b3fb3286-271c-47f6-ae52-1bd3958b1e9b":{"BNFC":"844811582","AHFS":"382789","BNF":"844811582","MARTINDALE":"2041-c"},"46d9672e-3313-452d-9bfd-a4ddf90b32f3":{"BNFC":"338844366","AHFS":"382749","BNF":"338844366","MARTINDALE":"9506-x"},"d4ccd444-8501-447d-848f-bc97c03774ba":{"BNFC":"694891763","AHFS":"396006","BNF":"694891763","MARTINDALE":"14676-j"},"88583afa-6bbd-4755-a21e-c63ab12370f0":{"AHFS":"301057","MARTINDALE":"17311-s"},"4866ce04-4d68-4b50-83f4-66283ea52c07":{"BNFC":"347445885","AHFS":"382826","BNF":"347445885","MARTINDALE":"11401-s"},"0f8c4ada-cd84-4c04-8860-01a81e07c1f9":{"AHFS":"312005","BNF":"758974083","MARTINDALE":"22005-r"},"3984222a-c42a-4f8a-bff1-f99645ade85d":{"BNFC":"190424995","AHFS":"393016","BNF":"190424995","MARTINDALE":"13424-s"},"4b33f194-29da-4239-aae9-c1746e2bda94":{"AHFS":"315041","BNF":"142886536","MARTINDALE":"25433-t"},"aff9d94e-1579-4f56-acb7-73775d12d818":{"AHFS":"313017","BNF":"379487049","MARTINDALE":"24489-b"},"1f043ef5-6686-4b38-a018-9dea67de1e36":{"BNFC":"107604022","AHFS":"382277","BNF":"107604022","MARTINDALE":"21515-l"},"6402d40a-aa86-4def-a6af-9d56b0e8ef3e":{"AHFS":"311009","BNF":"860832161","MARTINDALE":"20786-b"},"89dc308c-7daa-4c1f-a0c4-829a581f1936":{"BNFC":"169791712","AHFS":"389001","BNF":"169791712","MARTINDALE":"16956-z"},"a37dcf97-a50b-4776-ad01-6fd4a31bb295":{"BNFC":"829952202","AHFS":"382861","BNF":"829952202","MARTINDALE":"2052-t"},"a4adb6a6-1e28-4057-9789-361aa3c914b8":{"AHFS":"302012","BNF":"724890658","MARTINDALE":"20172-x"}};
            //]]>
         </script>
      </main>
      <!-- set the messages country code variable from region to be used from i18 plugin. Setting here so it's available in all pages -->
      <script>
         /*<![CDATA[*/
         
         var messagesCountryCode = "en_GB";
         /*]]>*/
           
      </script>
      <aside id="panel-nhs" class="card-block">
         <div id="access" class="col-sm-6">
            <div class="row">
               <div class="col-md-6">
                  <p>Access provided by:</p>
               </div>
               <div class="col-md-6">
                  <img src="../images/bmj-logo.png" alt="BMJ Group (Online access from BMA House)">
               </div>
            </div>
         </div>
      </aside>
      <footer id="footer">
         <div class="container">
            <div class="row">
               <nav class="col-md-9" role="navigation">
                  <div class="row">
                     <dl class="col-md-4" role="menu">
                        <dt>Browse</dt>
                        <dd><a href="https://bestpractice.bmj.com/">Home</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/recent-updates">Recent updates</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/specialties">Specialties</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/calculators">Calculators</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/patient-leaflets">Patient leaflets</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/procedural-videos">Procedural videos</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/evidence">Evidence</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/drugs">Drugs</a></dd>
                     </dl>
                     <!-- logged-in individual or institutional user -->
                     <!-- unknown user -->
                     <!--institutional user not logged in-->
                     <dl class="col-md-4" role="menu">
                        <dt>Services</dt>
                        <dd><a href="https://bestpractice.bmj.com/login">Log in</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/registration">Create an account</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/info/getting-started/" target="_blank">Getting started</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/info/faq/" target="_blank">FAQs</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/info/benefits-features/earn-cme-points/" target="_blank">About CME/CPD</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/info/benefits-features/" target="_blank">About us</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/info/app/" target="_blank">Mobile app</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/info/contact-us/" target="_blank">Contact us</a></dd>
                        <dd>
                           <a href="https://myaccount.bmj.com/myaccount/registration.html?regService=bestpractice-email-alert&amp;fwdUrl=https://bestpractice.bmj.com">
                           Sign up for email alerts
                           </a>
                        </dd>
                     </dl>
                     <dl class="col-md-4" role="menu">
                        <dt>Legal</dt>
                        <dd><a href="https://bestpractice.bmj.com/info/disclaimer/" target="_blank">Disclaimer</a></dd>
                        <dd><a href="https://www.bmj.com/company/legal-information/" target="_blank">Terms and conditions</a></dd>
                        <dd><a href="https://www.bmj.com/company/your-privacy/" target="_blank">Privacy notice</a></dd>
                        <dd><a href="https://www.bmj.com/company/your-privacy/cookies-policy/" target="_blank">Cookie policy</a></dd>
                     </dl>
                  </div>
                  <!-- row -->
               </nav>
               <div class="col-md-3">
                  <ul>
                     <li><a target="_blank" href="https://www.facebook.com/BMJBestPractice"><img alt="Facebook Logo" title="Facebook" src="../images/facebook-64.png" width="60" height="60"></a></li>
                     <li><a target="_blank" href="https://twitter.com/BMJBestPractice"><img alt="Twiter Logo" title="Twitter" src="../images/twitter-64.png" width="60" height="60"></a></li>
                     <li><a target="_blank" href="https://www.linkedin.com/showcase/15218227/"><img alt="LinkedIn Logo" title="LinkedIn" src="../images/linkedIn_logo_circle.png" width="60" height="60"></a></li>
                     <li><a target="_blank" href="https://www.youtube.com/channel/UCt72GZ0cPXpk4EzgFhdWYdQ"><img alt="Youtube Logo" title="YouTube" src="../images/youtube-64.png" width="60" height="60"></a></li>
                  </ul>
                  <p class="copyright mt-3"><small>© BMJ Publishing Group 2018</small></p>
                  <p class="issn"><small>ISSN 2515-9615</small></p>
               </div>
            </div>
            <!-- row -->  
         </div>
         <!-- container -->    
      </footer>
      <div class="container modal-registration-form" aria-hidden="true">

         <div id="feedbackContainer" class="modal fade" tabindex="-1" role="dialog" aria-labelledby="ModalFeedbackLabel" aria-hidden="true">
            <div class="modal-dialog modal-lg" role="document">
               <div class="modal-content pb-3">
                  <div class="modal-header">
                     <div class="row">
                        <div class="col-md-12">
                           <h2>Help us improve <abbr>BMJ</abbr> Best Practice</h2>
                           <button type="button" class="close" data-dismiss="modal" aria-label="Close">
                           <span aria-hidden="true">×</span>
                           </button>
                        </div>
                        <div class="col-md-12">
                           <p>Please complete all fields.</p>
                        </div>
                     </div>
                  </div>
                  <div class="modal-body">
                     <div class="row">
                        <div class="col-md-12">
                           <form id="feedbackForm" action="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" novalidate="novalidate">
                              <div class="row">
                                 <div class="col-md-6">
                                    <div class="form-group floating-label">
                                       <label for="feedbackName">Name</label> 
                                       <input id="feedbackName" class="form-control" name="feedbackName" type="text">
                                    </div>
                                 </div>
                                 <div class="col-md-6">
                                    <div class="form-group floating-label">
                                       <label for="feedbackEmail">Email</label> 
                                       <input id="feedbackEmail" class="form-control" name="feedbackEmail" type="email" value="">
                                    </div>
                                 </div>
                              </div>
                              <div class="row">
                                 <div class="col-md-12">
                                    <h2 id="feedbackPageTitle" class="h3">Page: Pulmonary embolism - Treatment algorithm | BMJ Best Practice</h2>
                                 </div>
                              </div>
                              <input id="feedbackPage" name="feedbackPage" type="hidden" value="Pulmonary embolism - Treatment algorithm | BMJ Best Practice">
                              <div class="row">
                                 <div class="col-md-4">
                                    <p>I have some feedback on:</p>
                                    <fieldset class="form-group" role="radiogroup">
                                       <legend>Feedback on: </legend>
                                       <label for="feedOn01"><input id="feedOn01" type="radio" name="feedbackOn" value="This page" checked="checked">&nbsp;This page</label>
                                       <label for="feedOn02"><input id="feedOn02" type="radio" name="feedbackOn" value="This website">&nbsp;The website in general</label>
                                       <label for="feedOn03"><input id="feedOn03" type="radio" name="feedbackOn" value="Something else">&nbsp;Something else</label>
                                    </fieldset>
                                 </div>
                                 <div class="col-md-8">
                                    <div class="form-group floating-label textarea">
                                       <label for="feedbackContent">I have some feedback on:</label>
                                       <textarea id="feedbackContent" name="feedbackContent"></textarea>
                                    </div>
                                 </div>
                              </div>
                              <div class="row">
                                 <div class="col-md-12">
                                    <p>We will respond to all feedback.</p>
                                 </div>
                              </div>
                              <div class="row">
                                 <div class="col-md-12">
                                    <button id="feedbackSubmit" type="submit" class="btn btn-secondary btn-lg">
                                    <span id="spinner2" class="progress-circular-inner progress-circular-left"></span>
                                    <span id="btnText2">Submit Feedback</span>
                                    </button>
                                 </div>
                              </div>
                              <div class="row smTxt">
                                 <div class="col-md-12">
                                    <p>For any urgent enquiries please contact our customer services team who are ready to help with any problems.</p>
                                 </div>
                              </div>
                              <div class="row smTxt">
                                 <div class="col-md-3">
                                    <p><b>Phone:</b> +44 (0) 207 111 1105</p>
                                 </div>
                                 <div class="col-md-3">
                                    <p><b>Email: </b> <a href="mailto:support@bmj.com">support@bmj.com</a></p>
                                 </div>
                              </div>
                           </form>
                        </div>
                     </div>
                  </div>
               </div>
            </div>
         </div>

         <div class="modal fade" id="editComo" tabindex="-1" role="dialog" aria-labelledby="editComo" aria-hidden="true" style="display: none;">
               <div class="modal-dialog" role="document" style="max-width: 50rem;">
                  <div class="modal-content">
                     <div class="modal-header" style="background: #fff; margin-top: 1rem;">
                        <h2 class="modal-title" id="exampleModalLabel" style="color: #333;">
                           <span style="font-size: 50px;" class="material-icons">
                                 <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                    <g>
                                       <g>
                                          <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                             c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                          <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                             c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                          <g>
                                             <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                          </g>
                                       </g>
                                       <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                          7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                    </g>
                                    </svg>
                              </span> Add your patient's comorbidities</h2>
                        <button type="button" class="close" data-dismiss="modal" aria-label="Close">
                        <span aria-hidden="true" style="color: #333 !important; font-size: 28px;">×</span>
                        </button>
                     </div>
                     <div class="modal-body">
                        <p>Treatment recommendations for <strong>Pulmonary embolism</strong> will change dependent on your <strong>patient's comorbitities</strong></p>
                        <div class="row">
                           <div class="col-md-12" style="margin-bottom: 0.75rem;">
                              <h3>Select comorbidities</h3>
                           </div>
                           <div class="col-md-6">
                              <div class="card">
                                 <ul class="list-group list-group-flush">
                                    <li class="list-group-item"><label for="Hypertension" class="custom-control custom-checkbox">
                                       <input type="checkbox" name="comorbidity" id="Hypertension" class="comotype custom-control-input" value="Hypertension"> 
                                       <span class="custom-control-indicator"></span> 
                                       <span class="custom-control-description">Hypertension</span>
                                       </label>
                                    </li>
                                    <li class="list-group-item"><label for="CAD" class="comotype custom-control custom-checkbox">
                                       <input type="checkbox" name="comorbidity" id="CAD" class="custom-control-input" value="Coronary artery disease"> 
                                       <span class="custom-control-indicator"></span> 
                                       <span class="custom-control-description">Coronary artery disease</span>
                                       </label>
                                    </li>
                                    <li class="list-group-item"><label for="HeartFailure" class="custom-control custom-checkbox">
                                       <input type="checkbox" name="comorbidity" id="HeartFailure" class="comotype custom-control-input" value="Heart failure"> 
                                       <span class="custom-control-indicator"></span> 
                                       <span class="custom-control-description">Heart failure</span>
                                       </label>
                                    </li>
                                    <li class="list-group-item"><label for="Stroke" class="comotype custom-control custom-checkbox">
                                       <input type="checkbox" name="comorbidity" id="Stroke" class="custom-control-input" value="Stroke"> 
                                       <span class="custom-control-indicator"></span> 
                                       <span class="custom-control-description">Stroke</span>
                                       </label>
                                    </li>
                                    <li class="list-group-item"><label for="Depression" class="comotype custom-control custom-checkbox">
                                       <input type="checkbox" name="comorbidity" id="Depression" class="custom-control-input" value="Depression"> 
                                       <span class="custom-control-indicator"></span> 
                                       <span class="custom-control-description">Depression</span>
                                       </label>
                                    </li>
                                 </ul>
                              </div>
                           </div>
                           <div class="col-md-6">
                              <div class="card">
                                 <ul class="list-group list-group-flush">
                                    <li class="list-group-item"><label for="Diabetes" class="custom-control custom-checkbox">
                                       <input type="checkbox" name="comorbidity" id="Diabetes" class="comotype custom-control-input" value="Diabetes"> 
                                       <span class="custom-control-indicator"></span> 
                                       <span class="custom-control-description">Diabetes</span>
                                       </label>
                                    </li>
                                    <li class="list-group-item"><label for="Asthma" class="custom-control custom-checkbox">
                                       <input type="checkbox" name="comorbidity" id="Asthma" class="comotype custom-control-input" value="Asthma"> 
                                       <span class="custom-control-indicator"></span> 
                                       <span class="custom-control-description">Asthma</span>
                                       </label>
                                    </li>
                                    <li class="list-group-item"><label for="COPD" class="comotype custom-control custom-checkbox">
                                       <input type="checkbox" name="comorbidity" id="COPD" class="custom-control-input" value="COPD"> 
                                       <span class="custom-control-indicator"></span> 
                                       <span class="custom-control-description">COPD</span>
                                       </label>
                                    </li>
                                    <li class="list-group-item"><label for="CKD" class="comotype custom-control custom-checkbox">
                                       <input type="checkbox" name="comorbidity" id="CKD" class="custom-control-input" value="Chronic kidney disease (CKD)"> 
                                       <span class="custom-control-indicator"></span> 
                                       <span class="custom-control-description">Chronic kidney disease (CKD)</span>
                                       </label>
                                    </li>
                                    <li class="list-group-item"><label for="Dementia" class="comotype custom-control custom-checkbox">
                                       <input type="checkbox" name="comorbidity" id="Dementia" class="custom-control-input" value="Dementia"> 
                                       <span class="custom-control-indicator"></span> 
                                       <span class="custom-control-description">Dementia</span>
                                       </label>
                                    </li>
                                 </ul>
                              </div>
                           </div>
                        </div>
                           
                        <p style="margin-top: 1rem;">Please remember that treatment regimes may change for comorbidities not yet covered by this list.</p>
                        <button type="button" class="btn btn-secondary showalg not-ticked" data-dismiss="modal" aria-label="Close">CLOSE</button>
                        <button type="button" class="btn btn-secondary showalg ticked" data-dismiss="modal" aria-label="Show treatment algorithm">Show treatment algorithm</button>

                     </div>
                  </div>
               </div>
            </div>

            <!-- LOOK OUT POPUP BOX lookOutPopUp -->
            
         <div class="modal fade" id="lookOutPopUp" tabindex="-1" role="dialog" aria-labelledby="lookOutPopUp" aria-hidden="true" style="display: none;">
            <div class="modal-dialog" role="document">
               <div class="modal-content">
                  <div class="modal-header">
                     
                     <button type="button" class="close" data-dismiss="modal" aria-label="Close">
                     <span aria-hidden="true" style="color: #333 !important; font-size: 28px;">×</span>
                     </button>

                  </div>
                  <div class="modal-body">
                     
                     <div class="row">
                        <div class="col-md-12">
                           <p>Look out for this icon:
                              <span class="material-icons">
                                 <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                    <g>
                                       <g>
                                          <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                             c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                          <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                             c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                          <g>
                                             <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                          </g>
                                       </g>
                                       <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                          7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                    </g>
                                    </svg>
                              </span>                                    
                              <span>for treatment options that are affected, or added, as a result of your patient's comorbidities.</span>
                           </p>                           
                        </div>
                     </div>   
                     
                     <div class="row">
                        <div class="col-md-12 got-it">
                           <button type="button" class="btn btn-secondary showalg" data-dismiss="modal" aria-label="Close">Got it</button>
                        </div>
                     </div>                                          

                  </div>
               </div>
            </div>
         </div>
         <!-- LOOK OUT POPUP BOX lookOutPopUp ENDS -->

         <div id="feedbackSuccess" class="modal fade" tabindex="-1" role="dialog" aria-labelledby="ModalFeedbackConfirmedLabel" aria-hidden="true">
            <div class="modal-dialog modal-lg" role="document">
               <div class="modal-content pb-3">
                  <div class="modal-body">
                     <div class="row">
                        <div class="col-md-12">
                           <h2>Thank you</h2>
                           <button type="button" class="close" data-dismiss="modal" aria-label="Close">
                           <span aria-hidden="true">×</span>
                           </button>
                        </div>
                     </div>
                     <div class="row">
                        <div class="col-md-12">
                           <p>Your feedback has been submitted successfully.</p>
                        </div>
                     </div>
                  </div>
               </div>
            </div>
         </div>
         <div id="feedBackBtn">
            <p role="button"><a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"><span class="material-icons"></span>&nbsp;FEEDBACK</a></p>
         </div>
      </div>
      <script type="text/javascript" src="../js/common.js"></script>
      <script type="text/javascript" src="../js/main.js"></script>
      <script>
         // Code for the recently viewed topics suggestion, needs to be inlined to use the Java values
         /*<![CDATA[*/       
         function dedupe(array) {
           var seen = {};
           return array.filter(function(item) {
               return seen.hasOwnProperty(item.id) ? false : (seen[item.id] = true);
           });
         }
         function TopicViewed(id, title, lang) {
           this.id = id;
           this.title = title;
           this.lang = lang;
         }
         jQuery(document).ready(function() {
           var topicId = 116;
           var topicLang = "en-gb";
           var topicTitle = "Pulmonary embolism";
           if(topicId){
               
             var topicsViewed = [];
             if (localStorage.getItem("topicsViewed") !== null) {
               topicsViewed = JSON.parse(localStorage.topicsViewed);
             }
               
             topicsViewed.unshift(new TopicViewed(topicId, topicTitle, topicLang));// Add new topics at the beginning
             topicsViewed = dedupe(topicsViewed);// Remove duplicates
             if (topicsViewed.length > 15){// Drop if size is bigger than 15
               topicsViewed = topicsViewed.slice(0,14);  
             }
         
             localStorage.topicsViewed = JSON.stringify(topicsViewed);
           }
          });       
         /*]]>*/
      </script>
      
   </body>
</html>